61 results on '"Masih Tajdini"'
Search Results
2. The need for permanent pacemaker after restoration of conduction following atrioventricular block: a retrospective cohort study
- Author
-
Ali Bozorgi, Sajad Ahmadzadeh, Seyedeh Hamideh Mortazavi, Saeed Sadeghian, Ali Vasheghani Farahani, Kaveh Hosseini, Arash Jalali, Keyvan Ghasemi, Mehdi Mehrani, and Masih Tajdini
- Subjects
atrioventricular block ,drug-induced atrioventricular block ,permanent pacemaker. ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: A permanent pacemaker (PPM) is necessary for patients with a symptomatic third-degree or advanced second-degree atrioventricular (AV) block. An AV block due to medication use can often be reversed; however, subsequent relapse can occur and necessitate subsequent PPM implantation. The aim of this study was to explore the course and prognosis of patients with an AV block. Methods: This historical cohort study was conducted between January 2013 and June 2018. A total of 1900 patient records were analyzed and 1123 subjects with an AV block on admission were enrolled. The patients were categorized into 2 groups: Group 1 comprised patients with an AV block due to medication use (n=316, 28%) and Group 2 included patients with an AV block caused by other etiologies (n=807, 72%). Data of the cause of AV block, recurrence, and PPM implantation were analyzed. Patients in both groups who did not require a PPM during the index admission were followed up regarding subsequent implantation of a PPM. Results: AV conduction was recovered in 38 (12%) patients in Group 1 and 48 (6%) patients in Group 2 during the index hospitalization. However, recurrence of the AV block was observed in 18% of Group 1 patients and 40% of Group 2 patients. Only 25 patients in each group (4.5% of the whole study population) remained PPM-free during a median 3-year follow-up period. Conclusion: The study findings suggest that drug-induced AV blocks may not be as benign as previously thought. The high relapse rate indicates that watchful follow-up may be required despite discontinuation of the responsible medication and that consideration of earlier PPM implantation in cases of early recurrence may be warranted.
- Published
- 2020
- Full Text
- View/download PDF
3. Coronary slow flow phenomenon and microalbuminuria: Is there any relationship?
- Author
-
Alireza Amirzadegan, Rosa Ghaderpanah, Elham Rayzan, Arya Aminorroaya, and Masih Tajdini
- Subjects
coronary slow flow phenomenon ,coronary slow flow ,endothelial dysfunction ,microalbuminuria. ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: The pathophysiology of coronary slow flow phenomenon (CSFP) is poorly understood. Evidence suggesting endothelial dysfunction in patients with slow coronary flow (SCF) led to this evaluation of a possible correlation between microalbuminuria (MAU), as an indicator of endothelial dysfunction, and CSFP in order to investigate a mutual pathophysiology. Methods: In this case-control study, 15786 patients who presented between September 2016 and April 2018 were screened. All patients with CSFP had chest pain and coronary angiography was indicated due to a positive noninvasive test. All cases had a Thrombosis in Myocardial Infarction (TIMI) flow grade of 2 or a corrected TIMI frame count of >27 without any evidence of obstructive coronary artery disease. The patients used as controls had completely normal coronary angiograms. Fasting mid-stream urine samples were analyzed using an immunoturbidimetric assay to determine the albumin-creatinine ratio (ACR) as a surrogate of microalbuminuria (MAU) (ACR: 30–300 mg/g). The prevalence of MAU in the case and control groups was analyzed. Results: A total of 154 individuals with a normal coronary angiogram and 46 patients with SCF were enrolled in the study. The prevalence of MAU was greater in patients with SCF than in the control group (8.7% vs 1.9%, respectively; p=0.048). Even after adjustment for major risk factors, the association between MAU and CSPF remained significant. Conclusion: The results of this study indicated that there was a relationship between MAU and CSFP and confirmed that endothelial dysfunction is a contributing factor to CSFP. These findings are of utmost importance due to the prognostic value of MAU for both all-cause and cardiovascular mortality rates.
- Published
- 2019
- Full Text
- View/download PDF
4. Complicated endocarditis with bilateral pseudoaneurysm formation in a patient with valvular heart disease
- Author
-
Reza Mohseni Badalabadi, Mehdi Mohseni Badalabadi, Kyomars Abbasi, and Masih Tajdini
- Subjects
endocarditis ,pseudoaneurysm ,valvular heart disease ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2020
- Full Text
- View/download PDF
5. Unusual case of tricuspid atresia and transposition of the great arteries presenting with aortic dissection: A rare condition
- Author
-
Keyvan Ghasemi, Ali Hosseinsabet, Saeed Tofighi, and Masih Tajdini
- Subjects
tricuspid atresia ,transposition of the great arteries ,aortic dissection ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2020
- Full Text
- View/download PDF
6. Clinical implications and indicators of mortality among patients hospitalized with concurrent COVID-19 and myocardial infarction
- Author
-
Mina Pashang, Maryam Masoudi, Hamidreza Pourhosseini, Kaveh Hosseini, Hamed Tavolinejad, Reza Mohseni Badalabadi, Babak Sattartabar, Masoumeh Lotfi-Tokaldany, Afsaneh Aein, Masih Tajdini, Farzad Masoudkabir, Akbar Shafiee, and Saeed Sadeghian
- Subjects
Male ,Acute coronary syndrome ,medicine.medical_specialty ,Myocardial Infarction ,Internal medicine ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Myocardial infarction ,Blood urea nitrogen ,Aged ,Retrospective Studies ,Aged, 80 and over ,Management of acute coronary syndrome ,business.industry ,COVID-19 ,Retrospective cohort study ,Length of Stay ,Middle Aged ,medicine.disease ,RC31-1245 ,RC666-701 ,Absolute neutrophil count ,Medicine ,Myocardial infarction complications ,Female ,Myocardial infarction diagnosis ,business - Abstract
Objective Acute ischemic cardiac events can complicate coronavirus disease 2019 (COVID-19). We report the in-hospital characteristics of patients with acute myocardial infarction and concomitant COVID-19. Methods This was a registry-based retrospective analysis of patients admitted with positive COVID-19 tests who suffered acute myocardial infarction either before or during hospitalization; from 1 March 2020 to 1 April 2020 in a tertiary cardiovascular center-Tehran Heart Center. We performed an exploratory analysis to compare the clinical characteristics of patients who died during hospitalization or were discharged alive. Results In March 2020, 57 patients who had acute myocardial infarction and a confirmed diagnosis of COVID-19 were included in the study. During hospitalization, 13 patients (22.8%) died after a mean hospital stay of 8.4 days. The deceased were older than the survivors. No significant association between mortality and sex or length of hospital stay was observed. Hypertensive individuals were more likely to have a fatal outcome. Previously receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers did not show any association with mortality. Regarding the laboratory data during hospitalization, higher cardiac troponin T, neutrophil count, C-reactive protein, urea, and blood urea nitrogen/creatinine ratio were observed in the mortality group. The deceased had a lower lymphocyte count than the survivors. Conclusions Markers of worsening renal function and immune system disturbance seem to be associated with mortality in concurrent acute myocardial infarction and COVID-19. Optimizing the management of acute coronary syndrome complicating COVID-19 requires addressing such potential contributors to mortality.
- Published
- 2021
- Full Text
- View/download PDF
7. Prognostic Impact of Prediabetes on Patient Outcomes After Coronary Artery Bypass Grafting: A Single-center Cohort Study
- Author
-
Mina Pashang, Ali Sheikhy, Abbas Salehi Omran, Ali Vasheghani Farahani, Jamshid Bagheri, M Shirzad, Saeed Sadeghian, Aida Fallahzadeh, Masih Tajdini, Farzad Masoudkabir, Kaveh Hosseini, and Hamed Tavolinejad
- Subjects
medicine.medical_specialty ,business.industry ,Hazard ratio ,Prognosis ,medicine.disease ,Cohort Studies ,Prediabetic State ,Coronary artery disease ,Percutaneous Coronary Intervention ,Treatment Outcome ,Diabetes mellitus ,Internal medicine ,Risk of mortality ,medicine ,Cardiology ,Humans ,Prospective Studies ,Prediabetes ,Coronary Artery Bypass ,Cardiology and Cardiovascular Medicine ,business ,Prospective cohort study ,Glycemic ,Cohort study - Abstract
BACKGROUND Prediabetes, as a precursor stage, has an important role in development of overt diabetes as well as coronary artery disease (CAD). The aim of this study is to evaluate the association between prediabetes and adverse outcomes (major adverse cardiovascular and cerebrovascular events [MACCE] and all-cause mortality) in patients who underwent coronary artery bypass grafting (CABG). METHODS In this prospective study, we included 3754 patients with CAD who underwent elective isolated CABG between January 2016 to January 2020. Patients were categorized based on their glycemic status at the time of CABG as follows: diabetics (n = 2707), prediabetics (n = 471), and nondiabetics (n = 576). Primary endpoints were occurrence of all-cause mortality and MACCE. RESULTS We studied 3754 patients for a median of 32.25 months after CABG. MACCE occurred in 474 (12.6%) patients. After adjusting for potential confounders, diabetic patients had a higher risk of MACCE (hazard ratio [HR] 1.69; 95% confidence intervals [CI], 1.24-2.29) and death (HR 2.33, 95% CI, 1.45-3.7) compared with nondiabetic and prediabetic ones. However, patients with prediabetes had lower HR of MACCE, but the association was nonsignificant (HR 1.02; 95% CI, 0.67-1.56). CONCLUSIONS Diabetes is significantly associated with higher risk of mortality and MACCE; however, prediabetes did not show a prognostic impact in terms of overall and MACCE-free survival.
- Published
- 2021
- Full Text
- View/download PDF
8. Personalized medicine in cardiovascular disease: review of literature
- Author
-
Ali Sheikhy, Mandana Hasanzad, Masih Tajdini, Aida Fallahzadeh, Hamid Reza Aghaei Meybodi, and Kaveh Hosseini
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,Warfarin ,Review Article ,Disease ,Clopidogrel ,medicine.disease ,Human genetics ,Coronary artery disease ,Internal Medicine ,medicine ,Drug reaction ,Personalized medicine ,business ,Intensive care medicine ,Genetic testing ,medicine.drug - Abstract
PURPOSE: Personalized medicine (PM) is the concept of managing patients based on their characteristics, including genotypes. In the field of cardiology, advantages of PM could be found in the diagnosis and treatment of several conditions such as arrhythmias and cardiomyopathies; moreover, it may be beneficial to prevent adverse drug reactions (ADR) and select the best medication. Genetic background can help us in selecting effective treatments, appropriate dose requirements, and preventive strategies in individuals with particular genotypes. METHOD: In this review, we provide examples of personalized medicine based on human genetics for the most used pharmaceutics in cardiology, including warfarin, clopidogrel, and statins. We also review cardiovascular diseases, including coronary artery disease, arrhythmia, and cardiomyopathies. CONCLUSION: Genetic factors are as important as environmental factors and they should be tested and evaluated more in the future by improving in genetic testing tools. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40200-021-00840-0.
- Published
- 2021
- Full Text
- View/download PDF
9. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial
- Author
-
Roghayeh Mohammadi, Hamed Tavolinejad, Behzad Rahimi, Arya Aminorroaya, Farshid Alaeddini, Alireza Oraii, Adel Joharimoghadam, Masih Tajdini, Saeed Oraii, Hamid Ariannejad, Saeed Sadeghian, Abolfazl Mohsenizade, Javad Shahabi, Mohamadreza Kiarsi, Reza Mollazadeh, Zahra Emkanjoo, Arash Jalali, Ali Bozorgi, Sanatcha Apakuppakul, Mohammad Ali Akbarzadeh, and Tachapong Ngarmukos
- Subjects
Pediatrics ,medicine.medical_specialty ,Randomization ,Fludrocortisone ,Midodrine ,Anti-Inflammatory Agents ,Syncopal episodes ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Quality of life ,Randomized controlled trial ,Recurrence ,law ,Surveys and Questionnaires ,Syncope, Vasovagal ,medicine ,Humans ,030212 general & internal medicine ,Vasovagal syncope ,business.industry ,medicine.disease ,Treatment Outcome ,Quality of Life ,Drug Therapy, Combination ,Adrenergic alpha-1 Receptor Agonists ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background The cornerstone of the treatment of vasovagal syncope (VVS) is lifestyle modifications; however, some patients incur life-disturbing attacks despite compliance with these treatments which underscores the importance of pharmacological interventions. Methods In this open-label multi-center randomized controlled trial, we are going to randomize 1375 patients with VVS who had ≥2 syncopal episodes in the last year into three parallel arms with a 2:2:1 ratio to receive midodrine, fludrocortisone, or no medication. All patients will be recommended to drink 2 to 3 liters of fluids per day, consume 10 grams of NaCl per day, and practice counter-pressure maneuvers. In medication arms, patients will start on 5 mg of midodrine TDS or 0.05 mg of fludrocortisone BD. After one week the dosage will be up-titrated to midodrine 30 mg/day and fludrocortisone 0.2 mg/day. Patient tolerance will be the principal guide to dosage adjustments. We will follow-up the patients on 3, 6, 9, and 12 months after randomization. The primary outcome is the time to first syncopal episode. Secondary outcomes include the recurrence rate of VVS, time interval between first and second episodes, changes in quality of life (QoL), and major and minor adverse drug reactions. QoL will be examined by the 36-Item Short Form Survey questionnaire at enrollment and 12 months after randomization. Conclusion The COMFORTS trial is the first study that aims to make a head-to-head comparison between midodrine and fludrocortisone, against a background of lifestyle modifications for preventing recurrences of VVS and improving QoL in patients with VVS.
- Published
- 2021
- Full Text
- View/download PDF
10. Intrapericardial solitary fibrous tumor: A case report and review of literature
- Author
-
Ali Sheikhy, Aida Fallahzadeh, Kaveh Hosseini, Masih Tajdini, Seyyed Mojtaba Ghorashi, Reza Mohseni-Badalabadi, Seyed Hossein Ahmadi-Tafti, and Narges Shahbazi
- Subjects
Adult ,Solitary fibrous tumor ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Malignancy ,Complete resection ,Heart Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Edema ,Humans ,Medicine ,Pericardium ,Radiology, Nuclear Medicine and imaging ,Heart Atria ,business.industry ,medicine.disease ,medicine.anatomical_structure ,Ventricle ,Solitary Fibrous Tumors ,030220 oncology & carcinogenesis ,Cardiac chamber ,Female ,Radiology ,medicine.symptom ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Calcification - Abstract
Solitary fibrous tumor (SFT) is a mesenchymal neoplasm mostly originates from pleura, but rarely from other parts of the body including pericardium. We report a case of a 44-year-old woman with dyspnea and intermittent edema in whom a large intrapericardial mass was discovered by echocardiography. Computed tomography (CT) revealed a focal pericardial calcification in right AV grove with pressure on right ventricle and right atrial, with no connection to cardiac chambers. Histopathological findings after complete resection of the mass revealed fibroconnective tissue with heavy calcification and no evidence of inflammation or malignancy. We reviewed the literature on pericardial solitary fibrous tumors up to 2020.
- Published
- 2021
- Full Text
- View/download PDF
11. Cost-Effectiveness of Endovascular Versus Open Repair of Abdominal Aortic Aneurysm: A Systematic Review
- Author
-
Ali Abutorabi, Javad Salimi, Vahid Alipour, Shahin Nargesi, and Masih Tajdini
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Cost effectiveness ,Cost-Benefit Analysis ,Long Term Adverse Effects ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Global health ,Humans ,Medicine ,Pharmacology (medical) ,health care economics and organizations ,Pharmacology ,Surgical repair ,Health economics ,business.industry ,Patient Selection ,Endovascular Procedures ,General Medicine ,Cost-effectiveness analysis ,medicine.disease ,Checklist ,Abdominal aortic aneurysm ,030104 developmental biology ,Economic evaluation ,Emergency medicine ,Risk Adjustment ,Cardiology and Cardiovascular Medicine ,business ,Vascular Surgical Procedures ,Aortic Aneurysm, Abdominal - Abstract
Abdominal aortic aneurysm (AAA) is a life-threatening condition which, in the absence of increasing diameter or rupture, often remains asymptomatic, and a diameter greater than 5.5 cm requires elective surgical repair. This study aimed to evaluate the cost-effectiveness of endovascular repair (EVAR) versus open surgical repair (OSR) in patients with AAA through a systematic review of published health economics studies. Using a systematic review method, an electronic search was conducted for cost-effectiveness studies published on AAA (both in English and Persian) on PubMed, Embase, ISI/Web of Science (WoS), SCOPUS, Global Health databases, and the national databases of Iran from 1990 to 2020 including the keywords “cost-effectiveness”, “endovascular”, “open surgical”, and “abdominal aortic aneurysms”. The quality of the studies was assessed using the Quality of Health Economic Studies (QHES) checklist. In total, 958 studies were found, of which 16 were eligible for further study. All studies were conducted in developed countries, and quality-adjusted life years (QALY) and life years (LY) were used to measure the outcomes. According to the QHES checklist, most studies were of good quality. In European countries and Canada, EVAR has not been cost-effective, while most studies in the United States regard this technique as a cost-effective intervention. For example, incremental cost-effectiveness ratio (ICER) values ranged from $14,252.12 to $34,446.37 per QALY in the USA, while ICER was €116,600.40 per QALY in Portugal. According to the results, the EVAR technique has been more cost-effective than OSR for high-risk patients, but the need for continuous follow-up, increased costs, and re-intervention over the long term and for low-risk patients has reduced the cost-effectiveness of this method. As the health systems vary among different countries (i.e. quality of care, cost of devices, etc.), and due to the heterogeneity of studies in terms of the follow-up period, time horizon, and threshold, all of which are inherent features of economic evaluation, generalizing the results should be done with much caution, and policymaking must be based on national evidence.
- Published
- 2021
- Full Text
- View/download PDF
12. Association of folate and vitamin B12 deficiency with vasovagal syncope: a case-control study
- Author
-
Masih Tajdini, Ali Bozorgi, S Sadeghian, Masud Yunesian, Hamed Tavolinejad, Mohamamdali Boroumand, Ali Vasheghani-Farahani, Somayeh Yadangi, Arya Aminorroaya, and Arash Jalali
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Case-control study ,Medicine ,Vitamin B12 ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease ,Vasovagal syncope - Abstract
Background Studies demonstrated an association between vitamin B12 deficiency and vasovagal syncope (VVS) in pediatric patients. Moreover, some evidence suggested a pathophysiological role of plasma catecholamines elevation in VVS, which can arise from folate or vitamin B12 deficiency in terms of biochemical pathways. Purpose We aimed to evaluate the association of folate and vitamin B12 deficiency with VVS in adults. Methods In this case-control study, adult patients (18–70 years of age) with the diagnosis of VVS based on history and physical examination (2018 ESC guidelines) who underwent a head-up tilt test (HUTT) were included as the case group. The control group comprised age- and sex-matched individuals who participated in a population-based cohort study. The most important exclusion criteria were taking vitamin B12 or folate supplements, carbamazepine and phenobarbital, and a history of bariatric surgeries. Plasma levels of vitamin B12, folate, homocysteine, and thyroid-stimulating hormone (TSH), a possible confounder, were measured by Abbott Diagnostics chemiluminescence kits. We compared categorical variables and continuous variables by Chi-square and t-test, respectively. Logistic regression models were employed for adjusting for possible confounders, including age, sex, and TSH. Results From February 2020 to February 2021, we screened 157 patients with VVS, of whom 44 patients were included. After matching for age and sex, 44 healthy individuals without a history of syncope were examined as the control group. The mean age was 37.9 years in both groups, with 23 women (52.3%) in each group. Baseline characteristics were comparable across the study groups. There were no significant differences between serum levels of vitamin B12, folate, homocysteine, and TSH, as well as the prevalence of deficiency of folate and vitamin B12 between case and control groups (Table 1), even after adjusting for confounding variables. Serum levels of vitamin B12 were remarkably lower in patients with a lifetime syncopal episodes of ≥3 compared to patients with Conclusions In this study, we found that there is no significant difference between the prevalence of folate and vitamin B12 deficiency and serum levels of these vitamins in adult patients with VVS and healthy individuals; however, serum vitamin B12 was significantly lower in patients with recurrent VVS compared to patients with a lower burden of syncopal episodes. Future studies with larger sample sizes are recommended in the recurrent VVS subgroup. Therapeutic implications of these findings should be investigated in randomized-controlled trials. Funding Acknowledgement Type of funding sources: Foundation. Main funding source(s): Iran National Science Foundation Table 1Table 2
- Published
- 2021
- Full Text
- View/download PDF
13. Frequency and predictors of physical trauma during reflex syncope
- Author
-
Somayeh Yadangi, S Sadeghian, Hamed Tavolinejad, Masih Tajdini, and Ali Bozorgi
- Subjects
Physical trauma ,business.industry ,Anesthesia ,Medicine ,Reflex syncope ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background Reflex syncope is a common and generally benign condition; however, the occurrence of secondary trauma can be a potentially harmful complication. Identification of characteristics and conditions associated with trauma after syncope are important for clinicians. Purpose We aimed to investigate the frequency and predictors of secondary injury during reflex syncope in a large dataset from a tertiary syncope unit. Methods All patients referred with an episode of transient loss of consciousness between December 2017 and November 2020 were evaluated. Patients who received a diagnosis of reflex syncope based on 2018 European Society of Cardiology guidelines entered the study. Clinical characteristics, conditions surrounding syncope, and – in patients with a history of previous episodes – a detailed history of up to three prior syncopal attacks were documented. The primary outcome was the presence of any clinically relevant injury that was related to syncope. In a secondary per-episode analysis, the outcome was a combination of traumatic injuries related to the current and past syncopal episodes. Results Among 1258 consecutive patients with reflex syncope (Mean age: 42.3 years; 49.6% female), 239 (23.3%) had evidence of trauma in their initial visit. Female sex (prevalence ratio [PR]: 1.24; P=0.037), body mass index ≥25 kg/m2 (PR: 1.28; P=0.016), previous injury caused by syncope (PR: 1.63; P Conclusions Secondary trauma after reflex syncope is a common complication. Specific conditions at the time of syncope are associated with traumatic injuries, suggesting that interventions to avoid syncopal attacks in those conditions might reduce secondary trauma. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Tehran University of Medical Sciences
- Published
- 2021
- Full Text
- View/download PDF
14. Impact of supervised physical training on vasovagal syncope; a randomized controlled trial
- Author
-
S Sadeghian, Masih Tajdini, F Aghajani, Ali Bozorgi, Somayeh Yadangi, S Niyazi, and Hamed Tavolinejad
- Subjects
medicine.medical_specialty ,Randomized controlled trial ,law ,business.industry ,Physical therapy ,medicine ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease ,Vasovagal syncope ,law.invention - Abstract
Background Therapeutic interventions in vasovagal syncope (VVS) are centered on lifestyle modifications aimed to counteract the recognized mechanisms that precipitate syncope. In patients with recurrent VVS, supervised training might help reduce the symptomatic burden by increasing adherence to lifestyle modifications. Purpose We aimed to evaluate the effect of an integrated supervised training program versus standard care on syncopal recurrence rate among patients with VVS. Methods This randomized, controlled, 1:1 parallel-design, open-label trial was conducted between November 2019 and February 2021. Eligible patients were those aged between 18 and 70 years with newly-diagnosed medication-naïve VVS who had experienced ≥2 syncopal episodes in the prior year. All participants received education and reassurance about the benign nature of VVS, were advised to increase salt and fluid intake, and practice counter-pressure maneuvers based on 2018 European Society of Cardiology syncope guideline (standard care). Patients were randomized to standard VVS care or the training program. The intervention program consisted of thrice-weekly four-hours-long sessions during the first month after randomization; including tilt training, aerobic exercise (with rowing ergometer, recumbent biking), and standardized counter-pressure maneuvers supervised by a team of physical medicine and rehabilitation specialist and a cardiologist. After the first month, the intervention group were planned to attend a four-hours-long session every three months. The control group were followed by phone calls after the initial visit every three months. The intended follow-up duration was one year and the primary outcome was time to first syncopal episode. Results Out of 332 patients screened, 50 (mean age: 33.5 years; 64% female, figure 1) were equally randomized. Follow-up was completed for all participants. After one year, there was a significant reduction in syncope with supervised training compared to standard care (hazard ratio: 0.28; 95% confidence interval: 0.11 to 0.68; p=0.005, figure 2). Furthermore, frequency of syncope was lower in the supervised training arm versus standard of care (median [interquartile range]: 0 [0–1] versus 1 [0–3]; p=0.017). Conclusions In patients with recurrent VVS, supervised training showed promising results in reducing syncopal recurrence. Future research should focus on similar approaches to alter patients' lifestyle as an effective treatment for VVS. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Tehran University of Medical Sciences Figure 1Figure 2
- Published
- 2021
- Full Text
- View/download PDF
15. Comparison of trinitroglycerin and adenosine as provocative agents for head-up tilt test in patients with unexplained syncope: a semi-crossover randomized clinical trial with prospective follow-up
- Author
-
Danesh Soltani, Arya Aminorroaya, Ali Bozorgi, Saeed Sadeghian, Mehdi Easapour Moghadam, Seyedeh Hamideh Mortazavi, Masih Tajdini, Behzad Rahimi, and Ali Vasheghani Farahani
- Subjects
medicine.diagnostic_test ,biology ,business.industry ,Syncope (genus) ,Head up tilt ,030204 cardiovascular system & hematology ,Diagnostic evaluation ,medicine.disease ,biology.organism_classification ,law.invention ,03 medical and health sciences ,Tilt table test ,0302 clinical medicine ,Positive response ,Randomized controlled trial ,law ,Physiology (medical) ,Anesthesia ,Medicine ,In patient ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Vasovagal syncope - Abstract
Head-up tilt test (HUTT) is a reasonable diagnostic evaluation for patients with suspected vasovagal syncope; however, its lengthy duration is a remarkable limitation. Although adenosine (AD), as an alternative provocative agent, is a promising option for tackling this shortcoming, it received little appreciation in the literature. We aimed to compare the efficacy and the time to elicit a positive response to HUTT for sublingual trinitroglycerin (TNG) and intravenous AD. Furthermore, we evaluated patients’ outcomes in the follow-up. Patients with a chief complaint of transient loss of consciousness (TLOC) were evaluated. We randomized patients with the diagnosis of unexplained syncope after diagnostic evaluations, to undergo TNG-augmented HUTT or AD-augmented HUTT. They were crossed over to receive the other medication in case of negative response to the test. In the follow-up, we evaluated traumatic and non-traumatic TLOCs, hospitalization due to syncope, and death in patients. We randomized 132 patients (41.70 ± 19.37 years, 52.3% female) to receive TNG (n = 66) or AD (n = 66). Respectively, the positivity rate of TNG and AD for the first and the crossover-HUTT was 31.1% and 26.7%, and 20.5% and 26.2% with no statistically significant differences in both tests (P ˃ 0.50). The time to positive response was significantly shorter for AD than TNG (P < 0.001). In the follow-up, re-admission was significantly more prevalent in HUTT-negative patients compared to HUTT-positive patients (P = 0.04). We found that diagnostic yield of TNG and AD in HUTT is comparable, while AD acts 4 times faster than TNG in evoking a vasovagal response.
- Published
- 2020
- Full Text
- View/download PDF
16. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
- Author
-
Vahid Alipour, Masih Tajdini, Masoud Behzadifar, Nicola Luigi Bragazzi, Aziz Rezapour, Negar Omidi, Samad Azari, and Hossein Safari
- Subjects
medicine.medical_specialty ,Cost effectiveness ,business.industry ,Cost-Benefit Analysis ,PCSK9 Inhibitors ,Cost-effectiveness analysis ,Disease ,Systematic review ,Cardiovascular Diseases ,Risk Factors ,medicine ,Life years gained ,Humans ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Developed country ,health care economics and organizations - Abstract
To assess the cost-effectiveness of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in cardiovascular disease. We performed a comprehensive search strategy in electronic databases from January 2015 to January 2019. Out of 475 articles, 16 were entered into the study. Quality-adjusted life year, life years gained (LYG), annual cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of PCSK9 inhibitors were considered as the key outcomes. The cost-effectiveness threshold varied from $45,000 in Spain to $150,000 in the USA. The annual cost of PCSK9 inhibitors for studies undertaken in the USA was in the range of $14,000 to $15,000, while it was about $7000 for other developed countries. The results showed that reduction in the price of PCSK9 inhibitors changed from 20 to 88%. The means of QALY were 0.65 and 0.67 in the Markov and Cardiovascular Disease Policy Modeling (CVDPM) models; also, the ICER means were $197,707 and $625,555 for the Markov and CVDPM model, respectively. According to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors. This study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).
- Published
- 2019
- Full Text
- View/download PDF
17. A systematic review of the cost-effectiveness of heart valve replacement with a mechanical versus biological prosthesis in patients with heart valvular disease
- Author
-
Saeed Sadeghian, Nicola Luigi Bragazzi, Aziz Rezapour, Vahid Alipour, Negar Omidi, Samad Azari, and Masih Tajdini
- Subjects
medicine.medical_specialty ,Cost effectiveness ,Cost-Benefit Analysis ,medicine.medical_treatment ,Population ,Heart Valve Diseases ,030204 cardiovascular system & hematology ,Prosthesis ,03 medical and health sciences ,0302 clinical medicine ,Valve replacement ,medicine ,Humans ,030212 general & internal medicine ,Heart valve ,education ,Survival rate ,Heart Valve Prosthesis Implantation ,education.field_of_study ,business.industry ,Mortality rate ,Health Care Costs ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Heart Valve Prosthesis ,Heart failure ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine ,business - Abstract
Heart valve disease (HVD) affects 2.5% of the US population and one million individuals aged 65 years and older in the UK. Given its burden, the aim of the present review was to assess the cost-effectiveness of heart valve replacement with mechanical versus biological prosthesis in HVD patients. We performed a systematic search in various electronic databases from January 1990 to June 2019. Five out of 542 articles were entered into the study, from which 2 papers were subsequently excluded not meeting the minimum number of items of the CHEERS checklist. Quality-Adjusted Life Year, Life Years Gained, and the Incremental Cost-Effectiveness Ratio (ICER) regarding the type of replaced heart valve were extracted and reported. Studies were conducted in three different countries (Iran, France, and USA). ICER ranged from $1253 in Iran to €54,634 in France. Survival rate of mitral mechanical versus biological valves at 10 and 20 years was 72.9% versus 76.0% and 51% versus 30%, respectively. Survival rate at 20 years in patients undergoing atrial valve replacement was 20%. Ten- and 20-year death rates for biological valves were higher with respect to mechanical prosthesis (15.5% versus 8.4% at 10 years), with this difference becoming more relevant at 20 years (36.9% versus 13.9%). Due to higher ICER, mortality rate, and lower success rates in the long term for biological prostheses compared to mechanical ones, these appear to be more suitable for older patients (aged ≥ 70 years).
- Published
- 2019
- Full Text
- View/download PDF
18. Mid-term Outcome and Prognosis of Prediabetic Patients After Coronary Artery Bypass Graft Surgery, Regardless of the First Month After Surgery
- Author
-
Kaveh Hosseini, Masih Tajdini, Abbasali Karimi, Saeed Sadeghian, and Arash Jalali
- Subjects
Male ,Acute coronary syndrome ,medicine.medical_specialty ,Coronary Artery Disease ,Iran ,030204 cardiovascular system & hematology ,Risk Assessment ,Time ,Prediabetic State ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Diabetes mellitus ,Outcome Assessment, Health Care ,medicine ,Humans ,Prediabetes ,Coronary Artery Bypass ,Adverse effect ,Survival analysis ,Retrospective Studies ,Glycated Hemoglobin ,business.industry ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Surgery ,medicine.anatomical_structure ,Diabetes Mellitus, Type 2 ,Female ,Cardiology and Cardiovascular Medicine ,business ,Mace ,Artery - Abstract
OBJECTIVE Current knowledge of the effects of prediabetes on the postsurgical outcomes of mortality and major adverse cardiovascular events (MACE) after coronary artery bypass graft surgery (CABG) is limited. The aim of this study is to evaluate the MACE and overall 1-year survival of patients with prediabetes who underwent elective isolated CABG. MATERIAL AND METHODS After a thorough analysis of CABG database since January 2016, 3741 patients were included. Patients were categorized as follows: diabetes mellitus type 2 (n = 2695), prediabetics (fasting blood sugar = 100-125 mg/dL and hemoglobin A1c (HbA1c) = 5.7%-6.4%) (n = 471), and nondiabetics (fasting blood sugar < 100 mg/dL and HbA1c < 5.7%) (n = 575). Primary end point (MACE) was the composite death, acute coronary syndrome, coronary revascularization, and cerebrovascular events after 1 month of surgery. Event-free survival was assessed and compared between groups over a median follow-up of 1 year. RESULTS In this retrospective cohort design, 3741 patients who underwent elective isolated CABG were evaluated. One-year overall survival percent was 100% for nondiabetic and prediabetic patients and 99.9% for diabetic patients (P value = 0.56). One-year event-free survival was 97.4% for nondiabetics, 98.1% for prediabetics, and 96.8% for diabetic patients (P value = 0.08). CONCLUSIONS One-year overall survival and also the event-free survival of prediabetic patients were similar to those without diabetes mellitus. Over the median follow-up of 1 year, descending trends shows the higher probability of adverse events in diabetic patients with longer follow-ups.
- Published
- 2019
- Full Text
- View/download PDF
19. Diagnostic accuracy of 64-Slice computed tomography angiography in patients with chest pain vs. SPECT in the assessment of significant Coronary Artery Disease: A systematic review and meta-analysis.]
- Author
-
Masih Tajdini, Sajad Alaei, Maryam Jamali, Rajabali Daroudi, Ali Akbarisari, and Sahar Salehi
- Subjects
Receiver operating characteristic ,medicine.diagnostic_test ,business.industry ,Computed Tomography Angiography ,specificity ,Coronary Artery Disease ,Chest pain ,medicine.disease ,sensitivity ,Confidence interval ,lcsh:QH705-705.5 ,Coronary artery disease ,Single-photon emission computed tomography (SPECT) ,Meta-analysis ,lcsh:Economic biology ,medicine ,In patient ,medicine.symptom ,Nuclear medicine ,business ,Emission computed tomography ,Computed tomography angiography - Abstract
Context: This systematic review and meta-analysis intended to investigate the diagnostic accuracy of computed tomography angiography (CTA) in comparison with single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease (CAD) in chest pain patients with no history of cardiovascular diseases (CVDs). Methods: Invasive angiography was considered as the reference test with a stenosis threshold of ≥ 50%. Cochrane, Scopus, Science Direct, PubMed, and Embase databases were comprehensively searched from the time of inception of these databases to May 15, 2018. A manual search in Google Scholar, a reference review of the obtained studies, and a review of gray literature (including those presented in conferences and congresses) regarding diagnostic performances of CTA and SPECT techniques were performed independently by two researchers. A meta-analysis was performed to determine pooling estimates of sensitivity, specificity, diagnostic odds ratio, and positive as well as negative likelihood ratios in CTA and SPECT tests. According to the 2 × 2 contingency table of each study, at 0.95 confidence interval, the diagnostic accuracy of CTA and SPECT was meta-analyzed by pooling estimates of sensitivity, specificity, diagnostic odds ratio (DOR), and positive and negative likelihood ratios based on DerSimonian-Laird’s random-effects model. Heterogeneity was assessed by calculating I2. Analyses were performed using MetaDiSc version 1.4 and Stata version 11. The qualities of the selected studies were assessed independently by two researchers according to the quality assessment of diagnostic accuracy studies (QUADAS) questionnaire. Sensitivity analyses were performed by the Jackknife method. Publication bias was evaluated by Deeks’ funnel plot. Results: Fourteen studies related to CTA (1206 individuals) and 15 related to SPECT (1638 individuals) were eligible for meta-analysis. The pooled sensitivity and the specificity of CTA for CAD diagnosis were 91% (95% CI, 88% - 94%) and 87% (95% CI, 84% - 98%), respectively. The pooled positive and negative likelihood ratios, the diagnostic odds ratio, and the area under the ROC curve for CTA were 7.93 (95% CI, 5.11 - 12.29), 0.1 (95% CI, 0.06 - 0.17), 95.71 (95% CI, 59.81 - 153.15), and 0.96, respectively. The pooled sensitivity and the specificity of SPECT for CAD diagnosis were 81% (95% CI, 79% - 83%) and 74% (95% CI, 71% - 78%), respectively. The pooled positive and negative likelihood ratios, the diagnostic odds ratio, and the area under the ROC curve for SPECT were 3.03 (95% CI, 2.34 - 3.91), 0.25 (95% CI, 0.21 - 0.30), 13.56 (95% CI, 10.60 - 12.34), and 0.86, respectively. According to the sensitivity analyses, the removal of any single study at a time did not change the effect size of the remaining studies. We observed symmetry in the Deeks’ funnel plot, indicating that there was ignorable publication bias for CTA and SPECT studies. Conclusions: This study demonstrated that the diagnostic accuracies of CTA and SPECT tests lie in the ‘excellent’ and the ‘very good’ ranges, respectively. CTA is stronger evidence, than SPECT, to rule out CVDs in patients with low and intermediate risks of CAD with no history of cardiovascular diseases.
- Published
- 2021
20. Sex difference in the risk factor distributions and outcomes after coronary artery bypass graft surgery in the young population
- Author
-
Farzaneh Majdi Nassab, Negin Yavari, Mina Pashang, Arash Jalali, Hamidreza Poorhosseini, Abbas Salehi Omran, Seyed Hossein Ahmadi Tafti, Masih Tajdini, Mahdi Nalini, Mojtaba Salarifar, Saeed Sadeghian, Kaveh Hosseini, and Jamshid Bagheri
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Population ,Subgroup analysis ,Coronary Artery Disease ,Coronary artery disease ,Percutaneous Coronary Intervention ,Risk Factors ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Humans ,Risk factor ,Coronary Artery Bypass ,education ,education.field_of_study ,Sex Characteristics ,business.industry ,Hazard ratio ,General Medicine ,Middle Aged ,medicine.disease ,Obesity ,Confidence interval ,Surgery ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVES Coronary artery disease is becoming a major health concern in the young population. Male and female patients may experience different journeys after coronary artery disease events. We aimed to evaluate risk factors and compare outcomes between young male and female patients undergoing coronary artery bypass graft surgery (CABG). METHODS In this registry-based large sample size study, patients undergoing isolated CABG at a young age (premature isolated CABG) between 2007 and 2016 were included and followed up until 2020. Premature was defined as women and men younger than 55 years old. The main end points of the study were 7-year all-cause mortality and 7-year major adverse cardiovascular and cerebrovascular events (MACCEs). RESULTS Of a total of 24 428 patients who underwent CABG, 7217 patients (men-to-women ratio ≈4:1) with premature isolated CABG were included. The median follow-up duration was 78.5 months (75.2–81.6 months). The prevalence rates of diabetes mellitus, hypertension, dyslipidaemia and obesity were significantly higher in women than in men (58.3% vs 28.6%, 64.2% vs 38.5%, 69.7% vs 55.3% and 44.7 vs 23.9, respectively; all Ps < 0.05). The risk factor burden (mean of the risk factor count per year) was also higher among the female population. Diabetes mellitus was the common mortality predictor between men and women. In the subgroup analysis (interaction analysis in the adjusted model), hypertensive females had a higher rate of MACCE and a higher rate of mortality than hypertensive males; however, this difference was not significant in the non-hypertensive population. Opium addiction was a strong predictor of MACCE and all-cause mortality among men. Female patients had a higher rate of 7-year MACCE (hazard ratio, 1.33; 95% confidence interval, 1.16–1.51) and a higher rate of 7-year all-cause mortality (hazard ratio, 1.23; 95% confidence interval, 0.98–1.53). CONCLUSIONS The risk factor profile and predictors of outcomes were different between our female and male patients. Women carried a higher risk of events and mortality after CABG at a young age.
- Published
- 2021
21. Differences in the 2020 ESC versus 2019 ACC/AHA/HRS guidelines on atrial fibrillation
- Author
-
Ali Bozorgi, Masih Tajdini, and Alireza Oraii
- Subjects
medicine.medical_specialty ,business.industry ,MEDLINE ,Cardiology ,Atrial fibrillation ,American Heart Association ,medicine.disease ,United States ,Text mining ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
22. Cardiovascular health effects of wearing a particulate-filtering respirator to reduce particulate matter exposure: a randomized crossover trial
- Author
-
Saeed Sadeghian, Mohammad Sadegh Hassanvand, Ramin Nabizadeh Nodehi, Masih Tajdini, Robert D. Brook, Kazem Naddafi, Sasan Faridi, and Mansour Shamsipour
- Subjects
medicine.medical_specialty ,business.product_category ,030204 cardiovascular system & hematology ,Iran ,Cardiovascular System ,03 medical and health sciences ,0302 clinical medicine ,Heart Rate ,Heart rate ,Internal Medicine ,medicine ,Heart rate variability ,Humans ,030212 general & internal medicine ,Respirator ,Cross-Over Studies ,Ventilators, Mechanical ,business.industry ,Exhalation ,Crossover study ,Confidence interval ,Blood pressure ,Ambulatory ,Physical therapy ,Particulate Matter ,business - Abstract
This randomized crossover trial sought to determine whether wearing a high-efficiency particulate-filtering respirator (PFR) improves cardiovascular function over 48 h among healthy college students in Tehran. This trial was conducted from February 14th to 23rd, 2019 and twenty-six participants completed two 48-h intervention periods. Brachial blood pressure (BP) measured by 24-h ambulatory monitoring was the primary health outcome. Secondary outcomes included 48-h heart rate variability (HRV) indices, high-sensitive cardiac troponin (hs-TnT) and other biomarkers. The participants wore the PFR between 10.2 and 11.1 h while awake during the interventions. More than 80% of participants reported increased respiratory resistance while wearing the PFR due to a lack of an exhalation valve. There were no significant differences in brachial BP levels between subjects who wore PFR respirator and those did not. Except for high frequency (HF) power and heart rate (HR), no significant differences between interventions were observed for other HRV metrics. Wearing the PFR led to an increase of 66.0 ms2 (95% confidence interval [CI], 9.6-110.5) and 79.6 ms2 (95% CI, 19.0-140.1) in HF power during the first day when the two groups of participants wore the PFR. Night-time HR was significantly increased during the PFR intervention period. Other secondary outcomes were not significantly different between interventions. It is plausible that incomplete exposure reduction due to wearing the PFR less than half of the time or increased respiratory resistance mitigated potential health benefits. Additional trials are warranted to validate the CV protection of wearing PFRs in heavily-polluted cities.
- Published
- 2020
23. Time for clinicians to revisit their perspectives on C-statistic
- Author
-
Farzad Masoudkabir, Masih Tajdini, and Arya Aminorroaya
- Subjects
Coronary angiography ,Actuarial science ,business.industry ,Treatment outcome ,Coronary arteriosclerosis ,Coronary Artery Disease ,Patient Readmission ,Implantable defibrillators ,Net reclassification improvement ,Radiation exposure ,Deep Learning ,Primary prevention ,Medicine ,Feasibility Studies ,Humans ,Cardiology and Cardiovascular Medicine ,business ,Emergency Service, Hospital ,Statistic - Published
- 2020
24. Atomoxetine in patients with recurrent vasovagal syncope for preventing vasovagal attacks and improvement of depression and anxiety: a randomized double-blind placebo-controlled clinical trial
- Author
-
Nazila Shahmansouri, Shahin Akhondzadeh, Arya Aminorroaya, S Sadeghian, Ali Vasheghani-Farahani, Ali Bozorgi, Hamed Tavolinejad, Saeed Tofighi, Arash Jalali, Somayeh Yadangi, and Masih Tajdini
- Subjects
Presyncope ,business.industry ,Reboxetine ,Atomoxetine ,Hospital Anxiety and Depression Scale ,medicine.disease ,Placebo ,Clinical trial ,Anesthesia ,medicine ,Anxiety ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Vasovagal syncope ,medicine.drug - Abstract
Background Studies showed that sibutramine or reboxetine reduced head-up tilt (HUT)-induced syncope and pre-syncope by 78%. Furthermore, in an open-label series of highly symptomatic patients with vasovagal syncope (VVS), sibutramine reduced frequency of vasovagal spells. In a recent proof of principle study, atomoxetine reduced number of HUT-induced syncopal episodes by about 50% compared to placebo. Purpose In this study, we aimed to evaluate the effectiveness of atomoxetine on preventing recurrence of syncopal and pre-syncopal episodes in patients with recurrent VVS after three months of follow-up. Moreover, we determined whether it can improve patients' anxiety and depression. Methods In this double-blind placebo-controlled randomized clinical trial, we screened 843 patients with VVS. Patients with 10 < age < 70 years who had ≥3 syncopal episodes in the past three months were included. Eventually, 46 patients were randomized to receive atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks, N=23) or placebo (for four weeks, N=23). The primary endpoint was the number of syncopal and pre-syncopal episodes at one and three months and was analyzed by the repeated measures analysis of variance. Secondary endpoints were decrements of depression and anxiety measured by the Hospital Anxiety and Depression Scale after three months and were analyzed by the Mann-Whitney U test. Results The primary endpoint was lower after three months in the atomoxetine arm (2.3±1.3 vs 4.3±1.7), with a significant between-subjects effect by atomoxetine versus placebo (P0.05, Figure). Conclusions In patients with VVS, atomoxetine significantly reduced the recurrence of a composite of syncopal and pre-syncopal episodes, and remarkably improved anxiety and depression at three months. Anxiety and Depression of the Patients Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Tehran University of Medical Sciences
- Published
- 2020
- Full Text
- View/download PDF
25. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study
- Author
-
Gregory A. Roth, George A. Mensah, Catherine O. Johnson, Giovanni Addolorato, Enrico Ammirati, Larry M. Baddour, Noël C. Barengo, Andrea Z. Beaton, Emelia J. Benjamin, Catherine P. Benziger, Aimé Bonny, Michael Brauer, Marianne Brodmann, Thomas J. Cahill, Jonathan Carapetis, Alberico L. Catapano, Sumeet S. Chugh, Leslie T. Cooper, Josef Coresh, Michael Criqui, Nicole DeCleene, Kim A. Eagle, Sophia Emmons-Bell, Valery L. Feigin, Joaquim Fernández-Solà, Gerry Fowkes, Emmanuela Gakidou, Scott M. Grundy, Feng J. He, George Howard, Frank Hu, Lesley Inker, Ganesan Karthikeyan, Nicholas Kassebaum, Walter Koroshetz, Carl Lavie, Donald Lloyd-Jones, Hong S. Lu, Antonio Mirijello, Awoke Misganaw Temesgen, Ali Mokdad, Andrew E. Moran, Paul Muntner, Jagat Narula, Bruce Neal, Mpiko Ntsekhe, Glaucia Moraes de Oliveira, Catherine Otto, Mayowa Owolabi, Michael Pratt, Sanjay Rajagopalan, Marissa Reitsma, Antonio Luiz P. Ribeiro, Nancy Rigotti, Anthony Rodgers, Craig Sable, Saate Shakil, Karen Sliwa-Hahnle, Benjamin Stark, Johan Sundström, Patrick Timpel, Imad M. Tleyjeh, Marco Valgimigli, Theo Vos, Paul K. Whelton, Magdi Yacoub, Liesl Zuhlke, Christopher Murray, Valentin Fuster, Noel C. Barengo, Andrea Beaton, Aime Bonny, Jonathan R. Carapetis, Sumeet Chugh, Michael H. Criqui, Nicole K. DeCleene, Joaquim Fernández-Sola, F. Gerry R. Fowkes, Nicholas J. Kassebaum, Walter J. Koroshetz, Awoke T. Misganaw, Ali H. Mokdad, Gláucia M.M. Oliveira, Catherine M. Otto, Mayowa O. Owolabi, Marissa B. Reitsma, Nancy A. Rigotti, Craig A. Sable, Saate S. Shakil, Karen Sliwa, Benjamin A. Stark, Imad I. Tleyjeh, Liesl J. Zuhlke, Mohsen Abbasi-Kangevari, Alireza Abdi, Aidin Abedi, Victor Aboyans, Woldu A. Abrha, Eman Abu-Gharbieh, Abdelrahman I. Abushouk, Dilaram Acharya, Tim Adair, Oladimeji M. Adebayo, Zanfina Ademi, Shailesh M. Advani, Khashayar Afshari, Ashkan Afshin, Gina Agarwal, Pradyumna Agasthi, Sohail Ahmad, Sepideh Ahmadi, Muktar B. Ahmed, Budi Aji, Yonas Akalu, Wuraola Akande-Sholabi, Addis Aklilu, Chisom J. Akunna, Fares Alahdab, Ayman Al-Eyadhy, Khalid F. Alhabib, Sheikh M. Alif, Vahid Alipour, Syed M. Aljunid, François Alla, Amir Almasi-Hashiani, Sami Almustanyir, Rajaa M. Al-Raddadi, Adeladza K. Amegah, Saeed Amini, Arya Aminorroaya, Hubert Amu, Dickson A. Amugsi, Robert Ancuceanu, Deanna Anderlini, Tudorel Andrei, Catalina Liliana Andrei, Alireza Ansari-Moghaddam, Zelalem A. Anteneh, Ippazio Cosimo Antonazzo, Benny Antony, Razique Anwer, Lambert T. Appiah, Jalal Arabloo, Johan Ärnlöv, Kurnia D. Artanti, Zerihun Ataro, Marcel Ausloos, Leticia Avila-Burgos, Asma T. Awan, Mamaru A. Awoke, Henok T. Ayele, Muluken A. Ayza, Samad Azari, Darshan B. B, Nafiseh Baheiraei, Atif A. Baig, Ahad Bakhtiari, Maciej Banach, Palash C. Banik, Emerson A. Baptista, Miguel A. Barboza, Lingkan Barua, Sanjay Basu, Neeraj Bedi, Yannick Béjot, Derrick A. Bennett, Isabela M. Bensenor, Adam E. Berman, Yihienew M. Bezabih, Akshaya S. Bhagavathula, Sonu Bhaskar, Krittika Bhattacharyya, Ali Bijani, Boris Bikbov, Mulugeta M. Birhanu, Archith Boloor, Luisa C. Brant, Hermann Brenner, Nikolay I. Briko, Zahid A. Butt, Florentino Luciano Caetano dos Santos, Leah E. Cahill, Lucero Cahuana-Hurtado, Luis A. Cámera, Ismael R. Campos-Nonato, Carlos Cantu-Brito, Josip Car, Juan J. Carrero, Felix Carvalho, Carlos A. Castañeda-Orjuela, Ferrán Catalá-López, Ester Cerin, Jaykaran Charan, Vijay Kumar Chattu, Simiao Chen, Ken L. Chin, Jee-Young J. Choi, Dinh-Toi Chu, Sheng-Chia Chung, Massimo Cirillo, Sean Coffey, Sara Conti, Vera M. Costa, David K. Cundiff, Omid Dadras, Baye Dagnew, Xiaochen Dai, Albertino A.M. Damasceno, Lalit Dandona, Rakhi Dandona, Kairat Davletov, Vanessa De la Cruz-Góngora, Fernando P. De la Hoz, Jan-Walter De Neve, Edgar Denova-Gutiérrez, Meseret Derbew Molla, Behailu T. Derseh, Rupak Desai, Günther Deuschl, Samath D. Dharmaratne, Meghnath Dhimal, Raja Ram Dhungana, Mostafa Dianatinasab, Daniel Diaz, Shirin Djalalinia, Klara Dokova, Abdel Douiri, Bruce B. Duncan, Andre R. Duraes, Arielle W. Eagan, Sanam Ebtehaj, Aziz Eftekhari, Sahar Eftekharzadeh, Michael Ekholuenetale, Nevine El Nahas, Islam Y. Elgendy, Muhammed Elhadi, Shaimaa I. El-Jaafary, Sadaf Esteghamati, Atkilt E. Etisso, Oghenowede Eyawo, Ibtihal Fadhil, Emerito Jose A. Faraon, Pawan S. Faris, Medhat Farwati, Farshad Farzadfar, Eduarda Fernandes, Carlota Fernandez Prendes, Pietro Ferrara, Irina Filip, Florian Fischer, David Flood, Takeshi Fukumoto, Mohamed M. Gad, Shilpa Gaidhane, Morsaleh Ganji, Jalaj Garg, Abadi K. Gebre, Birhan G. Gebregiorgis, Kidane Z. Gebregzabiher, Gebreamlak G. Gebremeskel, Lemma Getacher, Abera Getachew Obsa, Alireza Ghajar, Ahmad Ghashghaee, Nermin Ghith, Simona Giampaoli, Syed Amir Gilani, Paramjit S. Gill, Richard F. Gillum, Ekaterina V. Glushkova, Elena V. Gnedovskaya, Mahaveer Golechha, Kebebe B. Gonfa, Amir Hossein Goudarzian, Alessandra C. Goulart, Jenny S. Guadamuz, Avirup Guha, Yuming Guo, Rajeev Gupta, Vladimir Hachinski, Nima Hafezi-Nejad, Teklehaimanot G. Haile, Randah R. Hamadeh, Samer Hamidi, Graeme J. Hankey, Arief Hargono, Risky K. Hartono, Maryam Hashemian, Abdiwahab Hashi, Shoaib Hassan, Hamid Y. Hassen, Rasmus J. Havmoeller, Simon I. Hay, Khezar Hayat, Golnaz Heidari, Claudiu Herteliu, Ramesh Holla, Mostafa Hosseini, Mehdi Hosseinzadeh, Mihaela Hostiuc, Sorin Hostiuc, Mowafa Househ, Junjie Huang, Ayesha Humayun, Ivo Iavicoli, Charles U. Ibeneme, Segun E. Ibitoye, Olayinka S. Ilesanmi, Irena M. Ilic, Milena D. Ilic, Usman Iqbal, Seyed Sina N. Irvani, Sheikh Mohammed Shariful Islam, Rakibul M. Islam, Hiroyasu Iso, Masao Iwagami, Vardhmaan Jain, Tahereh Javaheri, Sathish Kumar Jayapal, Shubha Jayaram, Ranil Jayawardena, Panniyammakal Jeemon, Ravi P. Jha, Jost B. Jonas, Jitendra Jonnagaddala, Farahnaz Joukar, Jacek J. Jozwiak, Mikk Jürisson, Ali Kabir, Tanvir Kahlon, Rizwan Kalani, Rohollah Kalhor, Ashwin Kamath, Ibrahim Kamel, Himal Kandel, Amit Kandel, André Karch, Ayele Semachew Kasa, Patrick D.M.C. Katoto, Gbenga A. Kayode, Yousef S. Khader, Mohammad Khammarnia, Muhammad S. Khan, Md Nuruzzaman Khan, Maseer Khan, Ejaz A. Khan, Khaled Khatab, Gulam M.A. Kibria, Yun Jin Kim, Gyu Ri Kim, Ruth W. Kimokoti, Sezer Kisa, Adnan Kisa, Mika Kivimäki, Dhaval Kolte, Ali Koolivand, Vladimir A. Korshunov, Sindhura Lakshmi Koulmane Laxminarayana, Ai Koyanagi, Kewal Krishan, Vijay Krishnamoorthy, Barthelemy Kuate Defo, Burcu Kucuk Bicer, Vaman Kulkarni, G. Anil Kumar, Nithin Kumar, Om P. Kurmi, Dian Kusuma, Gene F. Kwan, Carlo La Vecchia, Ben Lacey, Tea Lallukka, Qing Lan, Savita Lasrado, Zohra S. Lassi, Paolo Lauriola, Wayne R. Lawrence, Avula Laxmaiah, Kate E. LeGrand, Ming-Chieh Li, Bingyu Li, Shanshan Li, Stephen S. Lim, Lee-Ling Lim, Hualiang Lin, Ziqiang Lin, Ro-Ting Lin, Xuefeng Liu, Alan D. Lopez, Stefan Lorkowski, Paulo A. Lotufo, Alessandra Lugo, Nirmal K. M, Fabiana Madotto, Morteza Mahmoudi, Azeem Majeed, Reza Malekzadeh, Ahmad A. Malik, Abdullah A. Mamun, Navid Manafi, Mohammad Ali Mansournia, Lorenzo G. Mantovani, Santi Martini, Manu R. Mathur, Giampiero Mazzaglia, Suresh Mehata, Man Mohan Mehndiratta, Toni Meier, Ritesh G. Menezes, Atte Meretoja, Tomislav Mestrovic, Bartosz Miazgowski, Tomasz Miazgowski, Irmina Maria Michalek, Ted R. Miller, Erkin M. Mirrakhimov, Hamed Mirzaei, Babak Moazen, Masoud Moghadaszadeh, Yousef Mohammad, Dara K. Mohammad, Shafiu Mohammed, Mohammed A. Mohammed, Yaser Mokhayeri, Mariam Molokhia, Ahmed A. Montasir, Ghobad Moradi, Rahmatollah Moradzadeh, Paula Moraga, Lidia Morawska, Ilais Moreno Velásquez, Jakub Morze, Sumaira Mubarik, Walter Muruet, Kamarul Imran Musa, Ahamarshan J. Nagarajan, Mahdi Nalini, Vinay Nangia, Atta Abbas Naqvi, Sreenivas Narasimha Swamy, Bruno R. Nascimento, Vinod C. Nayak, Javad Nazari, Milad Nazarzadeh, Ruxandra I. Negoi, Sandhya Neupane Kandel, Huong L.T. Nguyen, Molly R. Nixon, Bo Norrving, Jean Jacques Noubiap, Brice E. Nouthe, Christoph Nowak, Oluwakemi O. Odukoya, Felix A. Ogbo, Andrew T. Olagunju, Hans Orru, Alberto Ortiz, Samuel M. Ostroff, Jagadish Rao Padubidri, Raffaele Palladino, Adrian Pana, Songhomitra Panda-Jonas, Utsav Parekh, Eun-Cheol Park, Mojtaba Parvizi, Fatemeh Pashazadeh Kan, Urvish K. Patel, Mona Pathak, Rajan Paudel, Veincent Christian F. Pepito, Arokiasamy Perianayagam, Norberto Perico, Hai Q. Pham, Thomas Pilgrim, Michael A. Piradov, Farhad Pishgar, Vivek Podder, Roman V. Polibin, Akram Pourshams, Dimas R.A. Pribadi, Navid Rabiee, Mohammad Rabiee, Amir Radfar, Alireza Rafiei, Fakher Rahim, Vafa Rahimi-Movaghar, Mohammad Hifz Ur Rahman, Muhammad Aziz Rahman, Amir Masoud Rahmani, Ivo Rakovac, Pradhum Ram, Sudha Ramalingam, Juwel Rana, Priyanga Ranasinghe, Sowmya J. Rao, Priya Rathi, Lal Rawal, Wasiq F. Rawasia, Reza Rawassizadeh, Giuseppe Remuzzi, Andre M.N. Renzaho, Aziz Rezapour, Seyed Mohammad Riahi, Ross L. Roberts-Thomson, Leonardo Roever, Peter Rohloff, Michele Romoli, Gholamreza Roshandel, Godfrey M. Rwegerera, Seyedmohammad Saadatagah, Maha M. Saber-Ayad, Siamak Sabour, Simona Sacco, Masoumeh Sadeghi, Sahar Saeedi Moghaddam, Saeed Safari, Amirhossein Sahebkar, Sana Salehi, Hamideh Salimzadeh, Mehrnoosh Samaei, Abdallah M. Samy, Itamar S. Santos, Milena M. Santric-Milicevic, Nizal Sarrafzadegan, Arash Sarveazad, Thirunavukkarasu Sathish, Monika Sawhney, Mete Saylan, Maria I. Schmidt, Aletta E. Schutte, Subramanian Senthilkumaran, Sadaf G. Sepanlou, Feng Sha, Saeed Shahabi, Izza Shahid, Masood A. Shaikh, Mahdi Shamali, Morteza Shamsizadeh, Md Shajedur Rahman Shawon, Aziz Sheikh, Mika Shigematsu, Min-Jeong Shin, Jae Il Shin, Rahman Shiri, Ivy Shiue, Kerem Shuval, Soraya Siabani, Tariq J. Siddiqi, Diego A.S. Silva, Jasvinder A. Singh, Ambrish Singh Mtech, Valentin Y. Skryabin, Anna A. Skryabina, Amin Soheili, Emma E. Spurlock, Leo Stockfelt, Stefan Stortecky, Saverio Stranges, Rizwan Suliankatchi Abdulkader, Hooman Tadbiri, Eyayou G. Tadesse, Degena B. Tadesse, Masih Tajdini, Md Tariqujjaman, Berhane F. Teklehaimanot, Mohamad-Hani Temsah, Ayenew K. Tesema, Bhaskar Thakur, Kavumpurathu R. Thankappan, Rekha Thapar, Amanda G. Thrift, Binod Timalsina, Marcello Tonelli, Mathilde Touvier, Marcos R. Tovani-Palone, Avnish Tripathi, Jaya P. Tripathy, Thomas C. Truelsen, Guesh M. Tsegay, Gebiyaw W. Tsegaye, Nikolaos Tsilimparis, Biruk S. Tusa, Stefanos Tyrovolas, Krishna Kishore Umapathi, Brigid Unim, Bhaskaran Unnikrishnan, Muhammad S. Usman, Muthiah Vaduganathan, Pascual R. Valdez, Tommi J. Vasankari, Diana Z. Velazquez, Narayanaswamy Venketasubramanian, Giang T. Vu, Isidora S. Vujcic, Yasir Waheed, Yanzhong Wang, Fang Wang, Jingkai Wei, Robert G. Weintraub, Abrha H. Weldemariam, Ronny Westerman, Andrea S. Winkler, Charles S. Wiysonge, Charles D.A. Wolfe, Befikadu Legesse Wubishet, Gelin Xu, Ali Yadollahpour, Kazumasa Yamagishi, Lijing L. Yan, Srikanth Yandrapalli, Yuichiro Yano, Hiroshi Yatsuya, Tomas Y. Yeheyis, Yigizie Yeshaw, Christopher S. Yilgwan, Naohiro Yonemoto, Chuanhua Yu, Hasan Yusefzadeh, Geevar Zachariah, Sojib Bin Zaman, Muhammed S. Zaman, Maryam Zamanian, Ramin Zand, Alireza Zandifar, Afshin Zarghi, Mikhail S. Zastrozhin, Anasthasia Zastrozhina, Zhi-Jiang Zhang, Yunquan Zhang, Wangjian Zhang, Chenwen Zhong, Zhiyong Zou, Yves Miel H. Zuniga, and Christopher J.L. Murray
- Subjects
BMI, body mass index ,GBD, Global Burden of Diseases, Injuries, and Risk Factors Study ,IS, ischemic stroke ,030204 cardiovascular system & hematology ,MV, mitral valve ,SDI, sociodemographic index ,Global Health ,UI, uncertainty interval ,Global Burden of Disease ,GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group ,0302 clinical medicine ,Cost of Illness ,LDL, low-density lipoprotein ,Case fatality rate ,Global health ,030212 general & internal medicine ,IKF, impaired kidney function ,1102 Cardiorespiratory Medicine and Haematology ,Incidence (epidemiology) ,Health Policy ,IHD, ischemic heart disease ,1. No poverty ,AC, alcoholic cardiomyopathy ,3. Good health ,HICs, high-income countries ,Cardiovascular Diseases ,DALYs, disability-adjusted life years ,TMREL, theoretical minimum risk exposure level ,Public Health ,HHD, hypertensive heart disease ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,AF, atrial fibrillation ,Population health ,CVD, cardiovascular disease ,LMICs, low- and middle-income countries ,PM, particulate matter ,1117 Public Health and Health Services ,03 medical and health sciences ,JACC State-of-the-Art Review ,RHD, rheumatic heart disease ,Environmental health ,medicine ,Humans ,LPA, low physical activity ,YLLs, years of life lost ,Health policy ,Disease burden ,PAD, peripheral artery disease ,business.industry ,SBP, systolic blood pressure ,Public health ,CKD, chronic kidney disease ,The Present and Future ,AFL, atrial flutter ,Correction ,HAP, household air pollution ,ICD, International Classification of Diseases ,CAVD, calcific aortic valve disease ,YLDs, years lived with disability ,Years of potential life lost ,CHA, congenital heart anomalies ,Cardiovascular System & Hematology ,Heart Disease Risk Factors ,business ,population health - Abstract
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases., Central Illustration, Highlights • The burden of CVD, in number of DALYs and deaths, continues to increase globally. • CVD burden attributable to modifiable risk factors continues to increase globally. • Countries should invest in existing cost-effective public health programs and clinical interventions to target modifiable risks, promote healthy aging across the lifespan, and reduce disability and premature death due to CVD.
- Published
- 2020
26. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- Author
-
Soufiane Boufous, Yousef Veisani, Mehran Asadi-Aliabadi, Sharath Burugina Nagaraja, Maziar Moradi-Lakeh, Getachew Mullu Kassa, Edward J Mills, Dimas Ria Angga Pribadi, William James Dangel, Mohamad-Hani Temsah, Catherine O. Johnson, Gregory A. Roth, Giuseppe Gorini, Fariborz Mansour-Ghanaei, Alberto Ortiz, Samad Azari, Assefa Ayalew Ayalew Ayalew Gebreslassie, Salime Goharinezhad, Stephanie R. M. Zimsen, Peng Zheng, Michael Assmus, Elisabetta Pupillo, Bach Xuan Tran, Lal B. Rawal, Narayanaswamy Venketasubramanian, Noushin Mohammadifard, Stephen S Lim, Ata Rafiee, Maria Inês Schmidt, Vincent C. Iannucci, Suzanne Lyn Barker-Collo, Leah E. Cahill, Tauseef Ahmad, Platon D. Lopukhov, Kazumasa Yamagishi, Abdullah Al Mamun, Iqbal R. F. Elyazar, Giovanni Damiani, Mohammad Hossein Bakhshaei, Mehdi Fazlzadeh, Virginia Núñez-Samudio, Alyssa Pennini, Dietrich Plass, Atkilt Esaiyas Etisso, Gebre Teklemariam Demoz, Alexandrea Watson, Arvin Haj-Mirzaian, Paul S Briant, Frank B. Osei, Blair R. Bumgarner, Maciej Banach, Ravensara S. Travillian, Kai-Lan Chang, Shirin Djalalinia, Hasan Yusefzadeh, Silvano Gallus, Seyyed Meysam Mousavi, Bernhard T. Baune, Aaron van Donkelaar, Azeem Majeed, Hans Kromhout, Robert Ancuceanu, Blessing J. Akombi, Pushpendra Singh, Nayu Ikeda, William M. Gardner, Zahid A Butt, Mohammad Abdollahi, Temesgen Yihunie Akalu, Rahman Shiri, Benn Sartorius, Ai-Min Wu, Bing Fang Hwang, Flavia M. Cicuttini, Hiroyasu Iso, Luis Camera, Amin Soheili, Félix Carvalho, Yun Jin Kim, Caleb Mackay Salpeter Irvine, Mehdi Mirzaei-Alavijeh, Iman Halvaei, Saqib Ali, Giulio Castelpietra, Catalina Liliana Andrei, Ali Kazemi Karyani, Parkes J Kendrick, Hamidreza Haririan, Lucas Guimarães Abreu, Mukhammad David Naimzada, Jeff T. Zhao, Samiah Alam, Sorin Hostiuc, Shaun Wen Huey Lee, João Mauricio Castaldelli-Maia, Behzad Karami Matin, Cyrus Alinia, Takahiro Tabuchi, Manu Raj Mathur, Søren Thorgaard Skou, Thomas Khaled Dwayne Classen, Reza Heidari-Soureshjani, Massimo Cirillo, Nikita Otstavnov, Mehdi Bohluli, Ruth W. Kimokoti, Animut Tagele Tamiru, Masoumeh Sadeghi, Mohammad Ali Jahani, Itamar S. Santos, Mekdes Tigistu Yilma, Lars Johansson, Arielle Wilder Eagan, Nevine El Nahas, Silvia Schiavolin, Kevin D. Shield, Dinh-Toi Chu, Shiva Borzouei, Paul S. F. Yip, Beatrix Haddock, Gianfranco Alicandro, Vasily Vlassov, Deanna Anderlini, Giuseppe Remuzzi, Khalid A Altirkawi, Farahnaz Joukar, Aso Mohammad Darwesh, Ratilal Lalloo, Panniyammakal Jeemon, Rohollah Kalhor, Daniel Youngwhan Cho, Weijia Fu, João Pedro Silva, Rodrigo Sarmiento-Suarez, Seth Christopher Yaw Appiah, Mehdi Ahmadi, Jacob Olusegun Olusanya, José Neves, Gaorui Guo, Tomas Y. Yeheyis, John S. Ji, Charles D. H. Parry, Maryam Ghadimi, Seyed-Mohammad Fereshtehnejad, Serge Resnikoff, Anna E. Torre, Vinod C Nayak, Jamileh Shadid, Susanne Breitner, Mohammad Khammarnia, Mathilde Touvier, Ensiyeh Jenabi, Hosna Janjani, Floriane Ausloos, Irmina Maria Michalek, Alexandra S. Boon-Dooley, Jessica A. Cruz, Syed Mohamed Aljunid, Abiodun M. Adeoye, André Faro, Bartosz Miazgowski, Jobert Richie Nansseu, Erin C Mullany, Giannina Ferrara, Martin McKee, Emmanuel Peprah, Oommen John, Reza Saeedi, Yasser Vasseghian, Dragos Virgil Davitoiu, Sarah Wulf Hanson, Yingxi Zhao, Omid Shafaat, Ali Rajabpour-Sanati, Farid Najafi, Ana Maria Mantilla Herrera, Fatemeh Rajati, Tarun Gupta, Łukasz Szumowski, Mohammed Ibrahim Mohialdeen Gubari, Peter Njenga Keiyoro, Dharmesh Kumar Lal, Zhi Jiang Zhang, Osayomwanbo Osarenotor, Tanvir M. Huda, Perminder S. Sachdev, Farhad Ghamari, Era Upadhyay, Vivek Kumar, Guoqing Hu, Vinay Nangia, Vladimir Andreevich Korshunov, Saeed Shahabi, Golnaz Heidari, Ashraf Nabhan, Robert C. Reiner, Aziz Rezapour, Justin J. Lang, Rakhi Dandona, Josephine W. Ngunjiri, Anna-Karin Danielsson, André Karch, Filippo Ariani, Ahmed Abdelalim, Masih Tajdini, Stefanos Tyrovolas, Mohamed Hsairi, Jae Il Shin, Jasvinder A. Singh, Meghan D. Mooney, Fiona B. Bennitt, Hesam Alizade, Segun Emmanuel Ibitoye, Pradhum Ram, Soraya Siabani, Evanson Z. Sambala, Reza Malekzadeh, Falk Schwendicke, Lalit Dandona, Masoud Moradi, Molly R Nixon, Roya Mirzaei, Rachel Feldman, Hosni Salem, Alberto L. García-Basteiro, Lorainne Tudor Car, Sharareh Eskandarieh, Ramesh Holla, Ritesh G. Menezes, Taraneh Yousefinezhadi, Hai Quang Pham, Hamideh Salimzadeh, Luisa Sorio Flor, Priya Rathi, Ali Bijani, Harvey Whiteford, Shanshan Li, Aleksandr Y. Aravkin, Joshua A. Salomon, Franz Castro, Lisa M. Force, Abdilahi Yousuf Yousuf, Mina Anjomshoa, Ken Takahashi, Maigeng Zhou, Telma Zahirian Moghadam, Maseer Khan, Irina Filip, Santi Martini, Randah R. Hamadeh, Somayeh Bohlouli, Joana Morgado-da-Costa, Tim Driscoll, Jingkai Wei, Hermann Brenner, Reza Rawassizadeh, Radoslaw Sierpinski, Saman Esmaeilnejad, Emmanuel Wandera Okunga, Marisa Freitas, Srikanta Banerjee, Feleke Mekonnen Demeke, Shahin Soltani, Naser Mohammad Gholi Mezerji, Reed J D Sorensen, Elena V. Gnedovskaya, Johan Ärnlöv, Ivo Rakovac, Reza Mohammadpourhodki, Hussain Jafari, Atte Meretoja, Yasir Waheed, Fahad Alanezi, Arya Haj-Mirzaian, Sezer Kisa, Jaifred Christian F. Lopez, Khalid F. Alhabib, Basema Saddik, Michael R. Phillips, Vishnu Renjith, Yafeng Wang, Kevan R. Polkinghorne, Liliana G Ciobanu, Jacek Jerzy Jozwiak, Gelin Xu, Richard C. Franklin, Junjie Wu, Thomas R. Hird, Mohammad Zamani, Diana Silva, Fotis Topouzis, Irena Ilic, Jeffrey D. Stanaway, Hadi Pourjafar, Huong Lan Thi Nguyen, Khaled Khatab, Ammas Siraj Mohammed, Ziyad Al-Aly, A. A. Fomenkov, Charlie Ashbaugh, Mowafa Househ, Paul I. Dargan, Endalkachew Worku Mengesha, Shaimaa I. El-Jaafary, Ernoiz Antriyandarti, Iffat Elbarazi, Dara K. Mohammad, Naznin Hossain, Reza Shirkoohi, João M. Furtado, Arash Ziapour, Morteza Jafarinia, M. Mofizul Islam, Anamika Pandey, Ahmed I. Hasaballah, Tanuj Kanchan, Lee Ling Lim, Muktar Omer Omer, Charles D.A. Wolfe, Ulrich O Mueller, Helen Bitew, V. Prakash, Fereshteh Mehri, Randall V. Martin, Claudiu Herteliu, Constance D. Pond, Min Jeong Shin, Morteza Oladnabi, Antonio Maria Borzì, Yousef Mohammad, Yuichiro Yano, Luke D. Knibbs, Kevin S Ikuta, Maryam Mirzaei, Andreea Mirica, Sofia Boston Redford, Siamak Sabour, Mariya Vladimirovna Titova, Davood Anvari, Ghobad Moradi, Jordi Alonso, Shiwei Liu, Theo Vos, Tuomo J. Meretoja, Ireneous N. Soyiri, Owen R. Cooper, Seyed Sina Naghibi Irvani, Kejia Hu, Hannah J. Henrikson, Sanni Yaya, Robert P. Dellavalle, Chidozie Declan Iwu, Sergey Soshnikov, Jee-Young Jasmine Choi, Satinath Mukhopadhyay, Zabihollah Yousefi, Iman El Sayed, Biresaw Wassihun Alemu, Neeti Kapoor, Ahmad Daryani, Cathleen Keller, Ibrahim Abdollahpour, Nuno Taveira, Masoud Foroutan, Fatemeh Amiri, Mariam Molokhia, Songhomitra Panda-Jonas, Amy E. Peden, Rufus Akinyemi, Ejaz Ahmad Khan, Mostafa Amini-Rarani, J. Becker, Hamidreza Pazoki Toroudi, Ben Lacey, Kidanemaryam Berhe, Simon Yadgir, Spencer L. James, Cory N. Spencer, Aletta E. Schutte, Mu'awiyyah Babale Sufiyan, Arash Tehrani-Banihashemi, Govinda Prasad Dhungana, Fereshteh Ansari, Rixing Xu, Jonathan F. Mosser, Josep Maria Haro, Enrico Rubagotti, Anurag Agrawal, Zahiruddin Quazi Syed, Hoa Thi Do, Ettore Beghi, Seyed Mohammad Kazem Aghamir, Abraham Geremew, Alireza Esteghamati, Paramjit Gill, Farzad Jalilian, J. Jason West, Mikhail Sergeevich Zastrozhin, Albertino Damasceno, Bruce Bartholow Duncan, Nazir Fattahi, Daniel Cury Ribeiro, Michael Brauer, Mark A. Stokes, Veincent Christian Filipino Pepito, Lidia Morawska, Fiona J Charlson, Babak Moazen, Dejana Braithwaite, Jonathan M. Kocarnik, Sergio I. Prada, Andrea Farioli, Zahra Atafar, Heather Orpana, Daniela Balzi, Marco Vacante, Rahmatollah Moradzadeh, Jacek A. Kopec, Iván Landires, Robert G. Weintraub, Leonardo Roever, Yannick Béjot, Markus P. Schlaich, Hamed Zandian, Subramanian Senthilkumaran, Klara Dokova, Vahid Alipour, Sowmya J. Rao, Rakesh Ghosh, Omar Mukhtar Salman, Faris Lami, Marcos Roberto Tovani-Palone, Hamid Reza Tohidinik, Seyed Mohammad Riahi, Adnan Kisa, Ghasem Azarian, Caroline Stein, Zulfiqar A. Bhutta, Sinead Langan, Kunihiro Matsushita, Lauren E. Schaeffer, Kathryn H. Jacobsen, Mehdi Naderi, Mehdi Hosseinzadeh, Nizal Sarrafzadegan, Bahram Armoon, Dan J. Stein, Jessica Fanzo, Morenike Oluwatoyin Folayan, Luca Ronfani, Phetole Walter Mahasha, Nicholas J K Breitborde, Adrian Oţoiu, Arash Sarveazad, Marc L. Serre, Mostafa Hosseini, Nicolas Cherbuin, George D. Thurston, Jalal Arabloo, Mokhtar Mahdavi, Andre Rodrigues Duraes, Ana Laura Manda, Ahmed Abualhasan, Nima Rezaei, Yuan-Pang Wang, Theodore Patrick Younker, Alireza Ansari-Moghaddam, Borhan Mansouri, Adam E. Berman, Khezar Hayat, Rosario Cárdenas, Bolajoko O. Olusanya, Tommi Vasankari, Simon I. Hay, Fatemeh Ghaffarifar, Leo Stockfelt, Ai Koyanagi, Giorgia Giussani, Yuming Guo, Sonia Saxena, Deborah Carvalho Malta, Mehedi Hasan, Negar Rezaei, Maja Pasovic, Jukka Takala, Bogdan Oancea, Sare Safi, A. Werdecker, Florian Fischer, Beatriz Paulina Ayala Quintanilla, Muhammad Shahdaat Bin Sayeed, Takeshi Fukumoto, Maha Atout, Brijesh Sathian, Cristina Bosetti, Mitchell T. Wallin, Agegnehu Bante, Helen Ippolito, Anthony Masaka, Chantal Huynh, Justin Lo, Jordan Weiss, Joemer C. Maravilla, Alberto Raggi, Peter W. Gething, Cristiana Abbafati, Daniela Ribeiro, Mohammad Farahmand, Yetunde O. John-Akinola, Isabela M. Benseñor, Emilie R Maddison, John J. McGrath, Salman Khazaei, Scott B. Patten, Jean Jacques Noubiap, Emmanuela Gakidou, Celine M. Barthelemy, Ashish Badiye, George C. Patton, Obinna Onwujekwe, Peter Allebeck, Victor Aboyans, Olayinka Stephen Ilesanmi, Mousa Yaminfirooz, Neeraj Bedi, Nicholas L S Roberts, Joht Singh Chandan, Hans W. Hoek, Usman Iqbal, Nima Hafezi-Nejad, Haley Lescinsky, Naohiro Yonemoto, Ahmad Ghashghaee, Anders Larsson, David C. Schwebel, Milena Ilic, Richard T. Burnett, Yang Liu, Carlo La Vecchia, Felix Akpojene Ogbo, Morteza Naserbakht, Sangram Kishor Patel, Melanie S. Hammer, Prasanna Mithra, Mohammad Amin Bahrami, Kanyin L. Ong, Mona Pathak, Afshin Maleki, Saeid Safiri, Masood Ali Shaikh, Kate Causey, Michael R.M. Abrigo, Jost B. Jonas, Dian Kusuma, Jagadish Rao Padubidri, Mihajlo Jakovljevic, Ali S. Shalash, Abdiwahab Hashi, Ionut Negoi, Nataliya A. Foigt, Andrey Nikolaevich Briko, François Alla, Giuseppe Grosso, Houman Goudarzi, Di H. Cross, Vera Marisa Costa, Eduarda Fernandes, Chandrashekhar T Sreeramareddy, Odgerel Chimed-Ochir, Sonia Rodríguez-Ramírez, Bo Norrving, Kerem Shuval, Jacob L. Stubbs, Muhammad Ali, Shuhei Nomura, Man Mohan Mehndiratta, Chisom Joyqueenet Akunna, Abdollah Mohammadian-Hafshejani, Navid Rabiee, Dana Bryazka, Hussen Mohammed, Asadollah Gholamian, Ashley Marks, Rizwan Kalani, Molly E. Herbert, Islam Y. Elgendy, Moritz U. G. Kraemer, Chuanhua Yu, Suzanne Polinder, Pascual R. Valdez, Jennifer Rickard, Kylie Ball, Turki Alanzi, Mohsen Bayati, Hamed Mirzaei, Christopher M Odell, Amira Shaheen, Ziad A. Memish, Thirunavukkarasu Sathish, Michael A. Piradov, Hamed Kalani, Lorenzo Monasta, Christopher S Yilgwan, Desalegn Getnet Demsie, Riaz Uddin, Rizwan Suliankatchi Abdulkader, Vinay Srinivasan, Hamid Ahmadieh, Claudio Alberto Dávila-Cervantes, Raffaele Palladino, Chukwudi A Nnaji, Mika Shigematsu, Stein Emil Vollset, Abbas Sheikhtaheri, Paulo A. Lotufo, Nasir Salam, Binyam Minuye Birihane, Mohammad Ali Mansournia, Tomislav Mestrovic, Samer Hamidi, Rajesh Sagar, Mayowa O. Owolabi, Kara Estep, Ester Cerin, Michael T. Chung, Simon Øverland, Amir Taherkhani, Sheng Chia Chung, Martin Amogre Ayanore, Nikolaos Dervenis, Joan B. Soriano, Tahereh Javaheri, Victor Adekanmbi, Seid Tiku Mereta, Gbenga A. Kayode, Christopher R. Cederroth, Razique Anwer, Rajan Nikbakhsh, Kaja Abbas, Fatemeh Heydarpour, Louisa Degenhardt, Tahiya Alam, Mohammad Miri, Alibek Mereke, David Laith Rawaf, Ippazio Cosimo Antonazzo, Erkin M. Mirrakhimov, Seyed Hossein Yahyazadeh Jabbari, Desta Debalkie Atnafu, Davide Sattin, Moslem Soofi, Edris Hasanpoor, Krittika Bhattacharyya, Mika Kivimäki, Nikolay Ivanovich Briko, Joanna L Whisnant, Christopher J L Murray, Simin Mouodi, Alize J. Ferrari, Damian Santomauro, Katrin Burkart, Tudorel Andrei, Alberto Baldasseroni, Hafiz Ansar Rasul Suleria, Valery L. Feigin, Nauman Khalid, Ewerton Cousin, S. Mohammad Sajadi, Francisco Rogerlândio Martins-Melo, Shankar M Bakkannavar, Themba G.G. Ginindza, Sadaf G. Sepanlou, Sheikh Mohammed Shariful Islam, Sanjay Basu, Getinet Ayano, Paula Moraga, Soheil Hassanipour, Jason A. Anderson, Catherine Bisignano, Iyad Sultan, Deepak Kumar Pasupula, Keivan Ahmadi, Fariba Dorostkar, Rajeev Gupta, David M. Pereira, Mustafa Z. Younis, Adel Spotin, Rasmus Havmoeller, Yeshambel T. Nigatu, Barthelemy Kuate Defo, Mithila Faruque, Alan D. Lopez, Shailesh Advani, Behshad Naghshtabrizi, Shane D. Morrison, Inga Dora Sigfusdottir, Konrad Pesudovs, Anna Gershberg Hayoon, Raaj Kishore Biswas, Reshmi Bhageerathy, H. Dean Hosgood, Giulia Carreras, Sarika Chaturvedi, James L. Fisher, In-Hwan Oh, G Anil Kumar, Christoph Nowak, Vijay Kumar Chattu, Puja C Rao, Marcel Ausloos, Ali Kabir, Rannveig Sigurvinsdottir, Leeberk Raja Inbaraj, Edgar Denova-Gutiérrez, Rafael Tabarés-Seisdedos, Minh Nguyen, Ashkan Afshin, Payman Salamati, Colin Angus, Mona M. Khater, Ehsan Sadeghi, Mahalaqua Nazli Khatib, Antonio Biondi, Valentin Yurievich Skryabin, Mohsen Abbasi-Kangevari, Andrew T Olagunju, Amir Radfar, Laith J. Abu-Raddad, Marcello Tonelli, Hesam Ghiasvand, Hanne Christensen, Juan Jesus Carrero, Maryam Adabi, Saravanan Muthupandian, Kurt Straif, Hossein Samadi Kafil, Lope H Barrero, Harish Chander Gugnani, Mohammad Fareed, Morteza Shamsizadeh, Jemal Abdu Mohammed, Juan A Rivera, Shai Linn, Saad M.A. Dahlawi, Janni Leung, Shokofeh Maleki, Mohd Anisul Karim, Kamarul Imran Musa, Farshad Pourmalek, Dietrich Rothenbacher, Kiomars Sharafi, Alessandra C. Goulart, Leila Doshmangir, Gabriele Nagel, Helena Manguerra, Olatunji O. Adetokunboh, Srinivasa Vittal Katikireddi, Nermin Ghith, Maha El Tantawi, Awoke Misganaw, Yunquan Zhang, Carl Abelardo T. Antonio, Vahid Rashedi, Mehran Shams-Beyranvand, Bhaskaran Unnikrishnan, Holly E. Erskine, Ann Kristin Knudsen, Marissa B Reitsma, Getayeneh Antehunegn Tesema, Javad Javidnia, Ismael R. Campos-Nonato, Biniyam Sahiledengle Geberemariyam, Godfrey Mutashambara Rwegerera, Alaa Badawi, James Leigh, Morteza Arab-Zozani, Kyle E. Simpson, Muluken Bekele Sorrie, Roghiyeh Faridnia, Vivekanand Jha, Tomasz Miazgowski, Aaron J Cohen, Chukwuma David Umeokonkwo, Alessandra Lugo, Adhanom Gebreegziabher Baraki, Akshaya Srikanth Bhagavathula, Caitlyn Steiner, Gholamreza Roshandel, Cuong Tat Nguyen, Tania G Sánchez-Pimienta, Ahamarshan Jayaraman Nagarajan, Laura Kemmer, Ihoghosa Osamuyi Iyamu, Seyedeh Zahra Masoumi, Vivian Chia-Rong Hsieh, Kris J. Krohn, Phoebe Anne Rhinehart, Sarah Wozniak, Sahar Saeedi Moghaddam, Kate E. LeGrand, Christian Kieling, Vahid Yazdi-Feyzabadi, Robin Room, Zelalem Nigussie Azene, Kelly Cercy, Paul H. Lee, Stanislav S. Otstavnov, Dinesh Bhandari, Rafael Alves Guimarães, Zemenu Tadesse Tessema, Aziz Sheikh, Michellr L. Bell, Marwa Rashad Salem, Kirsten E. Wiens, Emma U.R. Smith, Hassan Abolhassani, Cristiano Piccinelli, Kedir Hussein Abegaz, G.K. Mini, Christian Razo, Manuela L. Ferreira, Diego De Leo, Francesco Saverio Violante, Aristidis Tsatsakis, Zahra Sadat Dibaji Forooshani, Tea Lallukka, Dickson A. Amugsi, Anna Poznańska, Graeme J. Hankey, Kewal Krishan, Maryam Zamanian, Eirini Skiadaresi, Jai K Das, Felix Greaves, Tessa M. Pilz, Sameer Vali Gopalani, Mansour Ghafourifard, M. DeLang, Morteza Mahmoudi, Alton Lu, Brian J. Hall, Ravi Prakash Jha, David Edvardsson, Xiu Ju George Zhao, Farshad Farzadfar, Hadi Hassankhani, Samuel M. Ostroff, Gerhard Sulo, Keyghobad Ghadiri, Neeraj Bhala, Stefan Lorkowski, Mohammad Rabiee, Sivan Yegnanarayana Iyer Saraswathy, Amirhossein Sahebkar, Rashid Abdi Guled, Abdallah M. Samy, Roman Topor-Madry, Michal Grivna, Afsaneh Arzani, Ayesha Humayun, Simin Liu, Maryam Khayamzadeh, Davoud Adham, Ahad Bakhtiari, Shafiu Mohammed, Paolo Lauriola, Abbas Mosapour, Sophia Emmons-Bell, Khurshid Alam, Rajat Das Gupta, Matilde Leonardi, Muktar Beshir Ahmed, Jeffrey V. Lazarus, Mohamed M. Gad, Kelly Compton, Leila R Kalankesh, Abdelrahman Ibrahim Abushouk, Mikk Jürisson, Catherine M. Antony, Ali A. Asadi-Pooya, Daniel Diaz, Salman Rawaf, Gina Agarwal, Ted R. Miller, Rebecca Ivers, João Vasco Santos, Savita Lasrado, Abdul Moiz Hafiz, Amir Almasi-Hashiani, Praveen Hoogar, Fares Alahdab, Om P Kurmi, Anbissa Muleta Senbeta, Tomi Akinyemiju, Boris Bikbov, Muhammad Aziz Rahman, Amin Mousavi Khaneghah, Yahya Safari, Guilherme Borges, Carlos A Castañeda-Orjuela, Kenji Shibuya, Bahman Yousefi, Berrin Serdar, Karen M. Tabb, Sonali Kochhar, Till Bärnighausen, Kala M. Mehta, Mostafa Dianatinasab, Arash Etemadi, Melissa Y. Wei, Kiana Ramezanzadeh, Lingkan Barua, Zubair Kabir, Rade Vukovic, Hesham M. Al-Mekhlafi, Shoshana H. Ballew, Miriam Levi, Zainab Samad, Florentino Luciano Caetano dos Santos, Juan Sanabria, Ramu Rawat, Chinwe Juliana Iwu, Gabrielle B. Britton, Colm McAlinden, Mohsen Naghavi, Maarten J. Postma, Chhabi Lal Ranabhat, Jalil Jaafari, Walter Mendoza, Mahesh P A, Pallab K. Maulik, Ali H. Mokdad, Andre M. N. Renzaho, Milena Santric-Milicevic, Parvaiz A Koul, Foad Abd-Allah, Mihaela Hostiuc, Richard G. Cowden, Ronny Westerman, Meghdad Pirsaheb, Department of Earth Observation Science, UT-I-ITC-ACQUAL, Faculty of Geo-Information Science and Earth Observation, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Microbes in Health and Disease (MHD), Tampere University, Tays Research Services, Health Sciences, Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., Abegaz, K. H., Abolhassani, H., Aboyans, V., Abreu, L. G., Abrigo, M. R. M., Abualhasan, A., Abu-Raddad, L. J., Abushouk, A. I., Adabi, M., Adekanmbi, V., Adeoye, A. M., Adetokunboh, O. O., Adham, D., Advani, S. M., Agarwal, G., Aghamir, S. M. K., Agrawal, A., Ahmad, T., Ahmadi, K., Ahmadi, M., Ahmadieh, H., Ahmed, M. B., Akalu, T. Y., Akinyemi, R. O., Akinyemiju, T., Akombi, B., Akunna, C. J., Alahdab, F., Al-Aly, Z., Alam, K., Alam, S., Alam, T., Alanezi, F. M., Alanzi, T. M., Alemu, B. W., Alhabib, K. F., Ali, M., Ali, S., Alicandro, G., Alinia, C., Alipour, V., Alizade, H., Aljunid, S. M., Alla, F., Allebeck, P., Almasi-Hashiani, A., Al-Mekhlafi, H. M., Alonso, J., Altirkawi, K. A., Amini-Rarani, M., Amiri, F., Amugsi, D. A., Ancuceanu, R., Anderlini, D., Anderson, J. A., Andrei, C. L., Andrei, T., Angus, C., Anjomshoa, M., Ansari, F., Ansari-Moghaddam, A., Antonazzo, I. C., Antonio, C. A. T., Antony, C. M., Antriyandarti, E., Anvari, D., Anwer, R., Appiah, S. C. Y., Arabloo, J., Arab-Zozani, M., Ariani, F., Armoon, B., Arnlov, J., Arzani, A., Asadi-Aliabadi, M., Asadi-Pooya, A. A., Ashbaugh, C., Assmus, M., Atafar, Z., Atnafu, D. D., Atout, M. M. W., Ausloos, F., Ausloos, M., Ayala Quintanilla, B. P., Ayano, G., Ayanore, M. A., Azari, S., Azarian, G., Azene, Z. N., Badawi, A., Badiye, A. D., Bahrami, M. A., Bakhshaei, M. H., Bakhtiari, A., Bakkannavar, S. M., Baldasseroni, A., Ball, K., Ballew, S. H., Balzi, D., Banach, M., Banerjee, S. K., Bante, A. B., Baraki, A. G., Barker-Collo, S. L., Barnighausen, T. W., Barrero, L. H., Barthelemy, C. M., Barua, L., Basu, S., Baune, B. T., Bayati, M., Becker, J. S., Bedi, N., Beghi, E., Bejot, Y., Bell, M. L., Bennitt, F. B., Bensenor, I. M., Berhe, K., Berman, A. E., Bhagavathula, A. S., Bhageerathy, R., Bhala, N., Bhandari, D., Bhattacharyya, K., Bhutta, Z. A., Bijani, A., Bikbov, B., Bin Sayeed, M. S., Biondi, A., Birihane, B. M., Bisignano, C., Biswas, R. K., Bitew, H., Bohlouli, S., Bohluli, M., Boon-Dooley, A. S., Borges, G., Borzi, A. M., Borzouei, S., Bosetti, C., Boufous, S., Braithwaite, D., Breitborde, N. J. K., Breitner, S., Brenner, H., Briant, P. S., Briko, A. N., Briko, N. I., Britton, G. B., Bryazka, D., Bumgarner, B. R., Burkart, K., Burnett, R. T., Burugina Nagaraja, S., Butt, Z. A., Caetano dos Santos, F. L., Cahill, L. E., Camera, L. L. A., Campos-Nonato, I. R., Cardenas, R., Carreras, G., Carrero, J. J., Carvalho, F., Castaldelli-Maia, J. M., Castaneda-Orjuela, C. A., Castelpietra, G., Castro, F., Causey, K., Cederroth, C. R., Cercy, K. M., Cerin, E., Chandan, J. S., Chang, K. -L., Charlson, F. J., Chattu, V. K., Chaturvedi, S., Cherbuin, N., Chimed-Ochir, O., Cho, D. Y., Choi, J. -Y. J., Christensen, H., Chu, D. -T., Chung, M. T., Chung, S. -C., Cicuttini, F. M., Ciobanu, L. G., Cirillo, M., Classen, T. K. D., Cohen, A. J., Compton, K., Cooper, O. R., Costa, V. M., Cousin, E., Cowden, R. G., Cross, D. H., Cruz, J. A., Dahlawi, S. M. A., Damasceno, A. A. M., Damiani, G., Dandona, L., Dandona, R., Dangel, W. J., Danielsson, A. -K., Dargan, P. I., Darwesh, A. M., Daryani, A., Das, J. K., Das Gupta, R., das Neves, J., Davila-Cervantes, C. A., Davitoiu, D. V., De Leo, D., Degenhardt, L., Delang, M., Dellavalle, R. P., Demeke, F. M., Demoz, G. T., Demsie, D. G., Denova-Gutierrez, E., Dervenis, N., Dhungana, G. P., Dianatinasab, M., Dias da Silva, D., Diaz, D., Dibaji Forooshani, Z. S., Djalalinia, S., Do, H. T., Dokova, K., Dorostkar, F., Doshmangir, L., Driscoll, T. R., Duncan, B. B., Duraes, A. R., Eagan, A. W., Edvardsson, D., El Nahas, N., El Sayed, I., El Tantawi, M., Elbarazi, I., Elgendy, I. Y., El-Jaafary, S. I., Elyazar, I. R., Emmons-Bell, S., Erskine, H. E., Eskandarieh, S., Esmaeilnejad, S., Esteghamati, A., Estep, K., Etemadi, A., Etisso, A. E., Fanzo, J., Farahmand, M., Fareed, M., Faridnia, R., Farioli, A., Faro, A., Faruque, M., Farzadfar, F., Fattahi, N., Fazlzadeh, M., Feigin, V. L., Feldman, R., Fereshtehnejad, S. -M., Fernandes, E., Ferrara, G., Ferrari, A. J., Ferreira, M. L., Filip, I., Fischer, F., Fisher, J. L., Flor, L. S., Foigt, N. A., Folayan, M. O., Fomenkov, A. A., Force, L. M., Foroutan, M., Franklin, R. C., Freitas, M., Fu, W., Fukumoto, T., Furtado, J. M., Gad, M. M., Gakidou, E., Gallus, S., Garcia-Basteiro, A. L., Gardner, W. M., Geberemariyam, B. S., Gebreslassie, A. A. A. A., Geremew, A., Gershberg Hayoon, A., Gething, P. W., Ghadimi, M., Ghadiri, K., Ghaffarifar, F., Ghafourifard, M., Ghamari, F., Ghashghaee, A., Ghiasvand, H., Ghith, N., Gholamian, A., Ghosh, R., Gill, P. S., Ginindza, T. G. G., Giussani, G., Gnedovskaya, E. V., Goharinezhad, S., Gopalani, S. V., Gorini, G., Goudarzi, H., Goulart, A. C., Greaves, F., Grivna, M., Grosso, G., Gubari, M. I. M., Gugnani, H. C., Guimaraes, R. A., Guled, R. A., Guo, G., Guo, Y., Gupta, R., Gupta, T., Haddock, B., Hafezi-Nejad, N., Hafiz, A., Haj-Mirzaian, A., Hall, B. J., Halvaei, I., Hamadeh, R. R., Hamidi, S., Hammer, M. S., Hankey, G. J., Haririan, H., Haro, J. M., Hasaballah, A. I., Hasan, M. M., Hasanpoor, E., Hashi, A., Hassanipour, S., Hassankhani, H., Havmoeller, R. J., Hay, S. I., Hayat, K., Heidari, G., Heidari-Soureshjani, R., Henrikson, H. J., Herbert, M. E., Herteliu, C., Heydarpour, F., Hird, T. R., Hoek, H. W., Holla, R., Hoogar, P., Hosgood, H. D., Hossain, N., Hosseini, M., Hosseinzadeh, M., Hostiuc, M., Hostiuc, S., Househ, M., Hsairi, M., Hsieh, V. C. -R., Hu, G., Hu, K., Huda, T. M., Humayun, A., Huynh, C. K., Hwang, B. -F., Iannucci, V. C., Ibitoye, S. E., Ikeda, N., Ikuta, K. S., Ilesanmi, O. S., Ilic, I. M., Ilic, M. D., Inbaraj, L. R., Ippolito, H., Iqbal, U., Irvani, S. S. N., Irvine, C. M. S., Islam, M. M., Islam, S. M. S., Iso, H., Ivers, R. Q., Iwu, C. C. D., Iwu, C. J., Iyamu, I. O., Jaafari, J., Jacobsen, K. H., Jafari, H., Jafarinia, M., Jahani, M. A., Jakovljevic, M., Jalilian, F., James, S. L., Janjani, H., Javaheri, T., Javidnia, J., Jeemon, P., Jenabi, E., Jha, R. P., Jha, V., Ji, J. S., Johansson, L., John, O., John-Akinola, Y. O., Johnson, C. O., Jonas, J. B., Joukar, F., Jozwiak, J. J., Jurisson, M., Kabir, A., Kabir, Z., Kalani, H., Kalani, R., Kalankesh, L. R., Kalhor, R., Kanchan, T., Kapoor, N., Karami Matin, B., Karch, A., Karim, M. A., Kassa, G. M., Katikireddi, S. V., Kayode, G. A., Kazemi Karyani, A., Keiyoro, P. N., Keller, C., Kemmer, L., Kendrick, P. J., Khalid, N., Khammarnia, M., Khan, E. A., Khan, M., Khatab, K., Khater, M. M., Khatib, M. N., Khayamzadeh, M., Khazaei, S., Kieling, C., Kim, Y. J., Kimokoti, R. W., Kisa, A., Kisa, S., Kivimaki, M., Knibbs, L. D., Knudsen, A. K. S., Kocarnik, J. M., Kochhar, S., Kopec, J. A., Korshunov, V. A., Koul, P. A., Koyanagi, A., Kraemer, M. U. G., Krishan, K., Krohn, K. J., Kromhout, H., Kuate Defo, B., Kumar, G. A., Kumar, V., Kurmi, O. P., Kusuma, D., La Vecchia, C., Lacey, B., Lal, D. K., Lalloo, R., Lallukka, T., Lami, F. H., Landires, I., Lang, J. J., Langan, S. M., Larsson, A. O., Lasrado, S., Lauriola, P., Lazarus, J. V., Lee, P. H., Lee, S. W. H., Legrand, K. E., Leigh, J., Leonardi, M., Lescinsky, H., Leung, J., Levi, M., Li, S., Lim, L. -L., Linn, S., Liu, S., Liu, Y., Lo, J., Lopez, A. D., Lopez, J. C. F., Lopukhov, P. D., Lorkowski, S., Lotufo, P. A., Lu, A., Lugo, A., Maddison, E. R., Mahasha, P. W., Mahdavi, M. M., Mahmoudi, M., Majeed, A., Maleki, A., Maleki, S., Malekzadeh, R., Malta, D. C., Mamun, A. A., Manda, A. L., Manguerra, H., Mansour-Ghanaei, F., Mansouri, B., Mansournia, M. A., Mantilla Herrera, A. M., Maravilla, J. C., Marks, A., Martin, R. V., Martini, S., Martins-Melo, F. R., Masaka, A., Masoumi, S. Z., Mathur, M. R., Matsushita, K., Maulik, P. K., Mcalinden, C., Mcgrath, J. J., Mckee, M., Mehndiratta, M. M., Mehri, F., Mehta, K. M., Memish, Z. A., Mendoza, W., Menezes, R. G., Mengesha, E. W., Mereke, A., Mereta, S. T., Meretoja, A., Meretoja, T. J., Mestrovic, T., Miazgowski, B., Miazgowski, T., Michalek, I. M., Miller, T. R., Mills, E. J., Mini, G. K., Miri, M., Mirica, A., Mirrakhimov, E. M., Mirzaei, H., Mirzaei, M., Mirzaei, R., Mirzaei-Alavijeh, M., Misganaw, A. T., Mithra, P., Moazen, B., Mohammad, D. K., Mohammad, Y., Mohammad Gholi Mezerji, N., Mohammadian-Hafshejani, A., Mohammadifard, N., Mohammadpourhodki, R., Mohammed, A. S., Mohammed, H., Mohammed, J. A., Mohammed, S., Mokdad, A. H., Molokhia, M., Monasta, L., Mooney, M. D., Moradi, G., Moradi, M., Moradi-Lakeh, M., Moradzadeh, R., Moraga, P., Morawska, L., Morgado-da-Costa, J., Morrison, S. D., Mosapour, A., Mosser, J. F., Mouodi, S., Mousavi, S. M., Mousavi Khaneghah, A., Mueller, U. O., Mukhopadhyay, S., Mullany, E. C., Musa, K. I., Muthupandian, S., Nabhan, A. F., Naderi, M., Nagarajan, A. J., Nagel, G., Naghavi, M., Naghshtabrizi, B., Naimzada, M. D., Najafi, F., Nangia, V., Nansseu, J. R., Naserbakht, M., Nayak, V. C., Negoi, I., Ngunjiri, J. W., Nguyen, C. T., Nguyen, H. L. T., Nguyen, M., Nigatu, Y. T., Nikbakhsh, R., Nixon, M. R., Nnaji, C. A., Nomura, S., Norrving, B., Noubiap, J. J., Nowak, C., Nunez-Samudio, V., Otoiu, A., Oancea, B., Odell, C. M., Ogbo, F. A., Oh, I. -H., Okunga, E. W., Oladnabi, M., Olagunju, A. T., Olusanya, B. O., Olusanya, J. O., Omer, M. O., Ong, K. L., Onwujekwe, O. E., Orpana, H. M., Ortiz, A., Osarenotor, O., Osei, F. B., Ostroff, S. M., Otstavnov, N., Otstavnov, S. S., Overland, S., Owolabi, M. O., P A, M., Padubidri, J. R., Palladino, R., Panda-Jonas, S., Pandey, A., Parry, C. D. H., Pasovic, M., Pasupula, D. K., Patel, S. K., Pathak, M., Patten, S. B., Patton, G. C., Pazoki Toroudi, H., Peden, A. E., Pennini, A., Pepito, V. C. F., Peprah, E. K., Pereira, D. M., Pesudovs, K., Pham, H. Q., Phillips, M. R., Piccinelli, C., Pilz, T. M., Piradov, M. A., Pirsaheb, M., Plass, D., Polinder, S., Polkinghorne, K. R., Pond, C. D., Postma, M. J., Pourjafar, H., Pourmalek, F., Poznanska, A., Prada, S. I., Prakash, V., Pribadi, D. R. A., Pupillo, E., Quazi Syed, Z., Rabiee, M., Rabiee, N., Radfar, A., Rafiee, A., Raggi, A., Rahman, M. A., Rajabpour-Sanati, A., Rajati, F., Rakovac, I., Ram, P., Ramezanzadeh, K., Ranabhat, C. L., Rao, P. C., Rao, S. J., Rashedi, V., Rathi, P., Rawaf, D. L., Rawaf, S., Rawal, L., Rawassizadeh, R., Rawat, R., Razo, C., Redford, S. B., Reiner, R. C., Reitsma, M. B., Remuzzi, G., Renjith, V., Renzaho, A. M. N., Resnikoff, S., Rezaei, N., Rezapour, A., Rhinehart, P. -A., Riahi, S. M., Ribeiro, D. C., Ribeiro, D., Rickard, J., Rivera, J. A., Roberts, N. L. S., Rodriguez-Ramirez, S., Roever, L., Ronfani, L., Room, R., Roshandel, G., Roth, G. A., Rothenbacher, D., Rubagotti, E., Rwegerera, G. M., Sabour, S., Sachdev, P. S., Saddik, B., Sadeghi, E., Sadeghi, M., Saeedi, R., Saeedi Moghaddam, S., Safari, Y., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sajadi, S. M., Salam, N., Salamati, P., Salem, H., Salem, M. R. R., Salimzadeh, H., Salman, O. M., Salomon, J. A., Samad, Z., Samadi Kafil, H., Sambala, E. Z., Samy, A. M., Sanabria, J., Sanchez-Pimienta, T. G., Santomauro, D. F., Santos, I. S., Santos, J. V., Santric-Milicevic, M. M., Saraswathy, S. Y. I., Sarmiento-Suarez, R., Sarrafzadegan, N., Sartorius, B., Sarveazad, A., Sathian, B., Sathish, T., Sattin, D., Saxena, S., Schaeffer, L. E., Schiavolin, S., Schlaich, M. P., Schmidt, M. I., Schutte, A. E., Schwebel, D. C., Schwendicke, F., Senbeta, A. M., Senthilkumaran, S., Sepanlou, S. G., Serdar, B., Serre, M. L., Shadid, J., Shafaat, O., Shahabi, S., Shaheen, A. A., Shaikh, M. A., Shalash, A. S., Shams-Beyranvand, M., Shamsizadeh, M., Sharafi, K., Sheikh, A., Sheikhtaheri, A., Shibuya, K., Shield, K. D., Shigematsu, M., Shin, J. I., Shin, M. -J., Shiri, R., Shirkoohi, R., Shuval, K., Siabani, S., Sierpinski, R., Sigfusdottir, I. D., Sigurvinsdottir, R., Silva, J. P., Simpson, K. E., Singh, J. A., Singh, P., Skiadaresi, E., Skou, S. T. S., Skryabin, V. Y., Smith, E. U. R., Soheili, A., Soltani, S., Soofi, M., Sorensen, R. J. D., Soriano, J. B., Sorrie, M. B., Soshnikov, S., Soyiri, I. N., Spencer, C. N., Spotin, A., Sreeramareddy, C. T., Srinivasan, V., Stanaway, J. D., Stein, C., Stein, D. J., Steiner, C., Stockfelt, L., Stokes, M. A., Straif, K., Stubbs, J. L., Sufiyan, M. B., Suleria, H. A. R., Suliankatchi Abdulkader, R., Sulo, G., Sultan, I., Szumowski, Tabares-Seisdedos, R., Tabb, K. M., Tabuchi, T., Taherkhani, A., Tajdini, M., Takahashi, K., Takala, J. S., Tamiru, A. T., Taveira, N., Tehrani-Banihashemi, A., Temsah, M. -H., Tesema, G. A., Tessema, Z. T., Thurston, G. D., Titova, M. V., Tohidinik, H. R., Tonelli, M., Topor-Madry, R., Topouzis, F., Torre, A. E., Touvier, M., Tovani-Palone, M. R. R., Tran, B. X., Travillian, R., Tsatsakis, A., Tudor Car, L., Tyrovolas, S., Uddin, R., Umeokonkwo, C. D., Unnikrishnan, B., Upadhyay, E., Vacante, M., Valdez, P. R., van Donkelaar, A., Vasankari, T. J., Vasseghian, Y., Veisani, Y., Venketasubramanian, N., Violante, F. S., Vlassov, V., Vollset, S. E., Vos, T., Vukovic, R., Waheed, Y., Wallin, M. T., Wang, Y., Wang, Y. -P., Watson, A., Wei, J., Wei, M. Y. W., Weintraub, R. G., Weiss, J., Werdecker, A., West, J. J., Westerman, R., Whisnant, J. L., Whiteford, H. A., Wiens, K. E., Wolfe, C. D. A., Wozniak, S. S., Wu, A. -M., Wu, J., Wulf Hanson, S., Xu, G., Xu, R., Yadgir, S., Yahyazadeh Jabbari, S. H., Yamagishi, K., Yaminfirooz, M., Yano, Y., Yaya, S., Yazdi-Feyzabadi, V., Yeheyis, T. Y., Yilgwan, C. S., Yilma, M. T., Yip, P., Yonemoto, N., Younis, M. Z., Younker, T. P., Yousefi, B., Yousefi, Z., Yousefinezhadi, T., Yousuf, A. Y., Yu, C., Yusefzadeh, H., Zahirian Moghadam, T., Zamani, M., Zamanian, M., Zandian, H., Zastrozhin, M. S., Zhang, Y., Zhang, Z. -J., Zhao, J. T., Zhao, X. -J. G., Zhao, Y., Zhou, M., Ziapour, A., Zimsen, S. R. M., Brauer, M., Afshin, A., Lim, S. S., Lacey, B, Sartorius, B, Abbafati, C, Abbas, K, Abbasi-Kangevari, M, Abd-Allah, F, Abdelalim, A, Abdollahi, M, Abdollahpour, I, Abegaz, K, Abolhassani, H, Aboyans, V, Abreu, L, Abrigo, M, Abualhasan, A, Abu-Raddad, L, Abushouk, A, Adabi, M, Adekanmbi, V, Adeoye, A, Adetokunboh, O, Adham, D, Advani, S, Afshin, A, Agarwal, G, Aghamir, S, Agrawal, A, Ahmad, T, Ahmadi, K, Ahmadi, M, Ahmadieh, H, Ahmed, M, Akalu, T, Akinyemi, R, Akinyemiju, T, Akombi, B, Akunna, C, Alahdab, F, Al-Aly, Z, Alam, K, Alam, S, Alam, T, Alanezi, F, Alanzi, T, Alemu, B, Alhabib, K, Ali, M, Ali, S, Alicandro, G, Alinia, C, Alipour, V, Alizade, H, Aljunid, S, Alla, F, Allebeck, P, Almasi-Hashiani, A, Al-Mekhlafi, H, Alonso, J, Altirkawi, K, Amini-Rarani, M, Amiri, F, Amugsi, D, Ancuceanu, R, Anderlini, D, Anderson, J, Andrei, C, Andrei, T, Angus, C, Anjomshoa, M, Ansari, F, Ansari-Moghaddam, A, Antonazzo, I, Antonio, C, Antony, C, Antriyandarti, E, Anvari, D, Anwer, R, Appiah, S, Arabloo, J, Arab-Zozani, M, Aravkin, A, Ariani, F, Armoon, B, Arnlov, J, Arzani, A, Asadi-Aliabadi, M, Asadi-Pooya, A, Ashbaugh, C, Assmus, M, Atafar, Z, Atnafu, D, Atout, M, Ausloos, F, Ausloos, M, Ayala Quintanilla, B, Ayano, G, Ayanore, M, Azari, S, Azarian, G, Azene, Z, Badawi, A, Badiye, A, Bahrami, M, Bakhshaei, M, Bakhtiari, A, Bakkannavar, S, Baldasseroni, A, Ball, K, Ballew, S, Balzi, D, Banach, M, Banerjee, S, Bante, A, Baraki, A, Barker-Collo, S, Barnighausen, T, Barrero, L, Barthelemy, C, Barua, L, Basu, S, Baune, B, Bayati, M, Becker, J, Bedi, N, Beghi, E, Bejot, Y, Bell, M, Bennitt, F, Bensenor, I, Berhe, K, Berman, A, Bhagavathula, A, Bhageerathy, R, Bhala, N, Bhandari, D, Bhattacharyya, K, Bhutta, Z, Bijani, A, Bikbov, B, Bin Sayeed, M, Biondi, A, Birihane, B, Bisignano, C, Biswas, R, Bitew, H, Bohlouli, S, Bohluli, M, Boon-Dooley, A, Borges, G, Borzi, A, Borzouei, S, Bosetti, C, Boufous, S, Braithwaite, D, Brauer, M, Breitborde, N, Breitner, S, Brenner, H, Briant, P, Briko, A, Briko, N, Britton, G, Bryazka, D, Bumgarner, B, Burkart, K, Burnett, R, Burugina Nagaraja, S, Butt, Z, Caetano Dos Santos, F, Cahill, L, Camera, L, Campos-Nonato, I, Cardenas, R, Carreras, G, Carrero, J, Carvalho, F, Castaldelli-Maia, J, Castaneda-Orjuela, C, Castelpietra, G, Castro, F, Causey, K, Cederroth, C, Cercy, K, Cerin, E, Chandan, J, Chang, K, Charlson, F, Chattu, V, Chaturvedi, S, Cherbuin, N, Chimed-Ochir, O, Cho, D, Choi, J, Christensen, H, Chu, D, Chung, M, Chung, S, Cicuttini, F, Ciobanu, L, Cirillo, M, Classen, T, Cohen, A, Compton, K, Cooper, O, Costa, V, Cousin, E, Cowden, R, Cross, D, Cruz, J, Dahlawi, S, Damasceno, A, Damiani, G, Dandona, L, Dandona, R, Dangel, W, Danielsson, A, Dargan, P, Darwesh, A, Daryani, A, Das, J, Das Gupta, R, das Neves, J, Davila-Cervantes, C, Davitoiu, D, De Leo, D, Degenhardt, L, Delang, M, Dellavalle, R, Demeke, F, Demoz, G, Demsie, D, Denova-Gutierrez, E, Dervenis, N, Dhungana, G, Dianatinasab, M, Dias da Silva, D, Diaz, D, Dibaji Forooshani, Z, Djalalinia, S, Do, H, Dokova, K, Dorostkar, F, Doshmangir, L, Driscoll, T, Duncan, B, Duraes, A, Eagan, A, Edvardsson, D, El Nahas, N, El Sayed, I, El Tantawi, M, Elbarazi, I, Elgendy, I, El-Jaafary, S, Elyazar, I, Emmons-Bell, S, Erskine, H, Eskandarieh, S, Esmaeilnejad, S, Esteghamati, A, Estep, K, Etemadi, A, Etisso, A, Fanzo, J, Farahmand, M, Fareed, M, Faridnia, R, Farioli, A, Faro, A, Faruque, M, Farzadfar, F, Fattahi, N, Fazlzadeh, M, Feigin, V, Feldman, R, Fereshtehnejad, S, Fernandes, E, Ferrara, G, Ferrari, A, Ferreira, M, Filip, I, Fischer, F, Fisher, J, Flor, L, Foigt, N, Folayan, M, Fomenkov, A, Force, L, Foroutan, M, Franklin, R, Freitas, M, Fu, W, Fukumoto, T, Furtado, J, Gad, M, Gakidou, E, Gallus, S, Garcia-Basteiro, A, Gardner, W, Geberemariyam, B, Ayalew Gebreslassie, A, Geremew, A, Gershberg Hayoon, A, Gething, P, Ghadimi, M, Ghadiri, K, Ghaffarifar, F, Ghafourifard, M, Ghamari, F, Ghashghaee, A, Ghiasvand, H, Ghith, N, Gholamian, A, Ghosh, R, Gill, P, Ginindza, T, Giussani, G, Gnedovskaya, E, Goharinezhad, S, Gopalani, S, Gorini, G, Goudarzi, H, Goulart, A, Greaves, F, Grivna, M, Grosso, G, Gubari, M, Gugnani, H, Guimaraes, R, Guled, R, Guo, G, Guo, Y, Gupta, R, Gupta, T, Haddock, B, Hafezi-Nejad, N, Hafiz, A, Haj-Mirzaian, A, Hall, B, Halvaei, I, Hamadeh, R, Hamidi, S, Hammer, M, Hankey, G, Haririan, H, Haro, J, Hasaballah, A, Hasan, M, Hasanpoor, E, Hashi, A, Hassanipour, S, Hassankhani, H, Havmoeller, R, Hay, S, Hayat, K, Heidari, G, Heidari-Soureshjani, R, Henrikson, H, Herbert, M, Herteliu, C, Heydarpour, F, Hird, T, Hoek, H, Holla, R, Hoogar, P, Hosgood, H, Hossain, N, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hsairi, M, Hsieh, V, Hu, G, Hu, K, Huda, T, Humayun, A, Huynh, C, Hwang, B, Iannucci, V, Ibitoye, S, Ikeda, N, Ikuta, K, Ilesanmi, O, Ilic, I, Ilic, M, Inbaraj, L, Ippolito, H, Iqbal, U, Irvani, S, Irvine, C, Islam, M, Islam, S, Iso, H, Ivers, R, Iwu, C, Iyamu, I, Jaafari, J, Jacobsen, K, Jafari, H, Jafarinia, M, Jahani, M, Jakovljevic, M, Jalilian, F, James, S, Janjani, H, Javaheri, T, Javidnia, J, Jeemon, P, Jenabi, E, Jha, R, Jha, V, Ji, J, Johansson, L, John, O, John-Akinola, Y, Johnson, C, Jonas, J, Joukar, F, Jozwiak, J, Jurisson, M, Kabir, A, Kabir, Z, Kalani, H, Kalani, R, Kalankesh, L, Kalhor, R, Kanchan, T, Kapoor, N, Matin, B, Karch, A, Karim, M, Kassa, G, Katikireddi, S, Kayode, G, Kazemi Karyani, A, Keiyoro, P, Keller, C, Kemmer, L, Kendrick, P, Khalid, N, Khammarnia, M, Khan, E, Khan, M, Khatab, K, Khater, M, Khatib, M, Khayamzadeh, M, Khazaei, S, Kieling, C, Kim, Y, Kimokoti, R, Kisa, A, Kisa, S, Kivimaki, M, Knibbs, L, Knudsen, A, Kocarnik, J, Kochhar, S, Kopec, J, Korshunov, V, Koul, P, Koyanagi, A, Kraemer, M, Krishan, K, Krohn, K, Kromhout, H, Kuate Defo, B, Kumar, G, Kumar, V, Kurmi, O, Kusuma, D, La Vecchia, C, Lal, D, Lalloo, R, Lallukka, T, Lami, F, Landires, I, Lang, J, Langan, S, Larsson, A, Lasrado, S, Lauriola, P, Lazarus, J, Lee, P, Lee, S, Legrand, K, Leigh, J, Leonardi, M, Lescinsky, H, Leung, J, Levi, M, Li, S, Lim, L, Linn, S, Liu, S, Liu, Y, Lo, J, Lopez, A, Lopez, J, Lopukhov, P, Lorkowski, S, Lotufo, P, Lu, A, Lugo, A, Maddison, E, Mahasha, P, Mahdavi, M, Mahmoudi, M, Majeed, A, Maleki, A, Maleki, S, Malekzadeh, R, Malta, D, Mamun, A, Manda, A, Manguerra, H, Mansour-Ghanaei, F, Mansouri, B, Mansournia, M, Mantilla Herrera, A, Maravilla, J, Marks, A, Martin, R, Martini, S, Martins-Melo, F, Masaka, A, Masoumi, S, Mathur, M, Matsushita, K, Maulik, P, Mcalinden, C, Mcgrath, J, Mckee, M, Mehndiratta, M, Mehri, F, Mehta, K, Memish, Z, Mendoza, W, Menezes, R, Mengesha, E, Mereke, A, Mereta, S, Meretoja, A, Meretoja, T, Mestrovic, T, Miazgowski, B, Miazgowski, T, Michalek, I, Miller, T, Mills, E, Mini, G, Miri, M, Mirica, A, Mirrakhimov, E, Mirzaei, H, Mirzaei, M, Mirzaei, R, Mirzaei-Alavijeh, M, Misganaw, A, Mithra, P, Moazen, B, Mohammad, D, Mohammad, Y, Mohammad Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadifard, N, Mohammadpourhodki, R, Mohammed, A, Mohammed, H, Mohammed, J, Mohammed, S, Mokdad, A, Molokhia, M, Monasta, L, Mooney, M, Moradi, G, Moradi, M, Moradi-Lakeh, M, Moradzadeh, R, Moraga, P, Morawska, L, Morgado-Da-Costa, J, Morrison, S, Mosapour, A, Mosser, J, Mouodi, S, Mousavi, S, Khaneghah, A, Mueller, U, Mukhopadhyay, S, Mullany, E, Musa, K, Muthupandian, S, Nabhan, A, Naderi, M, Nagarajan, A, Nagel, G, Naghavi, M, Naghshtabrizi, B, Naimzada, M, Najafi, F, Nangia, V, Nansseu, J, Naserbakht, M, Nayak, V, Negoi, I, Ngunjiri, J, Nguyen, C, Nguyen, H, Nguyen, M, Nigatu, Y, Nikbakhsh, R, Nixon, M, Nnaji, C, Nomura, S, Norrving, B, Noubiap, J, Nowak, C, Nunez-Samudio, V, Oancea, B, Odell, C, Ogbo, F, Oh, I, Okunga, E, Oladnabi, M, Olagunju, A, Olusanya, B, Olusanya, J, Omer, M, Ong, K, Onwujekwe, O, Orpana, H, Ortiz, A, Osarenotor, O, Osei, F, Ostroff, S, Otoiu, A, Otstavnov, N, Otstavnov, S, Overland, S, Owolabi, M, Mahesh, P, Padubidri, J, Palladino, R, Panda-Jonas, S, Pandey, A, Parry, C, Pasovic, M, Pasupula, D, Patel, S, Pathak, M, Patten, S, Patton, G, Toroudi, H, Peden, A, Pennini, A, Pepito, V, Peprah, E, Pereira, D, Pesudovs, K, Pham, H, Phillips, M, Piccinelli, C, Pilz, T, Piradov, M, Pirsaheb, M, Plass, D, Polinder, S, Polkinghorne, K, Pond, C, Postma, M, Pourjafar, H, Pourmalek, F, Poznanska, A, Prada, S, Prakash, V, Pribadi, D, Pupillo, E, Syed, Z, Rabiee, M, Rabiee, N, Radfar, A, Rafiee, A, Raggi, A, Rahman, M, Rajabpour-Sanati, A, Rajati, F, Rakovac, I, Ram, P, Ramezanzadeh, K, Ranabhat, C, Rao, P, Rao, S, Rashedi, V, Rathi, P, Rawaf, D, Rawaf, S, Rawal, L, Rawassizadeh, R, Rawat, R, Razo, C, Redford, S, Reiner, R, Reitsma, M, Remuzzi, G, Renjith, V, Renzaho, A, Resnikoff, S, Rezaei, N, Rezapour, A, Rhinehart, P, Riahi, S, Ribeiro, D, Rickard, J, Rivera, J, Roberts, N, Rodriguez-Ramirez, S, Roever, L, Ronfani, L, Room, R, Roshandel, G, Roth, G, Rothenbacher, D, Rubagotti, E, Rwegerera, G, Sabour, S, Sachdev, P, Saddik, B, Sadeghi, E, Sadeghi, M, Saeedi, R, Saeedi Moghaddam, S, Safari, Y, Safi, S, Safiri, S, Sagar, R, Sahebkar, A, Sajadi, S, Salam, N, Salamati, P, Salem, H, Salem, M, Salimzadeh, H, Salman, O, Salomon, J, Samad, Z, Samadi Kafil, H, Sambala, E, Samy, A, Sanabria, J, Sanchez-Pimienta, T, Santomauro, D, Santos, I, Santos, J, Santric-Milicevic, M, Saraswathy, S, Sarmiento-Suarez, R, Sarrafzadegan, N, Sarveazad, A, Sathian, B, Sathish, T, Sattin, D, Saxena, S, Schaeffer, L, Schiavolin, S, Schlaich, M, Schmidt, M, Schutte, A, Schwebel, D, Schwendicke, F, Senbeta, A, Senthilkumaran, S, Sepanlou, S, Serdar, B, Serre, M, Shadid, J, Shafaat, O, Shahabi, S, Shaheen, A, Shaikh, M, Shalash, A, Shams-Beyranvand, M, Shamsizadeh, M, Sharafi, K, Sheikh, A, Sheikhtaheri, A, Shibuya, K, Shield, K, Shigematsu, M, Shin, J, Shin, M, Shiri, R, Shirkoohi, R, Shuval, K, Siabani, S, Sierpinski, R, Sigfusdottir, I, Sigurvinsdottir, R, Silva, J, Simpson, K, Singh, J, Singh, P, Skiadaresi, E, Skou, S, Skryabin, V, Smith, E, Soheili, A, Soltani, S, Soofi, M, Sorensen, R, Soriano, J, Sorrie, M, Soshnikov, S, Soyiri, I, Spencer, C, Spotin, A, Sreeramareddy, C, Srinivasan, V, Stanaway, J, Stein, C, Stein, D, Steiner, C, Stockfelt, L, Stokes, M, Straif, K, Stubbs, J, Sufiyan, M, Suleria, H, Suliankatchi Abdulkader, R, Sulo, G, Sultan, I, Tabares-Seisdedos, R, Tabb, K, Tabuchi, T, Taherkhani, A, Tajdini, M, Takahashi, K, Takala, J, Tamiru, A, Taveira, N, Tehrani-Banihashemi, A, Temsah, M, Tesema, G, Tessema, Z, Thurston, G, Titova, M, Tohidinik, H, Tonelli, M, Topor-Madry, R, Topouzis, F, Torre, A, Touvier, M, Tovani-Palone, M, Tran, B, Travillian, R, Tsatsakis, A, Tudor Car, L, Tyrovolas, S, Uddin, R, Umeokonkwo, C, Unnikrishnan, B, Upadhyay, E, Vacante, M, Valdez, P, van Donkelaar, A, Vasankari, T, Vasseghian, Y, Veisani, Y, Venketasubramanian, N, Violante, F, Vlassov, V, Vollset, S, Vos, T, Vukovic, R, Waheed, Y, Wallin, M, Wang, Y, Watson, A, Wei, J, Wei, M, Weintraub, R, Weiss, J, Werdecker, A, West, J, Westerman, R, Whisnant, J, Whiteford, H, Wiens, K, Wolfe, C, Wozniak, S, Wu, A, Wu, J, Wulf Hanson, S, Xu, G, Xu, R, Yadgir, S, Yahyazadeh Jabbari, S, Yamagishi, K, Yaminfirooz, M, Yano, Y, Yaya, S, Yazdi-Feyzabadi, V, Yeheyis, T, Yilgwan, C, Yilma, M, Yip, P, Yonemoto, N, Younis, M, Younker, T, Yousefi, B, Yousefi, Z, Yousefinezhadi, T, Yousuf, A, Yu, C, Yusefzadeh, H, Moghadam, T, Zamani, M, Zamanian, M, Zandian, H, Zastrozhin, M, Zhang, Y, Zhang, Z, Zhao, J, Zhao, X, Zhao, Y, Zheng, P, Zhou, M, Ziapour, A, Zimsen, S, Lim, S, Murray, C, GBD 2019 Risk Factors Collaborator, Violante FS, Biosciences, Department of Public Health, Clinicum, Department of Neurosciences, HUS Comprehensive Cancer Center, Environmental Sciences, Sub Foundations&PhilosophyofNaturSc begr, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Public Health, Bin Sayeed, M. S. B., Caetano Dos Santos, F. L., Camera, L. A., Elyazar, I. R. F., Ayalew Gebreslassie, A. A. A., Ginindza, T. G., Matin, B. K., Morgado-Da-Costa, J., Khaneghah, A. M., Mahesh, P. A., Toroudi, H. P., Syed, Z. Q., Salem, M. R., Skou, S. T., Tovani-Palone, M. R., Tudor Car, L. T., and Moghadam, T. Z.
- Subjects
Male ,Nutritional Sciences ,Specific risk ,Contaminación del Aire Interior ,030204 cardiovascular system & hematology ,Socioeconomic Factor ,systematic analysis ,Global Health ,Body Mass Index ,Global Burden of Disease ,Health Risk Behavior ,Health Risk Behaviors ,Disease studies ,0302 clinical medicine ,Risk Factors ,METABOLIC RISKS ,030212 general & internal medicine ,11 Medical and Health Sciences ,Factores de Riesgo ,2. Zero hunger ,education.field_of_study ,Public health ,Injuries ,Public Health, Global Health, Social Medicine and Epidemiology ,General Medicine ,GBD ,risck factors ,attributable burden of disease ,3142 Public health care science, environmental and occupational health ,3. Good health ,Relative risk ,Environmental health ,Health ,Hypertension ,Global Burden of Diseases, Injuries, Risk Factors ,A990 Medicine and Dentistry not elsewhere classified ,Female ,Leading risk factors ,Global Health Metrics ,Cohort study ,Human ,medicine.medical_specialty ,Substance-Related Disorders ,Population ,UNITED-STATES ,Risk Assessment ,DIET ,ITC-HYBRID ,03 medical and health sciences ,Life Expectancy ,MORTALITY ,DISABILITY ,POLLUTION ,CLUSTERS ,SDG 3 - Good Health and Well-being ,General & Internal Medicine ,medicine ,Humans ,Global Burden of Disease Study ,Risk factor ,education ,Global burden ,business.industry ,Risk Factor ,Malnutrition ,Klinisk medicin ,Global Burden of Diseases ,Environmental Exposure ,medicine.disease ,Enfermedades ,purl.org/pe-repo/ocde/ford#3.02.00 [https] ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Years of potential life lost ,Socioeconomic Factors ,Risk factors ,Disease study ,Hyperglycemia ,ITC-ISI-JOURNAL-ARTICLE ,NA ,Clinical Medicine ,business ,RA - Abstract
Background Rigorous analysis of levels and trends in exposure to leading risk factors and quantification of their effect on human health are important to identify where public health is making progress and in which cases current efforts are inadequate. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a standardised and comprehensive assessment of the magnitude of risk factor exposure, relative risk, and attributable burden of disease. Methods GBD 2019 estimated attributable mortality, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 87 risk factors and combinations of risk factors, at the global level, regionally, and for 204 countries and territories. GBD uses a hierarchical list of risk factors so that specific risk factors (eg, sodium intake), and related aggregates (eg, diet quality), are both evaluated. This method has six analytical steps. (1) We included 560 risk-outcome pairs that met criteria for convincing or probable evidence on the basis of research studies. 12 risk-outcome pairs included in GBD 2017 no longer met inclusion criteria and 47 risk-outcome pairs for risks already included in GBD 2017 were added based on new evidence. (2) Relative risks were estimated as a function of exposure based on published systematic reviews, 81 systematic reviews done for GBD 2019, and meta-regression. (3) Levels of exposure in each age-sex-location-year included in the study were estimated based on all available data sources using spatiotemporal Gaussian process regression, DisMod-MR 2.1, a Bayesian meta-regression method, or alternative methods. (4) We determined, from published trials or cohort studies, the level of exposure associated with minimum risk, called the theoretical minimum risk exposure level. (5) Attributable deaths, YLLs, YLDs, and DALYs were computed by multiplying population attributable fractions (PAFs) by the relevant outcome quantity for each age-sex-location-year. (6) PAFs and attributable burden for combinations of risk factors were estimated taking into account mediation of different risk factors through other risk factors. Across all six analytical steps, 30 652 distinct data sources were used in the analysis. Uncertainty in each step of the analysis was propagated into the final estimates of attributable burden. Exposure levels for dichotomous, polytomous, and continuous risk factors were summarised with use of the summary exposure value to facilitate comparisons over time, across location, and across risks. Because the entire time series from 1990 to 2019 has been re-estimated with use of consistent data and methods, these results supersede previously published GBD estimates of attributable burden. Findings The largest declines in risk exposure from 2010 to 2019 were among a set of risks that are strongly linked to social and economic development, including household air pollution; unsafe water, sanitation, and handwashing; and child growth failure. Global declines also occurred for tobacco smoking and lead exposure. The largest increases in risk exposure were for ambient particulate matter pollution, drug use, high fasting plasma glucose, and high body-mass index. In 2019, the leading Level 2 risk factor globally for attributable deaths was high systolic blood pressure, which accounted for 10.8 million (95% uncertainty interval [UI] 9.51-12.1) deaths (19.2% [16.9-21.3] of all deaths in 2019), followed by tobacco (smoked, second-hand, and chewing), which accounted for 8.71 million (8.12-9.31) deaths (15.4% [14.6-16.2] of all deaths in 2019). The leading Level 2 risk factor for attributable DALYs globally in 2019 was child and maternal malnutrition, which largely affects health in the youngest age groups and accounted for 295 million (253-350) DALYs (11.6% [10.3-13.1] of all global DALYs that year). The risk factor burden varied considerably in 2019 between age groups and locations. Among children aged 0-9 years, the three leading detailed risk factors for attributable DALYs were all related to malnutrition. Iron deficiency was the leading risk factor for those aged 10-24 years, alcohol use for those aged 25-49 years, and high systolic blood pressure for those aged 50-74 years and 75 years and older. Interpretation Overall, the record for reducing exposure to harmful risks over the past three decades is poor. Success with reducing smoking and lead exposure through regulatory policy might point the way for a stronger role for public policy on other risks in addition to continued efforts to provide information on risk factor harm to the general public. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
- Published
- 2020
- Full Text
- View/download PDF
27. Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review
- Author
-
Abedin Teimourizad, Masih Tajdini, Saeed Sadeghian, and Aziz Rezapour
- Subjects
Medicine (General) ,medicine.medical_specialty ,Cost effectiveness ,medicine.medical_treatment ,Cardiac resynchronization therapy ,MEDLINE ,Heart failure ,Review ,030204 cardiovascular system & hematology ,Cochrane Library ,03 medical and health sciences ,R5-920 ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,health care economics and organizations ,business.industry ,Health Policy ,Health services research ,Implantable cardioverter-defibrillator ,medicine.disease ,Checklist ,Emergency medicine ,Systematic review ,Cost-effectiveness ,business ,Implantable cardiac devices - Abstract
Introduction Heart failure (HF) is an unusual heart function that causes reduction in cardiac or pulmonary output. Cardiac resynchronization therapy (CRT) is a mechanical device that helps to recover ventricular dysfunction by pacing the ventricles. This study planned to systematically review cost-effectiveness of CRT combined with an implantable cardioverter-defibrillator (ICD) versus ICD in patients with HF. Methods We used five databases (NHS Economic Evaluation Database, Cochrane Library, Medline, PubMed, and Scopus) to systematically reviewed studies published in the English language on the cost-effectiveness of CRT with defibrillator (CRT-D) Vs. ICD in patients with HF over 2000 to 2020. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was applied to assess the quality of the selected studies. Results Five studies reporting the cost-effectiveness of CRT-D vs ICD were finally identified. The results revealed that time horizon, direct medical costs, type of model, discount rate, and sensitivity analysis obviously mentioned in almost all studies. All studies used quality-adjusted life years (QALYs) as an effectiveness measurement. The highest and the lowest Incremental cost-effectiveness ratio (ICER) were reported in the USA ($138,649per QALY) and the UK ($41,787per QALY), respectively. Conclusion Result of the study showed that CRT-D compared to ICD alone was the most cost-effective treatment in patients with HF.
- Published
- 2020
28. One-Year Outcome of Patients with Coronary Artery Ectasia Undergoing Percutaneous Coronary Intervention: Clinical Implications and Question Marks
- Author
-
Arash Jalali, Hamidreza Pourhosseini, Zahra Hosseini, Seyed-Ali Sadre-Bafghi, Mohammad Alidoosti, Hassan Aghajani, Mehrnaz Mohebi, Mojtaba Salarifar, Alireza Amirzadegan, Negar Omidi, Saeed Ghodsi, Hamidreza Soleimani, Yones Nozari, Masih Tajdini, Yaser Jenab, Alimohammad Hajizeinali, and Ebrahim Nematipour
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Revascularization ,Coronary artery disease ,Dilatation, pathologic ,Percutaneous coronary intervention ,Internal medicine ,Angioplasty ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Myocardial infarction ,cardiovascular diseases ,Mortality ,business.industry ,Coronary artery ectasia ,medicine.disease ,Prognosis ,RC666-701 ,Cardiology ,Dilatation ,pathologic ,Original Article ,Cardiology and Cardiovascular Medicine ,business ,TIMI ,Mace - Abstract
Background: Coronary artery ectasia (CAE) is a rare condition with unclear pathophysiology, optimal treatment, and prognosis. We aimed to determine the prognostic implications of CAE following coronary angioplasty. Methods: We conducted a retrospective cohort study on 385 patients, including 87 subjects with CAE, who underwent percutaneous coronary intervention (PCI). Major adverse cardiovascular events (MACE) were considered to consist of mortality, nonfatal myocardial infarction (MI), repeated revascularization, and stroke. Results: The mean age of the participants was 57.31±6.70 years. Multivariate regression analysis revealed that patients with diabetes, ST-segment–elevation MI at presentation, and high thrombus grades were more likely to have suboptimal postPCI thrombolysis in myocardial infarction (TIMI) flow. However, CAE was not a predictor of a decreased TIMI flow (OR: 1.46, 95% CI: 0.78–8.32; P=0.391). The Cox-regression model showed that CAE, the body mass index, and a family history of MI were risk factors for MACE, while short lesion lengths (20 mm) had an inverse relationship. The adjusted hazard ratio (HR) for the prediction of MACE in the presence of CAE was 1.65 (95% CI: 1.08–4.78; P=0.391). All-cause mortality (HR: 1.69, 95% CI: 0.12–3.81; P=0.830) and nonfatal MI (HR: 1.03, 95% CI: 0.72–4.21; P=0.341) occurred similarly in the CAE and non-CAE groups. Conversely, CAE increased urgent repeat revascularization (HR: 2.40; 95% CI: 1.13–5.86; P=0.013) Conclusion: Although CAE had no substantial short-term prognostic effects on post-PCI TIMI flow, considerable concerns regarding adverse outcomes emerged during our extended follow-up. Stringent follow-ups of these patients should be underscored due to the high likelihood of urgent revascularization.
- Published
- 2020
29. The Syncope Unit of Tehran Heart Center
- Author
-
Masih Tajdini, Arya Aminorroaya, and Saeed Sadeghian
- Subjects
medicine.medical_specialty ,biology ,business.industry ,MEDLINE ,Syncope (genus) ,Heart ,Iran ,biology.organism_classification ,Syncope ,Emergency medicine ,medicine ,Humans ,Center (algebra and category theory) ,Cardiology and Cardiovascular Medicine ,business ,Emergency Service, Hospital - Published
- 2020
30. Unusual case of tricuspid atresia and transposition of the great arteries presenting with aortic dissection: A rare condition
- Author
-
Ali Hosseinsabet, Saeed Tofighi, Keyvan Ghasemi, and Masih Tajdini
- Subjects
medicine.medical_specialty ,lcsh:Internal medicine ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Chest Pain ,Transposition of Great Vessels ,lcsh:Medicine ,Tricuspid Atresia ,Transposition (music) ,Diagnosis, Differential ,Young Adult ,Aneurysm ,medicine ,Humans ,Tricuspid atresia ,lcsh:RC31-1245 ,Aortic dissection ,transposition of the great arteries ,Unusual case ,business.industry ,lcsh:R ,medicine.disease ,Surgery ,Aortic Dissection ,Dyspnea ,Great arteries ,lcsh:RC666-701 ,Echocardiography ,Female ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
31. A New Feasible Syncope Risk Score Appropriate for Emergency Department: A Prospective Cohort Study
- Author
-
Arash Jalali, Masih Tajdini, Kaveh Hosseini, and Ali Bozorgi
- Subjects
Male ,Pacemaker, Artificial ,San Francisco Syncope Rule ,Myocardial Infarction ,030204 cardiovascular system & hematology ,Cohort Studies ,Electrocardiography ,0302 clinical medicine ,Natriuretic Peptide, Brain ,Odds Ratio ,Oximetry ,Prospective Studies ,030212 general & internal medicine ,Hypoxia ,Prospective cohort study ,education.field_of_study ,Framingham Risk Score ,Incidence ,Middle Aged ,Prognosis ,Defibrillators, Implantable ,Stroke ,Cardiovascular Diseases ,Area Under Curve ,Female ,Emergency Service, Hospital ,Cardiology and Cardiovascular Medicine ,Intracranial Hemorrhages ,Cohort study ,Adult ,medicine.medical_specialty ,Population ,Risk Assessment ,Syncope ,Prosthesis Implantation ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Cardiac Surgical Procedures ,Mortality ,education ,business.industry ,Stroke Volume ,Odds ratio ,Emergency department ,Subarachnoid Hemorrhage ,Peptide Fragments ,Confidence interval ,Feasibility Studies ,business ,Follow-Up Studies - Abstract
BACKGROUND We aimed to compare current syncope risk stratification scores and propose a new more feasible and easy-to-use one. METHODS In this prospective cohort study, we enrolled all patients (≥18 years) with chief complaint of syncope if they were not eligible for admission in terms of high-risk features. San Francisco Syncope Rule, Osservatorio Epidemiologico sulla Sincope nel Lazio, and risk stratification of syncope in the emergency department scores were compared in our population. RESULTS Overall, 356 patients (mean age: 44.5 years, 46.3% male) were followed for 3 months. Serious adverse events occurred in 26 (7.3%) patients including 4 deaths. Odds ratio for adverse events was 6.8 [95% confidence interval (CI), 2.8-16.1; P < 0.001; area under the curve (AUC): 66.3], 7.7 (95% CI, 3.2-18; P < 0.001; AUC: 72.8), and 18 (95% CI, 7.1-45.4; P < 0.001; AUC: 70.8) when considering San Francisco Syncope Rule, Osservatorio Epidemiologico sulla Sincope nel Lazio, and risk stratification of syncope in the emergency department scores as the predicting tools, respectively. We proposed a relatively more feasible risk score (presenting symptoms, history of cardiovascular diseases, ejection fraction
- Published
- 2018
- Full Text
- View/download PDF
32. Tehran cohort study (TeCS) on cardiovascular diseases, injury, and mental health: Design, methods, and recruitment data
- Author
-
Farshid Alaeddini, Haleh Ashraf, Ahmad Ali Noorbala, Saeed Sadeghian, Nazila Shahmansouri, Mashyaneh Haddadi, Arash Jalali, Mohammadreza Zafarghandi, Farzad Masoudkabir, Mohamamdali Boroumand, Negar Omidi, Mojtaba Salarifar, Abbasali Karimi, Soheil Saadat, Hamidreza Poorhosseini, Akbar Shafiee, Masih Tajdini, and Mohammad Ali Mansournia
- Subjects
Past medical history ,medicine.medical_specialty ,Epidemiology ,business.industry ,Incidence (epidemiology) ,Population sample ,Cohort ,Public Health, Environmental and Occupational Health ,Injury ,Study design ,Infectious and parasitic diseases ,RC109-216 ,Disease ,Anthropometry ,medicine.disease ,Mental health ,Biobank ,Angina ,Psychosocial health ,Cardiovascular diseases ,Infectious Diseases ,Family medicine ,Medicine ,business ,Cohort study - Abstract
Cardiovascular disease, mental health, and injury are among the top health issues globally. In Tehran Cohort Study, we aimed to determine the prevalence, incidence, and trend of cardiovascular diseases, psychiatric symptoms, injury, and risk factors in Tehran households. We enrolled 4215 households in the recruitment phase from March 2016 to March 2019. Demographic characteristics, past medical history, medications, and familial history of the participants were collected. Rose angina pectoris, general health Questionnaire-28 (GHQ-28), and injury questionnaires were completed. Fasting blood samples were collected to measure routine biochemistry and store samples in the biobank. Anthropometric and physiological measurements and electrocardiograms were performed. The participants are followed every three years for up to 12 years. In total, 8296 individuals participated in the cardiovascular section, 10247 completed the GHQ-28, and 4167 households completed the injury questionnaire. The mean age of the participants was 48.2 (16.41), and 46.5% were male. 64.3% of recruited individuals had no symptoms of psychiatric disorders, and 3729 (89.5%) households did not have any severe injury requiring treatment. The participants' diversity and their invaluable data will help us provide a general picture of the current prevalence and incidence of the main study objectives.
- Published
- 2021
- Full Text
- View/download PDF
33. Association of serum gamma-glutamyltransferase and premature coronary artery disease
- Author
-
Alireza Amirzadegan, Masih Tajdini, M Sotoudeh Anvari, Hamidreza Poorhosseini, Akbar Shafiee, Arash Jalali, and Mahboobeh Sheikh
- Subjects
0301 basic medicine ,Acute coronary syndrome ,medicine.medical_specialty ,Coronary angiography ,Premature coronary artery disease ,Disease ,030204 cardiovascular system & hematology ,Chest pain ,digestive system ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Gamma-glutamyltransferase ,medicine.diagnostic_test ,biology ,Receiver operating characteristic ,business.industry ,Confounding ,medicine.disease ,digestive system diseases ,030104 developmental biology ,Angiography ,biology.protein ,Cardiology ,Original Article ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Lipid profile ,business - Abstract
Background Serum gamma-glutamyltransferase (GGT) has been introduced as a predictive factor for cardiovascular disease. In this study, we investigated the association of serum GGT and premature coronary artery disease (CAD) in candidates for coronary angiography. Methods In this cross-sectional study, we enrolled male subjects aged ≤45 years and female subjects ≤55 years who were candidates for elective coronary angiography due to typical chest pain or a positive non-invasive test. Baseline characteristics were recorded for all the participants and serum levels of blood glucose, lipid profile and GGT were measured. Patients were divided into CAD and non-CAD groups based on angiography for further comparisons. Results From a total of 367 patients (age 45.1 ± 6.1 years, 161 males [43.9%]), 176 (47.9%) patients had premature CAD. A high level of GGT was significantly associated with the presence of CAD (p < 0.001). A 10-unit increase in GGT could strongly predict the presence of premature coronary artery disease (OR: 13.34, 95% CI: 7.19–24.78; p < 0.001) after adjustment for confounders. The area under the receiver operating characteristic curve for GGT was 80.9% (range 76.5–85.3) and the sensitivity and specificity of GGT at a cut-point of 22.5 IU/l was 80.1% and 70.2%, respectively. Diagnostic accuracy of GGT was 74.9%. The positive predictive value and negative predictive value for GGT was 71.3 and 79.3, respectively. Conclusion We observed that GGT levels in patients with typical chest pain or positive non-invasive tests could predict the presence of premature CAD in young patients.
- Published
- 2017
34. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- Author
-
Sorin Hostiuc, Shaun Wen Huey Lee, Jorge R. Ledesma, Carsten Flohr, Masoumeh Sadeghi, João Mauricio Castaldelli-Maia, Behzad Karami Matin, Cyrus Alinia, Mehdi Bohluli, Félix Carvalho, Yun Jin Kim, Catalina Liliana Andrei, Seyyed Meysam Mousavi, Bernhard T. Baune, Ehsan Ahmadpour, Dinh-Toi Chu, Beatrix Haddock, Gianfranco Alicandro, Vasily Vlassov, Mohammad Taghi Khodayari, Gianna Gayle Herrera Amul, Arash Tehrani-Banihashemi, Govinda Prasad Dhungana, Fereshteh Ansari, Michael K. Hole, Azeem Majeed, Iman Halvaei, Saqib Ali, Arianna Maever L. Amit, Tomas Y. Yeheyis, John S. Ji, Martin McKee, Jamileh Shadid, Leonardo Roever, Peng Jia, Ettore Beghi, Pablo M. Lavados, Young Eun Kim, Vahid Alipour, Sowmya J. Rao, Ahmad Daryani, Cathleen Keller, Ibrahim Abdollahpour, Nicole K. DeCleene, Ebrahim Babaee, Saman Esmaeilnejad, Boris Bikbov, William M. Gardner, Lydia M. Haile, Luca Ronfani, Azalea M. Thomson, Irena Ilic, Ruth W. Kimokoti, Yingxi Zhao, Guoqing Hu, Mehran Shams-Beyranvand, Ilais Moreno Velásquez, Nathaniel J. Henry, Brijesh Sathian, Daniel Kim, Peter Memiah, Mohammad Hadi Abbasi, Andrea Farioli, Zahra Kamiab, Bolajoko O. Olusanya, Matthew C. Doxey, Tommi Vasankari, Hamideh Salimzadeh, Luisa Sorio Flor, Priya Rathi, Shanshan Li, Tanvir M. Huda, Dillon O Sylte, Rosario Cárdenas, Agegnehu Bante, Helen Ippolito, Alyssa Acebedo, Jeffrey D. Stanaway, Anwar Faraj, João Pedro Silva, Amin Mousavi Khaneghah, Pushpendra Kumar, Sangram Kishor Patel, Josephine W. Ngunjiri, Holly E. Erskine, Eugene Sobngwi, Filippo Ariani, Shane D. Morrison, Mohammad Aghaali, Meghan D. Mooney, Vera Marisa Costa, Palash Chandra Banik, Rupak Desai, Ken Takahashi, Maigeng Zhou, Morteza Oladnabi, Bogdan Oancea, Daniela Ribeiro, Mohammad Farahmand, Irmina Maria Michalek, Yetunde O. John-Akinola, Khem Narayan Pokhrel, Emilie R Maddison, Syed Mohamed Aljunid, Damian G. Hoy, Hosni Salem, V. Prakash, Shuhei Nomura, Inga Dora Sigfusdottir, Anders Larsson, Sharareh Eskandarieh, Abdollah Mohammadian-Hafshejani, Somayeh Bohlouli, Joana Morgado-da-Costa, Siamak Sabour, Theo Vos, Han Yong Wunrow, Khaled Khatab, Alireza Zangeneh, Ann Kristin Knudsen, Marissa B Reitsma, Hannah J. Henrikson, Randah R. Hamadeh, Tuomo J. Meretoja, Ireneous N. Soyiri, Giuseppe Grosso, Ziyad Al-Aly, Taraneh Yousefinezhadi, Joseph L Ward, Roba Khundkar, Ricardo Santiago Gomez, Reza Malekzadeh, John J. McGrath, Sandra B. Munro, Shahin Soltani, Amy E. Peden, Rufus Akinyemi, Marcel Ausloos, Naohiro Yonemoto, Bogdan Wojtyniak, Ahmad Ghashghaee, Guilherme Borges, Sadia Bibi, Farhad Islami, Hamed Mirzaei, Mohammad Ali Sahraian, M. Ashworth Dirac, Hosna Janjani, Kairat Davletov, Hermann Brenner, Yuichiro Yano, Elissa M. Abrams, Ana Vukovic, Bartosz Miazgowski, Jobert Richie Nansseu, Jennifer O Lam, Mona Pathak, Leeberk Raja Inbaraj, Thirunavukkarasu Sathish, Asadollah Gholamian, Carlos A Castañeda-Orjuela, Babak Eshrati, Edgar Denova-Gutiérrez, Atte Meretoja, Lorenzo Monasta, Ronan A. Lyons, Neda Kianipour, Desalegn Getnet Demsie, Yasir Waheed, Desta Debalkie Atnafu, Davide Sattin, Kevin S Ikuta, Ghobad Moradi, Srinivas Goli, Krittika Bhattacharyya, Mika Kivimäki, Christopher Troeger, Jordi Alonso, Alireza Ahmadi, Navid Manafi, Caroline Stein, Songhomitra Panda-Jonas, Jason Nguyen, Moses K. Muriithi, Aziz Rezapour, Ismael R. Campos-Nonato, Adrian Pana, H. Dean Hosgood, Noore Alam, James L. Fisher, Mariam Molokhia, Susan F. Rumisha, Ernoiz Antriyandarti, Ayman Grada, Emma Nichols, Babak Asghari, André Luiz Sena Guimarães, Ferrán Catalá-López, Aletta E. Schutte, Fiona B. Bennitt, Maciej Banach, Antonio Biondi, Donal Bisanzio, Josip Car, Ronny Westerman, Shafiu Mohammed, Biniyam Sahiledengle Geberemariyam, Kenji Shibuya, Meghdad Pirsaheb, Milena Santric-Milicevic, Karen M. Tabb, Paula Moraga, Soheil Hassanipour, Hasan Yusefzadeh, Avina Vongpradith, Dara K. Mohammad, Ralph Maddison, Babak Moazen, Getachew Mullu Kassa, Rahman Shiri, Fernando Neves Hugo, Hmwe H Kyu, Zachary V Dingels, Florian Fischer, Valentin Yurievich Skryabin, Rafael Tabarés-Seisdedos, Massimo Cirillo, Nikita Otstavnov, Robert C. Reiner, Van C. Lansingh, Rodrigo Sarmiento-Suarez, Ashkan Afshin, Benjamin A Stark, Mohsen Abbasi-Kangevari, Natalie C. Galles, Behnam Heidari, Eun-Kee Park, Mohammad Ali Jahani, Suzanne Polinder, Mahalaqua Nazli Khatib, Farhad Jadidi-Niaragh, Amir Radfar, Mowafa Househ, Derrick A Bennett, Gaorui Guo, Hesam Ghiasvand, Taweewat Wiangkham, Tamás Joó, Cristiana Abbafati, Kathryn Mei Ming Lau, Anita K. Nandi, Miklós Szócska, Manasi Kumar, Eduardo A. Undurraga, Oladimeji M. Adebayo, Simon Yadgir, Victor Aboyans, Justin J. Lang, Catherine O. Johnson, Soewarta Kosen, Carla Sofia e.Sá Farinha, Marcos Roberto Tovani-Palone, Kamarul Imran Musa, Farshad Pourmalek, Kiomars Sharafi, Heather Orpana, Samuel B. Albertson, Mahdi Afshari, Nicholas J K Breitborde, Nelson J. Alvis-Zakzuk, Adrian Oţoiu, Iván Landires, Robert G. Weintraub, Kidanemaryam Berhe, André Faro, Sophia Emmons-Bell, Lauren E. Schaeffer, Alexandre C. Pereira, Mehdi Naderi, Yordanos Gizachew Yeshitila, Mehdi Hosseinzadeh, Arash Etemadi, Oleguer Plana-Ripoll, Theodore Patrick Younker, Joemer C. Maravilla, Alireza Ansari-Moghaddam, Borhan Mansouri, Narayanaswamy Venketasubramanian, Seyed Mohammad Kazem Aghamir, Linda Morales, Amanda Deen, Noushin Mohammadifard, Obinna Onwujekwe, Ai Koyanagi, Michele Nguyen, Chieh Han, Kiana Ramezanzadeh, Mika Shigematsu, Mohammed Shannawaz, Khurshid Alam, Javad Nazari, Bryan L. Sykes, Rajat Das Gupta, Stephen S Lim, Lingkan Barua, Zubair Kabir, Michael Brauer, Afarin Rahimi-Movaghar, Deepa Jahagirdar, Kaja Abbas, Gholamreza Bazmandegan, Mark A. Stokes, Rajaa Al-Raddadi, Kanyin L. Ong, Kate Causey, Ahmed Omar Bali, Matilde Leonardi, Jeffrey V. Lazarus, Wondimeneh Shibabaw Shiferaw, André Karch, Blair R. Bumgarner, Nelson Alvis-Guzman, Jennifer H MacLachlan, Saeed Amini, Parvaiz A Koul, Blessing J. Akombi, Ro Ting Lin, Dabere Nigatu, Alaa Badawi, Flavia M. Cicuttini, Deanna Anderlini, Claudio Alberto Dávila-Cervantes, Rupert R A Bourne, Tanuj Kanchan, Catherine P. Benziger, Tahiya Alam, M. Mofizul Islam, Muktar Omer Omer, Leila Zaki, Mehdi Mirzaei-Alavijeh, Inbal Salz, Katharine J Looker, Shiwei Liu, Fatemeh Amiri, Christopher R. Cederroth, Mitra Abbasifard, Hamidreza Pazoki Toroudi, Gbenga A. Kayode, Antonio Luiz Pinho Ribeiro, Krishna Kumar Aryal, Mu'awiyyah Babale Sufiyan, Mohamed M. Gad, Assefa Desalew, Lidia Morawska, Davood Anvari, Mohammad Reza Salahshoor, Hadi Pourjafar, Abdu A. Adamu, Maryam Adabi, Zulfiqar A. Bhutta, Jessica A. Cruz, Foad Abd-Allah, Amir Hasanzadeh, Jordan Weiss, Maryam Ghadimi, Seyed-Mohammad Fereshtehnejad, Serge Resnikoff, Joanna L Whisnant, Kelly Compton, Priya Parmar, Sanjay Basu, Leila R Kalankesh, Nickolas Reinig, Ana Maria Mantilla Herrera, Fatemeh Rajati, Damian Santomauro, Mojisola Oluwasanu, Sheikh Mohammed Shariful Islam, David M. Pereira, Joht Singh Chandan, Deepak Kumar Pasupula, Aristidis Tsatsakis, Hoa Thi Do, Whitney L. Teagle, Hans W. Hoek, James Leigh, Morteza Arab-Zozani, Yasser Vasseghian, Stephanie R M Zimsen, Charlie Ashbaugh, Fariba Dorostkar, Abdelrahman Ibrahim Abushouk, Mikk Jürisson, Golnaz Heidari, Kala M. Mehta, Saeed Shahabi, Sarah Wulf Hanson, Nizal Sarrafzadegan, Dharmesh Kumar Lal, Hai Quang Pham, Aleksandr Y. Aravkin, Joshua A. Salomon, David C. Schwebel, Milena Ilic, Kareha M Agesa, Jost B. Jonas, Dian Kusuma, Benjamin B. Massenburg, Santosh Varughese, Yousef Mohammad, Beatriz Paulina Ayala Quintanilla, Mihaela Hostiuc, Richard G. Cowden, Morteza Shamsizadeh, Thomas Pilgrim, Alessandra C. Goulart, Leila Doshmangir, Gabriele Nagel, Saravanan Muthupandian, Zahra Sadat Dibaji Forooshani, Maryam Mirzaei, Zabihollah Yousefi, Shadrach Wilson, Iman El Sayed, Juanita A. Haagsma, Segun Emmanuel Ibitoye, Eirini Skiadaresi, Reza Shirkoohi, Tim Driscoll, Morteza Jafarinia, Maha El Tantawi, Telma Zahirian Moghadam, Katarzyna Kissimova-Skarbek, Abdilahi Yousuf Yousuf, Dickson A. Amugsi, Awoke Misganaw, Maseer Khan, Norito Kawakami, Jingkai Wei, Jai K Das, Vishnu Renjith, Tessa M. Pilz, Sameer Vali Gopalani, Roghiyeh Faridnia, Islam Y. Elgendy, Prateek Rastogi, Lauren B. Wilner, Josep Maria Haro, Zahiruddin Quazi Syed, Ben Lacey, Ketema Bizuwork Gebremedhin, Sam Rolfe, Iffat Elbarazi, Yannick Béjot, Raimundas Lunevicius, Sezer Kisa, Harish Chander Gugnani, Basema Saddik, Manu Raj Mathur, Mansour Ghafourifard, Riaz Uddin, Anna Poznańska, Faris Lami, Niguse Meles Alema, Michael T. Chung, Arya Aminorroaya, Arash Sarveazad, Erkin M. Mirrakhimov, Seyed Hossein Yahyazadeh Jabbari, João M. Furtado, Hamid Ahmadieh, Sara Conti, Yunquan Zhang, Manthan D Janodia, Aislyn U. Orji, S. Mohammad Sajadi, Jalal Arabloo, Gabrielle B. Britton, Colm McAlinden, Francisco Rogerlândio Martins-Melo, Simona Cătălina Ştefan, Ester Cerin, Nuno Taveira, Lars Jacob Stovner, Amir Taherkhani, Masoud Foroutan, Tomasz Miazgowski, Amir Manafi, Yeshambel T. Nigatu, Barthelemy Kuate Defo, Mithila Faruque, Alan D. Lopez, Man Mohan Mehndiratta, Graeme J. Hankey, Mojgan Gitimoghaddam, Chantal Huynh, G Anil Kumar, Martin Amogre Ayanore, Abbas Sheikhtaheri, Turki Alanzi, Simon Øverland, David Laith Rawaf, Brian J. Hall, Edward J Mills, Ali Kabir, Ravi Prakash Jha, Akbar Barzegar, Simin Mouodi, Alize J. Ferrari, Chirag P. Doshi, Saleh Salehi Zahabi, Mohsen Naghavi, Mohammad Hassan Emamian, Amir Jalali, Chukwudi A Nnaji, Kebadnew Mulatu Mihretie, Maarten J. Postma, David Edvardsson, Chhabi Lal Ranabhat, Catherine M. Antony, Hannah Han, Ken Lee Chin, Getinet Ayano, Kewal Krishan, Maryam Zamanian, Farshad Farzadfar, Ali A. Asadi-Pooya, Daniel Diaz, Oliver J. Brady, Mohsen Bayati, Christopher M Odell, Jalil Jaafari, Walter Mendoza, Susanna Dunachie, Raffaele Palladino, Raaj Kishore Biswas, Alessandra Lugo, Reshmi Bhageerathy, Paulo A. Lotufo, Maia Kereselidze, Salman Rawaf, Olayinka Stephen Ilesanmi, Mousa Yaminfirooz, Neeraj Bedi, Mahesh P A, Harvey Whiteford, Gina Agarwal, Pallab K. Maulik, Ranjitha S Shetty, Adhanom Gebreegziabher Baraki, Prasanna Mithra, Binyam Minuye Birihane, Mohammad Ali Mansournia, Tomislav Mestrovic, Razique Anwer, Marcello Tonelli, Hanne Christensen, Juan Jesus Carrero, Ali H. Mokdad, Alberto Ortiz, Samad Azari, Ted R. Miller, Rebecca Ivers, Stephen R. Robinson, Saeid Safiri, Masood Ali Shaikh, Rajesh Sagar, Kelly Cercy, Mehran Asadi-Aliabadi, João Vasco Santos, Maziar Moradi-Lakeh, Sarah Lewington, Dimas Ria Angga Pribadi, Savita Lasrado, Abdul Moiz Hafiz, Amir Almasi-Hashiani, Burcu Kucuk Bicer, Praveen Hoogar, Fatemeh Heydarpour, Hala Rashad Elhabashy, Peng Zheng, Senthilkumar Balakrishnan, Paul H. Lee, Cameron J. Kneib, Srinivasa Rao Bolla, Harrison Chase Gottlich, Andrew M. Briggs, Alibek Mereke, Om P Kurmi, Kavumpurathu Raman Thankappan, Nikolay Ivanovich Briko, Shahram Saeidi, Anbissa Muleta Senbeta, Assefa Ayalew Ayalew Ayalew Gebreslassie, Aminu K. Bello, Tomi Akinyemiju, Ambrish Singh, Anamika Pandey, Matthew Cunningham, Endalkachew Worku Mengesha, Christine Linehan, Ata Rafiee, Maria Inês Schmidt, Vincent C. Iannucci, Stanislav S. Otstavnov, Andre M. N. Renzaho, Dinesh Bhandari, Masoud Moghadaszadeh, Atkilt Esaiyas Etisso, Valery L. Feigin, Christopher J L Murray, James D. Harvey, Daniel Cury Ribeiro, Girikumar Kumaresh, Javad Yoosefi Lebni, Elisabetta Pupillo, Shaimaa I. El-Jaafary, Marlena S Bannick, Caitlyn Steiner, Agus Sudaryanto, Eduardo Bernabé, Fereshteh Mehri, Rafael Alves Guimarães, Zemenu Tadesse Tessema, Shaun Roberts, Rajeev Gupta, Jamal A. Yearwood, Nima Rezaei, Muhammad Shahdaat Bin Sayeed, David M. Pigott, Hadi Hassankhani, Samuel M. Ostroff, Gerhard Sulo, Keyghobad Ghadiri, Pankaj Bhardwaj, Suzanne Lyn Barker-Collo, Fiona J Charlson, Norberto Perico, Jonathan M. Kocarnik, Sergio I. Prada, Mohammad Sadegh Rezai, Mustafa Z. Younis, Neeraj Bhala, Mahmoud Yousefifard, Hue Thi Mai, Marwa Rashad Salem, Reza Pourmirza Kalhori, Carl Abelardo T. Antonio, Stefan Lorkowski, Farzad Jalilian, Nicholas J Kassebaum, Haley Lescinsky, Gholamreza Roshandel, Reza Heidari-Soureshjani, Kirsten E. Wiens, Ionut Negoi, Bhaskaran Unnikrishnan, Daniel J. Weiss, Sare Safi, Hamid Reza Tohidinik, Fablina Sharara, François Alla, Mohammad Rabiee, Sivan Yegnanarayana Iyer Saraswathy, Jack T Fox, Amirhossein Sahebkar, Ratilal Lalloo, Panniyammakal Jeemon, Rohollah Kalhor, Firooz Esmaeilzadeh, Brittney S. Sheena, Kyle E. Simpson, Muluken Bekele Sorrie, Vivekanand Jha, Morteza Abdullatif Khafaie, Seyed Mohammad Riahi, Nader Jahanmehr, Yuming Guo, George C. Patton, Rashid Abdi Guled, Tim C.D. Lucas, Alberto Raggi, Peter W. Gething, Mohaimenul Islam, Abdallah M. Samy, Cuong Tat Nguyen, Kaleab Alemayehu Zewdie, Ahamarshan Jayaraman Nagarajan, Roman Topor-Madry, C. E. G. Brayne, Phoebe Anne Rhinehart, Isabela M. Benseñor, Michal Grivna, Taren M. Gorman, Natalie C. Momen, Afsaneh Arzani, Tufa Kolola, Maryam Khayamzadeh, Alexandra S. Boon-Dooley, Ihoghosa Osamuyi Iyamu, Nima Hafezi-Nejad, Hassan Abolhassani, Perminder S. Sachdev, Vivek Kumar, Anton Sokhan, Mahmood Moosazadeh, Davoud Adham, Ahad Bakhtiari, Nataliya A. Foigt, Venkatesh Maled, Henok Biresaw Netsere, Seyedeh Zahra Masoumi, Ashley Marks, Rizwan Kalani, Soraya Siabani, Jiayu Wang, Samath Dhamminda Dharmaratne, Lucas Guimarães Abreu, Vivian Chia-Rong Hsieh, Kris J. Krohn, Falk Schwendicke, Alex R. Chang, Muhammad Ali, Christine Lin, Rose G Bender, Arielle Wilder Eagan, Tissa Wijeratne, Chris D Castle, Saif Ullah, Nikolaos Dervenis, Joan B. Soriano, Syed Amir Gilani, Jianing Ma, Giuseppe Remuzzi, Dana Bryazka, Christian Razo, Manuela L. Ferreira, Ankur Joshi, Alireza Rafiei, Vinay Nangia, Victor Adekanmbi, Frances E. Dean, Chuanhua Yu, Elizabeth A. Cromwell, Pascual R. Valdez, Jennifer Rickard, Daniel Youngwhan Cho, Ashish Pathak, Angel Paternina-Caicedo, Mehdi Ahmadi, Zichen Liu, Achala Upendra Jayatilleke, Diego De Leo, Sarah Charlotte Johnson, Getenet Dessie, Zhi Jiang Zhang, Christopher S. Crowe, Farhad Ghamari, Behshad Naghshtabrizi, Francesco Saverio Violante, Muhammad Aziz Rahman, Ramesh Holla, Kate E. LeGrand, Christian Kieling, Vahid Yazdi-Feyzabadi, Shivanthi Balalla, Molly H Biehl, Mostafa Dianatinasab, Mina Anjomshoa, Abdel Douiri, Laith J. Abu-Raddad, Rade Vukovic, Amiran Gamkrelidze, Michael R. Phillips, Yafeng Wang, Sachin R Atre, Miriam Levi, Zelalem Nigussie Azene, Kevan R. Polkinghorne, Deepak Paudel, Hung Chun Liu, Zainab Samad, Robert P. Dellavalle, Florentino Luciano Caetano dos Santos, Juan Sanabria, Mohammad Fareed, Enrico Rubagotti, Samantha Leigh Larson, Anurag Agrawal, Shai Linn, Saad M.A. Dahlawi, Janni Leung, Shokofeh Maleki, Michael R.M. Abrigo, Michael Kravchenko, Mohd Anisul Karim, Alyssa N. Sbarra, Jacob L. Stubbs, Timothy J. Steiner, Helena Manguerra, Olatunji O. Adetokunboh, Amira Shaheen, Stein Emil Vollset, Yared Asmare Aynalem, Rajan Nikbakhsh, Ilana N. Ackerman, Srinivasa Vittal Katikireddi, Davide Rasella, Hedayat Abbastabar, Floriane Ausloos, Nauman Khalid, Ewerton Cousin, Nermin Ghith, Nebiyu Dereje Dereje, Rakhi Dandona, Mojtaba Bagherzadeh, Ahmed Abdelalim, Benn Sartorius, Giulio Castelpietra, Masih Tajdini, Stefanos Tyrovolas, Akram Pourshams, Ritesh G. Menezes, Eve E. Wool, Mohamed Hsairi, Alberto L. García-Basteiro, Lorainne Tudor Car, Rachelle Buchbinder, Franz Castro, Samiah Alam, Iman Ansari, Ahmed I. Hasaballah, Sanni Yaya, Silvia Schiavolin, Reza Mohammadpourhodki, Khalid A Altirkawi, Marco Vacante, Jacek A. Kopec, Archith Boloor, Simon I. Hay, Mathilde Touvier, Ensiyeh Jenabi, Deborah Carvalho Malta, Scott B. Patten, Arash Ziapour, Carlo La Vecchia, Seyed Sina Naghibi Irvani, Thomas Truelsen, Houman Goudarzi, Ryan Fitzgerald, Di H. Cross, Eduarda Fernandes, Chandrashekhar T Sreeramareddy, Odgerel Chimed-Ochir, Iqbal R. F. Elyazar, Alexandrea Watson, Bo Norrving, Kerem Shuval, Chidozie Declan Iwu, Jasvinder A. Singh, Bárbara Niegia Garcia Goulart, Shirin Djalalinia, Marisa Freitas, Feleke Mekonnen Demeke, Hiroyasu Iso, Hussain Jafari, Lee Ling Lim, Roman V. Polibin, Charles D.A. Wolfe, Ulrich O Mueller, Luis Camera, Fabiana Madotto, Gregory A. Roth, Nevine El Nahas, Paul S. F. Yip, Miguel A Barboza, Anna E. Torre, Ali Rajabpour-Sanati, Hailey Hagins, Tauseef Ahmad, Platon D. Lopukhov, Giovanni Damiani, Mohammad Hossein Bakhshaei, Hirut Teame, Silvano Gallus, Tudorel Andrei, Suzanne H. Keddie, Madgalene K. Walters, Mohammad Abdollahi, Temesgen Yihunie Akalu, Catherine Bisignano, Iyad Sultan, Ira Martopullo, Emma L. Collins, Spencer L. James, Rasmus Havmoeller, Alireza Esteghamati, Seok Jun Yoon, Paramjit Gill, Maryam Hashemian, Klara Dokova, Weijia Fu, Anna Gershberg Hayoon, Kathryn H. Jacobsen, Zohra S Lassi, Morenike Oluwatoyin Folayan, Sanjeev Nair, Phetole Walter Mahasha, Shelly Balassyano, Giulia Carreras, Ruxandra Irina Negoi, Reinhard Busse, Takeshi Fukumoto, Abdullah Al Mamun, Sarika Chaturvedi, Stefania Mondello, Christoph Nowak, Vijay Kumar Chattu, Efat Mohamadi, Mohammad Ebrahimi Kalan, Paul S Briant, M Alijanzadeh, Giuseppe Gorini, Berhane Fseha Teklehaimanot, Jacqueline Elizabeth Alcalde-Rabanal, Katya Anne Shackelford, Mehdi Fazlzadeh, Virginia Núñez-Samudio, Minh Nguyen, Payman Salamati, Itamar S. Santos, Bach Xuan Tran, Lal B. Rawal, Louisa Degenhardt, Dietrich Plass, Jacob Olusegun Olusanya, José Neves, Kazumasa Yamagishi, Mona M. Khater, Alyssa Pennini, Ehsan Sadeghi, Salah Eddin Karimi, Ravensara S. Travillian, Alexander C. Tsai, Emilie E. Agardh, Rahmatollah Moradzadeh, Hamed Zandian, Zahid A Butt, Subramanian Senthilkumaran, Ai-Min Wu, Bing Fang Hwang, Sadaf G. Sepanlou, Jeff T. Zhao, Paolo Cortesi, Giorgia Giussani, Gregory J. Bertolacci, Andrew T Olagunju, Søren Thorgaard Skou, Peter Allebeck, Benjamin C Cowie, Aso Mohammad Darwesh, In-Hwan Oh, Erin B. Hamilton, Puja C Rao, Vinod C Nayak, Carla Fornari, Khezar Hayat, Rannveig Sigurvinsdottir, Emmanuel Peprah, Oommen John, Sonyah Terrason, Mohammed Ibrahim Mohialdeen Gubari, Sojib Bin Zaman, Jean Jacques Noubiap, Emmanuela Gakidou, Abiyu Mekonnen Gebrehiwot, Celine M. Barthelemy, Nicholas L S Roberts, Jagadish Rao Padubidri, Navid Rabiee, Alireza Ghajar, Mark G. Shrime, Hamed Kalani, Mayowa O. Owolabi, Lisa M. Force, Irina Filip, Jacek Jerzy Jozwiak, Gelin Xu, Thomas R. Hird, Kara Estep, Mohammad Zamani, Lalit Dandona, João Massano, Antonio Maria Borzì, Masoud Moradi, Molly R Nixon, Delia Hendrie, Mostafa Amini-Rarani, Mikhail Sergeevich Zastrozhin, Rachel Feldman, Emmanuel Wandera Okunga, Bruce Bartholow Duncan, Nazir Fattahi, Joshua R. Ehrlich, Adnan Kisa, Ghasem Azarian, Naser Mohammad Gholi Mezerji, Reed J D Sorensen, Roderick J. Hay, Johan Ärnlöv, Liliana G Ciobanu, Claudiu Herteliu, Andreea Mirica, Sofia Boston Redford, Wahengbam Bigyananda Meitei, Jae Il Shin, Kanaan Hamagharib Abdullah, Abhijit Pakhare, Santosh Kumar Tadakamadla, Rixing Xu, Jonathan F. Mosser, Meresa Berwo Mengesha, Veincent Christian Filipino Pepito, Andre Rodrigues Duraes, Yuan-Pang Wang, Jaimie D. Adelson, Felix Akpojene Ogbo, Alireza Vakilian, Mihajlo Jakovljevic, Ali S. Shalash, Vos, T, Lim, S, Abbafati, C, Abbas, K, Abbasi, M, Abbasifard, M, Abbasi-Kangevari, M, Abbastabar, H, Abd-Allah, F, Abdelalim, A, Abdollahi, M, Abdollahpour, I, Abolhassani, H, Aboyans, V, Abrams, E, Abreu, L, Abrigo, M, Abu-Raddad, L, Abushouk, A, Acebedo, A, Ackerman, I, Adabi, M, Adamu, A, Adebayo, O, Adekanmbi, V, Adelson, J, Adetokunboh, O, Adham, D, Afshari, M, Afshin, A, Agardh, E, Agarwal, G, Agesa, K, Aghaali, M, Aghamir, S, Agrawal, A, Ahmad, T, Ahmadi, A, Ahmadi, M, Ahmadieh, H, Ahmadpour, E, Akalu, T, Akinyemi, R, Akinyemiju, T, Akombi, B, Al-Aly, Z, Alam, K, Alam, N, Alam, S, Alam, T, Alanzi, T, Albertson, S, Alcalde-Rabanal, J, Alema, N, Ali, M, Ali, S, Alicandro, G, Alijanzadeh, M, Alinia, C, Alipour, V, Aljunid, S, Alla, F, Allebeck, P, Almasi-Hashiani, A, Alonso, J, Al-Raddadi, R, Altirkawi, K, Alvis-Guzman, N, Alvis-Zakzuk, N, Amini, S, Amini-Rarani, M, Aminorroaya, A, Amiri, F, Amit, A, Amugsi, D, Amul, G, Anderlini, D, Andrei, C, Andrei, T, Anjomshoa, M, Ansari, F, Ansari, I, Ansari-Moghaddam, A, Antonio, C, Antony, C, Antriyandarti, E, Anvari, D, Anwer, R, Arabloo, J, Arab-Zozani, M, Aravkin, A, Ariani, F, Arnlov, J, Aryal, K, Arzani, A, Asadi-Aliabadi, M, Asadi-Pooya, A, Asghari, B, Ashbaugh, C, Atnafu, D, Atre, S, Ausloos, F, Ausloos, M, Ayala Quintanilla, B, Ayano, G, Ayanore, M, Aynalem, Y, Azari, S, Azarian, G, Azene, Z, Babaee, E, Badawi, A, Bagherzadeh, M, Bakhshaei, M, Bakhtiari, A, Balakrishnan, S, Balalla, S, Balassyano, S, Banach, M, Banik, P, Bannick, M, Bante, A, Baraki, A, Barboza, M, Barker-Collo, S, Barthelemy, C, Barua, L, Barzegar, A, Basu, S, Baune, B, Bayati, M, Bazmandegan, G, Bedi, N, Beghi, E, Bejot, Y, Bello, A, Bender, R, Bennett, D, Bennitt, F, Bensenor, I, Benziger, C, Berhe, K, Bernabe, E, Bertolacci, G, Bhageerathy, R, Bhala, N, Bhandari, D, Bhardwaj, P, Bhattacharyya, K, Bhutta, Z, Bibi, S, Biehl, M, Bikbov, B, Bin Sayeed, M, Biondi, A, Birihane, B, Bisanzio, D, Bisignano, C, Biswas, R, Bohlouli, S, Bohluli, M, Bolla, S, Boloor, A, Boon-Dooley, A, Borges, G, Borzi, A, Bourne, R, Brady, O, Brauer, M, Brayne, C, Breitborde, N, Brenner, H, Briant, P, Briggs, A, Briko, N, Britton, G, Bryazka, D, Buchbinder, R, Bumgarner, B, Busse, R, Butt, Z, Caetano dos Santos, F, Camera, L, Campos-Nonato, I, Car, J, Cardenas, R, Carreras, G, Carrero, J, Carvalho, F, Castaldelli-Maia, J, Castaneda-Orjuela, C, Castelpietra, G, Castle, C, Castro, F, Catala-Lopez, F, Causey, K, Cederroth, C, Cercy, K, Cerin, E, Chandan, J, Chang, A, Charlson, F, Chattu, V, Chaturvedi, S, Chimed-Ochir, O, Chin, K, Cho, D, Christensen, H, Chu, D, Chung, M, Cicuttini, F, Ciobanu, L, Cirillo, M, Collins, E, Compton, K, Conti, S, Cortesi, P, Costa, V, Cousin, E, Cowden, R, Cowie, B, Cromwell, E, Cross, D, Crowe, C, Cruz, J, Cunningham, M, Dahlawi, S, Damiani, G, Dandona, L, Dandona, R, Darwesh, A, Daryani, A, Das, J, Das Gupta, R, das Neves, J, Davila-Cervantes, C, Davletov, K, De Leo, D, Dean, F, Decleene, N, Deen, A, Degenhardt, L, Dellavalle, R, Demeke, F, Demsie, D, Denova-Gutierrez, E, Dereje, N, Dervenis, N, Desai, R, Desalew, A, Dessie, G, Dharmaratne, S, Dhungana, G, Dianatinasab, M, Diaz, D, Dibaji Forooshani, Z, Dingels, Z, Dirac, M, Djalalinia, S, Do, H, Dokova, K, Dorostkar, F, Doshi, C, Doshmangir, L, Douiri, A, Doxey, M, Driscoll, T, Dunachie, S, Duncan, B, Duraes, A, Eagan, A, Ebrahimi Kalan, M, Edvardsson, D, Ehrlich, J, El Nahas, N, El Sayed, I, El Tantawi, M, Elbarazi, I, Elgendy, I, Elhabashy, H, El-Jaafary, S, Elyazar, I, Emamian, M, Emmons-Bell, S, Erskine, H, Eshrati, B, Eskandarieh, S, Esmaeilnejad, S, Esmaeilzadeh, F, Esteghamati, A, Estep, K, Etemadi, A, Etisso, A, Farahmand, M, Faraj, A, Fareed, M, Faridnia, R, Farinha, C, Farioli, A, Faro, A, Faruque, M, Farzadfar, F, Fattahi, N, Fazlzadeh, M, Feigin, V, Feldman, R, Fereshtehnejad, S, Fernandes, E, Ferrari, A, Ferreira, M, Filip, I, Fischer, F, Fisher, J, Fitzgerald, R, Flohr, C, Flor, L, Foigt, N, Folayan, M, Force, L, Fornari, C, Foroutan, M, Fox, J, Freitas, M, Fu, W, Fukumoto, T, Furtado, J, Gad, M, Gakidou, E, Galles, N, Gallus, S, Gamkrelidze, A, Garcia-Basteiro, A, Gardner, W, Geberemariyam, B, Gebrehiwot, A, Gebremedhin, K, Gebreslassie, A, Gershberg Hayoon, A, Gething, P, Ghadimi, M, Ghadiri, K, Ghafourifard, M, Ghajar, A, Ghamari, F, Ghashghaee, A, Ghiasvand, H, Ghith, N, Gholamian, A, Gilani, S, Gill, P, Gitimoghaddam, M, Giussani, G, Goli, S, Gomez, R, Gopalani, S, Gorini, G, Gorman, T, Gottlich, H, Goudarzi, H, Goulart, A, Goulart, B, Grada, A, Grivna, M, Grosso, G, Gubari, M, Gugnani, H, Guimaraes, A, Guimaraes, R, Guled, R, Guo, G, Guo, Y, Gupta, R, Haagsma, J, Haddock, B, Hafezi-Nejad, N, Hafiz, A, Hagins, H, Haile, L, Hall, B, Halvaei, I, Hamadeh, R, Hamagharib Abdullah, K, Hamilton, E, Han, C, Han, H, Hankey, G, Haro, J, Harvey, J, Hasaballah, A, Hasanzadeh, A, Hashemian, M, Hassanipour, S, Hassankhani, H, Havmoeller, R, Hay, R, Hay, S, Hayat, K, Heidari, B, Heidari, G, Heidari-Soureshjani, R, Hendrie, D, Henrikson, H, Henry, N, Herteliu, C, Heydarpour, F, Hird, T, Hoek, H, Hole, M, Holla, R, Hoogar, P, Hosgood, H, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hoy, D, Hsairi, M, Hsieh, V, Hu, G, Huda, T, Hugo, F, Huynh, C, Hwang, B, Iannucci, V, Ibitoye, S, Ikuta, K, Ilesanmi, O, Ilic, I, Ilic, M, Inbaraj, L, Ippolito, H, Irvani, S, Islam, M, Islam, S, Islami, F, Iso, H, Ivers, R, Iwu, C, Iyamu, I, Jaafari, J, Jacobsen, K, Jadidi-Niaragh, F, Jafari, H, Jafarinia, M, Jahagirdar, D, Jahani, M, Jahanmehr, N, Jakovljevic, M, Jalali, A, Jalilian, F, James, S, Janjani, H, Janodia, M, Jayatilleke, A, Jeemon, P, Jenabi, E, Jha, R, Jha, V, Ji, J, Jia, P, John, O, John-Akinola, Y, Johnson, C, Johnson, S, Jonas, J, Joo, T, Joshi, A, Jozwiak, J, Jurisson, M, Kabir, A, Kabir, Z, Kalani, H, Kalani, R, Kalankesh, L, Kalhor, R, Kamiab, Z, Kanchan, T, Karami Matin, B, Karch, A, Karim, M, Karimi, S, Kassa, G, Kassebaum, N, Katikireddi, S, Kawakami, N, Kayode, G, Keddie, S, Keller, C, Kereselidze, M, Khafaie, M, Khalid, N, Khan, M, Khatab, K, Khater, M, Khatib, M, Khayamzadeh, M, Khodayari, M, Khundkar, R, Kianipour, N, Kieling, C, Kim, D, Kim, Y, Kimokoti, R, Kisa, A, Kisa, S, Kissimova-Skarbek, K, Kivimaki, M, Kneib, C, Knudsen, A, Kocarnik, J, Kolola, T, Kopec, J, Kosen, S, Koul, P, Koyanagi, A, Kravchenko, M, Krishan, K, Krohn, K, Kuate Defo, B, Kucuk Bicer, B, Kumar, G, Kumar, M, Kumar, P, Kumar, V, Kumaresh, G, Kurmi, O, Kusuma, D, Kyu, H, La Vecchia, C, Lacey, B, Lal, D, Lalloo, R, Lam, J, Lami, F, Landires, I, Lang, J, Lansingh, V, Larson, S, Larsson, A, Lasrado, S, Lassi, Z, Lau, K, Lavados, P, Lazarus, J, Ledesma, J, Lee, P, Lee, S, Legrand, K, Leigh, J, Leonardi, M, Lescinsky, H, Leung, J, Levi, M, Lewington, S, Li, S, Lim, L, Lin, C, Lin, R, Linehan, C, Linn, S, Liu, H, Liu, S, Liu, Z, Looker, K, Lopez, A, Lopukhov, P, Lorkowski, S, Lotufo, P, Lucas, T, Lugo, A, Lunevicius, R, Lyons, R, Ma, J, Maclachlan, J, Maddison, E, Maddison, R, Madotto, F, Mahasha, P, Mai, H, Majeed, A, Maled, V, Maleki, S, Malekzadeh, R, Malta, D, Mamun, A, Manafi, A, Manafi, N, Manguerra, H, Mansouri, B, Mansournia, M, Mantilla Herrera, A, Maravilla, J, Marks, A, Martins-Melo, F, Martopullo, I, Masoumi, S, Massano, J, Massenburg, B, Mathur, M, Maulik, P, Mcalinden, C, Mcgrath, J, Mckee, M, Mehndiratta, M, Mehri, F, Mehta, K, Meitei, W, Memiah, P, Mendoza, W, Menezes, R, Mengesha, E, Mengesha, M, Mereke, A, Meretoja, A, Meretoja, T, Mestrovic, T, Miazgowski, B, Miazgowski, T, Michalek, I, Mihretie, K, Miller, T, Mills, E, Mirica, A, Mirrakhimov, E, Mirzaei, H, Mirzaei, M, Mirzaei-Alavijeh, M, Misganaw, A, Mithra, P, Moazen, B, Moghadaszadeh, M, Mohamadi, E, Mohammad, D, Mohammad, Y, Mohammad Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadifard, N, Mohammadpourhodki, R, Mohammed, S, Mokdad, A, Molokhia, M, Momen, N, Monasta, L, Mondello, S, Mooney, M, Moosazadeh, M, Moradi, G, Moradi, M, Moradi-Lakeh, M, Moradzadeh, R, Moraga, P, Morales, L, Morawska, L, Moreno Velasquez, I, Morgado-da-Costa, J, Morrison, S, Mosser, J, Mouodi, S, Mousavi, S, Mousavi Khaneghah, A, Mueller, U, Munro, S, Muriithi, M, Musa, K, Muthupandian, S, Naderi, M, Nagarajan, A, Nagel, G, Naghshtabrizi, B, Nair, S, Nandi, A, Nangia, V, Nansseu, J, Nayak, V, Nazari, J, Negoi, I, Negoi, R, Netsere, H, Ngunjiri, J, Nguyen, C, Nguyen, J, Nguyen, M, Nichols, E, Nigatu, D, Nigatu, Y, Nikbakhsh, R, Nixon, M, Nnaji, C, Nomura, S, Norrving, B, Noubiap, J, Nowak, C, Nunez-Samudio, V, Otoiu, A, Oancea, B, Odell, C, Ogbo, F, Oh, I, Okunga, E, Oladnabi, M, Olagunju, A, Olusanya, B, Olusanya, J, Oluwasanu, M, Omar Bali, A, Omer, M, Ong, K, Onwujekwe, O, Orji, A, Orpana, H, Ortiz, A, Ostroff, S, Otstavnov, N, Otstavnov, S, Overland, S, Owolabi, M, P A, M, Padubidri, J, Pakhare, A, Palladino, R, Pana, A, Panda-Jonas, S, Pandey, A, Park, E, Parmar, P, Pasupula, D, Patel, S, Paternina-Caicedo, A, Pathak, A, Pathak, M, Patten, S, Patton, G, Paudel, D, Pazoki Toroudi, H, Peden, A, Pennini, A, Pepito, V, Peprah, E, Pereira, A, Pereira, D, Perico, N, Pham, H, Phillips, M, Pigott, D, Pilgrim, T, Pilz, T, Pirsaheb, M, Plana-Ripoll, O, Plass, D, Pokhrel, K, Polibin, R, Polinder, S, Polkinghorne, K, Postma, M, Pourjafar, H, Pourmalek, F, Pourmirza Kalhori, R, Pourshams, A, Poznanska, A, Prada, S, Prakash, V, Pribadi, D, Pupillo, E, Quazi Syed, Z, Rabiee, M, Rabiee, N, Radfar, A, Rafiee, A, Rafiei, A, Raggi, A, Rahimi-Movaghar, A, Rahman, M, Rajabpour-Sanati, A, Rajati, F, Ramezanzadeh, K, Ranabhat, C, Rao, P, Rao, S, Rasella, D, Rastogi, P, Rathi, P, Rawaf, D, Rawaf, S, Rawal, L, Razo, C, Redford, S, Reiner, R, Reinig, N, Reitsma, M, Remuzzi, G, Renjith, V, Renzaho, A, Resnikoff, S, Rezaei, N, Rezai, M, Rezapour, A, Rhinehart, P, Riahi, S, Ribeiro, A, Ribeiro, D, Rickard, J, Roberts, N, Roberts, S, Robinson, S, Roever, L, Rolfe, S, Ronfani, L, Roshandel, G, Roth, G, Rubagotti, E, Rumisha, S, Sabour, S, Sachdev, P, Saddik, B, Sadeghi, E, Sadeghi, M, Saeidi, S, Safi, S, Safiri, S, Sagar, R, Sahebkar, A, Sahraian, M, Sajadi, S, Salahshoor, M, Salamati, P, Salehi Zahabi, S, Salem, H, Salem, M, Salimzadeh, H, Salomon, J, Salz, I, Samad, Z, Samy, A, Sanabria, J, Santomauro, D, Santos, I, Santos, J, Santric-Milicevic, M, Saraswathy, S, Sarmiento-Suarez, R, Sarrafzadegan, N, Sartorius, B, Sarveazad, A, Sathian, B, Sathish, T, Sattin, D, Sbarra, A, Schaeffer, L, Schiavolin, S, Schmidt, M, Schutte, A, Schwebel, D, Schwendicke, F, Senbeta, A, Senthilkumaran, S, Sepanlou, S, Shackelford, K, Shadid, J, Shahabi, S, Shaheen, A, Shaikh, M, Shalash, A, Shams-Beyranvand, M, Shamsizadeh, M, Shannawaz, M, Sharafi, K, Sharara, F, Sheena, B, Sheikhtaheri, A, Shetty, R, Shibuya, K, Shiferaw, W, Shigematsu, M, Shin, J, Shiri, R, Shirkoohi, R, Shrime, M, Shuval, K, Siabani, S, Sigfusdottir, I, Sigurvinsdottir, R, Silva, J, Simpson, K, Singh, A, Singh, J, Skiadaresi, E, Skou, S, Skryabin, V, Sobngwi, E, Sokhan, A, Soltani, S, Sorensen, R, Soriano, J, Sorrie, M, Soyiri, I, Sreeramareddy, C, Stanaway, J, Stark, B, Stefan, S, Stein, C, Steiner, C, Steiner, T, Stokes, M, Stovner, L, Stubbs, J, Sudaryanto, A, Sufiyan, M, Sulo, G, Sultan, I, Sykes, B, Sylte, D, Szocska, M, Tabares-Seisdedos, R, Tabb, K, Tadakamadla, S, Taherkhani, A, Tajdini, M, Takahashi, K, Taveira, N, Teagle, W, Teame, H, Tehrani-Banihashemi, A, Teklehaimanot, B, Terrason, S, Tessema, Z, Thankappan, K, Thomson, A, Tohidinik, H, Tonelli, M, Topor-Madry, R, Torre, A, Touvier, M, Tovani-Palone, M, Tran, B, Travillian, R, Troeger, C, Truelsen, T, Tsai, A, Tsatsakis, A, Tudor Car, L, Tyrovolas, S, Uddin, R, Ullah, S, Undurraga, E, Unnikrishnan, B, Vacante, M, Vakilian, A, Valdez, P, Varughese, S, Vasankari, T, Vasseghian, Y, Venketasubramanian, N, Violante, F, Vlassov, V, Vollset, S, Vongpradith, A, Vukovic, A, Vukovic, R, Waheed, Y, Walters, M, Wang, J, Wang, Y, Ward, J, Watson, A, Wei, J, Weintraub, R, Weiss, D, Weiss, J, Westerman, R, Whisnant, J, Whiteford, H, Wiangkham, T, Wiens, K, Wijeratne, T, Wilner, L, Wilson, S, Wojtyniak, B, Wolfe, C, Wool, E, Wu, A, Wulf Hanson, S, Wunrow, H, Xu, G, Xu, R, Yadgir, S, Yahyazadeh Jabbari, S, Yamagishi, K, Yaminfirooz, M, Yano, Y, Yaya, S, Yazdi-Feyzabadi, V, Yearwood, J, Yeheyis, T, Yeshitila, Y, Yip, P, Yonemoto, N, Yoon, S, Yoosefi Lebni, J, Younis, M, Younker, T, Yousefi, Z, Yousefifard, M, Yousefinezhadi, T, Yousuf, A, Yu, C, Yusefzadeh, H, Zahirian Moghadam, T, Zaki, L, Zaman, S, Zamani, M, Zamanian, M, Zandian, H, Zangeneh, A, Zastrozhin, M, Zewdie, K, Zhang, Y, Zhang, Z, Zhao, J, Zhao, Y, Zheng, P, Zhou, M, Ziapour, A, Zimsen, S, Naghavi, M, Murray, C, Vos, Theo, S Lim, Stephen, Abbafati, Cristiana, M Abbas, Kaja, Abbasi, Mohammad, Abbasifard, Mitra, Abbasi-Kangevari, Mohsen, Abbastabar, Hedayat, Abd-Allah, Foad, Abdelalim, Ahmed, Abdollahi, Mohammad, Abdollahpour, Ibrahim, Abolhassani, Hassan, Aboyans, Victor, M Abrams, Elissa, Guimarães Abreu, Luca, M Abrigo, Michael R, Jamal Abu-Raddad, Laith, I Abushouk, Abdelrahman, Acebedo, Alyssa, N Ackerman, Ilana, Adabi, Maryam, A Adamu, Abdu, M Adebayo, Oladimeji, Adekanmbi, Victor, D Adelson, Jaimie, O Adetokunboh, Olatunji, Adham, Davoud, Afshari, Mahdi, Afshin, Ashkan, E Agardh, Emilie, Agarwal, Gina, M Agesa, Kareha, Aghaali, Mohammad, Mohammad Kazem Aghamir, Seyed, Agrawal, Anurag, Ahmad, Tauseef, Ahmadi, Alireza, Ahmadi, Mehdi, Ahmadieh, Hamid, Ahmadpour, Ehsan, Yihunie Akalu, Temesgen, Olusola Akinyemi, Rufu, Akinyemiju, Tomi, Akombi, Blessing, Al-Aly, Ziyad, Alam, Khurshid, Alam, Noore, Alam, Samiah, Alam, Tahiya, M Alanzi, Turki, B Albertson, Samuel, Elizabeth Alcalde-Rabanal, Jacqueline, Meles Alema, Niguse, Ali, Muhammad, Ali, Saqib, Alicandro, Gianfranco, Alijanzadeh, Mehran, Alinia, Cyru, Alipour, Vahid, Mohamed Aljunid, Syed, Alla, Françoi, Allebeck, Peter, Almasi-Hashiani, Amir, Alonso, Jordi, M Al-Raddadi, Rajaa, A Altirkawi, Khalid, Alvis-Guzman, Nelson, J Alvis-Zakzuk, Nelson, Amini, Saeed, Amini-Rarani, Mostafa, Aminorroaya, Arya, Amiri, Fatemeh, L Amit, Arianna Maever, A Amugsi, Dickson, Gayle Herrera Amul, Gianna, Anderlini, Deanna, Liliana Andrei, Catalina, Andrei, Tudorel, Anjomshoa, Mina, Ansari, Fereshteh, Ansari, Iman, Ansari-Moghaddam, Alireza, T Antonio, Carl Abelardo, M Antony, Catherine, Antriyandarti, Ernoiz, Anvari, Davood, Anwer, Razique, Arabloo, Jalal, Arab-Zozani, Morteza, Y Aravkin, Aleksandr, Ariani, Filippo, Ärnlöv, Johan, K Aryal, Krishna, Arzani, Afsaneh, Asadi-Aliabadi, Mehran, A Asadi-Pooya, Ali, Asghari, Babak, Ashbaugh, Charlie, Debalkie Atnafu, Desta, R Atre, Sachin, Ausloos, Floriane, Ausloos, Marcel, Paulina Ayala Quintanilla, Beatriz, Ayano, Getinet, Amogre Ayanore, Martin, Asmare Aynalem, Yared, Azari, Samad, Azarian, Ghasem, Nigussie Azene, Zelalem, Babaee, Ebrahim, Badawi, Alaa, Bagherzadeh, Mojtaba, Hossein Bakhshaei, Mohammad, Bakhtiari, Ahad, Balakrishnan, Senthilkumar, Balalla, Shivanthi, Balassyano, Shelly, Banach, Maciej, Chandra Banik, Palash, S Bannick, Marlena, Bante Bante, Agegnehu, Gebreegziabher Baraki, Adhanom, A Barboza, Miguel, Lyn Barker-Collo, Suzanne, M Barthelemy, Celine, Barua, Lingkan, Barzegar, Akbar, Basu, Sanjay, T Baune, Bernhard, Bayati, Mohsen, Bazmandegan, Gholamreza, Bedi, Neeraj, Beghi, Ettore, Béjot, Yannick, K Bello, Aminu, G Bender, Rose, A Bennett, Derrick, B Bennitt, Fiona, M Bensenor, Isabela, P Benziger, Catherine, Berhe, Kidanemaryam, Bernabe, Eduardo, J Bertolacci, Gregory, Bhageerathy, Reshmi, Bhala, Neeraj, Bhandari, Dinesh, Bhardwaj, Pankaj, Bhattacharyya, Krittika, A Bhutta, Zulfiqar, Bibi, Sadia, H Biehl, Molly, Bikbov, Bori, Shahdaat Bin Sayeed, Muhammad, Biondi, Antonio, Minuye Birihane, Binyam, Bisanzio, Donal, Bisignano, Catherine, Kishore Biswas, Raaj, Bohlouli, Somayeh, Bohluli, Mehdi, Rao Rao Bolla, Srinivasa, Boloor, Archith, S Boon-Dooley, Alexandra, Borges, Guilherme, Maria Borzì, Antonio, Bourne, Rupert, J Brady, Oliver, Brauer, Michael, Brayne, Carol, K Breitborde, Nicholas J, Brenner, Hermann, Svitil Briant, Paul, M Briggs, Andrew, Ivanovich Briko, Nikolay, B Britton, Gabrielle, Bryazka, Dana, Buchbinder, Rachelle, R Bumgarner, Blair, Busse, Reinhard, A Butt, Zahid, Luciano Caetano Dos Santos, Florentino, LA Alberto Cámera, Lui, R Campos-Nonato, Ismael, Car, Josip, Cárdenas, Rosario, Carreras, Giulia, J Carrero, Juan, Carvalho, Felix, Mauricio Castaldelli-Maia, Joao, A Castañeda-Orjuela, Carlo, Castelpietra, Giulio, D Castle, Chri, Castro, Franz, Catalá-López, Ferrán, Causey, Kate, R Cederroth, Christopher, M Cercy, Kelly, Cerin, Ester, Singh Chandan, Joht, R Chang, Alex, J Charlson, Fiona, Kumar Chattu, Vijay, Chaturvedi, Sarika, Chimed-Ochir, Odgerel, Lee Chin, Ken, Youngwhan Cho, Daniel, Christensen, Hanne, Chu, Dinh-Toi, T Chung, Michael, M Cicuttini, Flavia, G Ciobanu, Liliana, Cirillo, Massimo, L Collins, Emma, Compton, Kelly, Conti, Sara, Angelo Cortesi, Paolo, Marisa Costa, Vera, Cousin, Ewerton, G Cowden, Richard, C Cowie, Benjamin, A Cromwell, Elizabeth, H Cross, Di, Stephen Crowe, Christopher, A Cruz, Jessica, Cunningham, Matthew, A Dahlawi, Saad M, Damiani, Giovanni, Dandona, Lalit, Dandona, Rakhi, Mohammad Darwesh, Aso, Daryani, Ahmad, K Das, Jai, Das Gupta, Rajat, das Neves, José, Alberto Dávila-Cervantes, Claudio, Davletov, Kairat, De Leo, Diego, E Dean, France, K DeCleene, Nicole, Deen, Amanda, Degenhardt, Louisa, Paul Dellavalle, Robert, Mekonnen Demeke, Feleke, Getnet Demsie, Desalegn, Denova-Gutiérrez, Edgar, Dereje Dereje, Nebiyu, Dervenis, Nikolao, Desai, Rupak, Desalew, Assefa, Ayalew Dessie, Getenet, Dhamminda Dharmaratne, Samath, Prasad Dhungana, Govinda, Dianatinasab, Mostafa, Diaz, Daniel, Sadat Dibaji Forooshani, Zahra, V Dingels, Zachary, Ashworth Dirac, M, Djalalinia, Shirin, Thi Do, Hoa, Dokova, Klara, Dorostkar, Fariba, P Doshi, Chirag, Doshmangir, Leila, Douiri, Abdel, C Doxey, Matthew, Robert Driscoll, Tim, J Dunachie, Susanna, B Duncan, Bruce, Rodrigues Duraes, Andre, Wilder Eagan, Arielle, Ebrahimi Kalan, Mohammad, Edvardsson, David, R Ehrlich, Joshua, El Nahas, Nevine, El Sayed, Iman, El Tantawi, Maha, Elbarazi, Iffat, Y Elgendy, Islam, Rashad Elhabashy, Hala, I El-Jaafary, Shaimaa, Rf Elyazar, Iqbal, Hassan Emamian, Mohammad, Emmons-Bell, Sophia, E Erskine, Holly, Eshrati, Babak, Eskandarieh, Sharareh, Esmaeilnejad, Saman, Esmaeilzadeh, Firooz, Esteghamati, Alireza, Estep, Kara, Etemadi, Arash, Esaiyas Etisso, Atkilt, Farahmand, Mohammad, Faraj, Anwar, Fareed, Mohammad, Faridnia, Roghiyeh, E Sá Farinha, Carla Sofia, Farioli, Andrea, Faro, Andre, Faruque, Mithila, Farzadfar, Farshad, Fattahi, Nazir, Fazlzadeh, Mehdi, L Feigin, Valery, Feldman, Rachel, Fereshtehnejad, Seyed-Mohammad, Fernandes, Eduarda, J Ferrari, Alize, L Ferreira, Manuela, Filip, Irina, Fischer, Florian, L Fisher, Jame, Fitzgerald, Ryan, Flohr, Carsten, Sorio Flor, Luisa, A Foigt, Nataliya, Oluwatoyin Folayan, Morenike, M Force, Lisa, Fornari, Carla, Foroutan, Masoud, T Fox, Jack, Freitas, Marisa, Fu, Weijia, Fukumoto, Takeshi, M Furtado, João, M Gad, Mohamed, Gakidou, Emmanuela, C Galles, Natalie, Gallus, Silvano, Gamkrelidze, Amiran, L Garcia-Basteiro, Alberto, M Gardner, William, Sahiledengle Geberemariyam, Biniyam, Mekonnen Gebrehiwot, Abiyu, Bizuwork Gebremedhin, Ketema, Ayalew Ayalew Ayalew Gebreslassie, Assefa, Gershberg Hayoon, Anna, W Gething, Peter, Ghadimi, Maryam, Ghadiri, Keyghobad, Ghafourifard, Mansour, Ghajar, Alireza, Ghamari, Farhad, Ghashghaee, Ahmad, Ghiasvand, Hesam, Ghith, Nermin, Gholamian, Asadollah, Amir Gilani, Syed, Singh Gill, Paramjit, Gitimoghaddam, Mojgan, Giussani, Giorgia, Goli, Sriniva, Santiago Gomez, Ricardo, Vali Gopalani, Sameer, Gorini, Giuseppe, M Gorman, Taren, Chase Gottlich, Harrison, Goudarzi, Houman, C Goulart, Alessandra, Niegia Garcia Goulart, Bárbara, Grada, Ayman, Grivna, Michal, Grosso, Giuseppe, Ibrahim Mohialdeen Gubari, Mohammed, Chander Gugnani, Harish, Luiz Sena Guimaraes, Andre, Alves Guimarães, Rafael, Abdi Guled, Rashid, Guo, Gaorui, Guo, Yuming, Gupta, Rajeev, A Haagsma, Juanita, Haddock, Beatrix, Hafezi-Nejad, Nima, Hafiz, Abdul, Hagins, Hailey, M Haile, Lydia, J Hall, Brian, Halvaei, Iman, R Hamadeh, Randah, Hamagharib Abdullah, Kanaan, B Hamilton, Erin, Han, Chieh, Han, Hannah, J Hankey, Graeme, Maria Haro, Josep, D Harvey, Jame, I Hasaballah, Ahmed, Hasanzadeh, Amir, Hashemian, Maryam, Hassanipour, Soheil, Hassankhani, Hadi, J Havmoeller, Rasmu, J Hay, Roderick, I Hay, Simon, Hayat, Khezar, Heidari, Behnam, Heidari, Golnaz, Heidari-Soureshjani, Reza, Hendrie, Delia, J Henrikson, Hannah, J Henry, Nathaniel, Herteliu, Claudiu, Heydarpour, Fatemeh, R Hird, Thoma, W Hoek, Han, K Hole, Michael, Holla, Ramesh, Hoogar, Praveen, Dean Hosgood, H, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Hostiuc, Sorin, Househ, Mowafa, G Hoy, Damian, Hsairi, Mohamed, Chia-Rong Hsieh, Vivian, Hu, Guoqing, M Huda, Tanvir, N Hugo, Fernando, K Huynh, Chantal, Hwang, Bing-Fang, C Iannucci, Vincent, Emmanuel Ibitoye, Segun, S Ikuta, Kevin, Stephen Ilesanmi, Olayinka, M Ilic, Irena, D Ilic, Milena, Raja Inbaraj, Leeberk, Ippolito, Helen, Sina Naghibi Irvani, Seyed, Mofizul Islam, M, Islam, Mdmohaimenul, Mohammed Shariful Islam, Sheikh, Islami, Farhad, Iso, Hiroyasu, Q Ivers, Rebecca, D Iwu, Chidozie C, Osamuyi Iyamu, Ihoghosa, Jaafari, Jalil, H Jacobsen, Kathryn, Jadidi-Niaragh, Farhad, Jafari, Hussain, Jafarinia, Morteza, Jahagirdar, Deepa, Ali Jahani, Mohammad, Jahanmehr, Nader, Jakovljevic, Mihajlo, Jalali, Amir, Jalilian, Farzad, L James, Spencer, Janjani, Hosna, Dilipkumar Janodia, Manthan, Upendra Jayatilleke, Achala, Jeemon, Panniyammakal, Jenabi, Ensiyeh, Prakash Jha, Ravi, Jha, Vivekanand, S Ji, John, Jia, Peng, John, Oommen, O John-Akinola, Yetunde, Owens Johnson, Catherine, Charlotte Johnson, Sarah, B Jonas, Jost, Joo, Tama, Joshi, Ankur, Jerzy Jozwiak, Jacek, Jürisson, Mikk, Kabir, Ali, Kabir, Zubair, Kalani, Hamed, Kalani, Rizwan, R Kalankesh, Leila, Kalhor, Rohollah, Kamiab, Zahra, Kanchan, Tanuj, Karami Matin, Behzad, Karch, André, Anisul Karim, Mohd, Eddin Karimi, Salah, Mullu Kassa, Getachew, J Kassebaum, Nichola, Vittal Katikireddi, Srinivasa, Kawakami, Norito, A Kayode, Gbenga, H Keddie, Suzanne, Keller, Cathleen, Kereselidze, Maia, Abdullatif Khafaie, Morteza, Khalid, Nauman, Khan, Maseer, Khatab, Khaled, M Khater, Mona, Nazli Khatib, Mahalaqua, Khayamzadeh, Maryam, Taghi Khodayari, Mohammad, Khundkar, Roba, Kianipour, Neda, Kieling, Christian, Kim, Daniel, Kim, Young-Eun, Jin Kim, Yun, W Kimokoti, Ruth, Kisa, Adnan, Kisa, Sezer, Kissimova-Skarbek, Katarzyna, Kivimäki, Mika, J Kneib, Cameron, Kristin Skrindo Knudsen, Ann, M Kocarnik, Jonathan, Kolola, Tufa, A Kopec, Jacek, Kosen, Soewarta, A Koul, Parvaiz, Koyanagi, Ai, A Kravchenko, Michael, Krishan, Kewal, J Krohn, Kri, Kuate Defo, Barthelemy, Kucuk Bicer, Burcu, Anil Kumar, G, Kumar, Manasi, Kumar, Pushpendra, Kumar, Vivek, Kumaresh, Girikumar, P Kurmi, Om, Kusuma, Dian, Hmwe Kyu, Hmwe, La Vecchia, Carlo, Lacey, Ben, Kumar Lal, Dharmesh, Lalloo, Ratilal, O Lam, Jennifer, Hasan Lami, Fari, Landires, Iván, J Lang, Justin, Charles Lansingh, Van, Leigh Larson, Samantha, O Larsson, Ander, Lasrado, Savita, S Lassi, Zohra, Mei-Ming Lau, Kathryn, M Lavados, Pablo, V Lazarus, Jeffrey, R Ledesma, Jorge, H Lee, Paul, Wen Huey Lee, Shaun, E LeGrand, Kate, Leigh, Jame, Leonardi, Matilde, Lescinsky, Haley, Leung, Janni, Levi, Miriam, Lewington, Sarah, Li, Shanshan, Lim, Lee-Ling, Lin, Christine, Lin, Ro-Ting, Linehan, Christine, Linn, Shai, Liu, Hung-Chun, Liu, Shiwei, Liu, Zichen, J Looker, Katharine, D Lopez, Alan, D Lopukhov, Platon, Lorkowski, Stefan, A Lotufo, Paulo, D Lucas, Tim C, Lugo, Alessandra, Lunevicius, Raimunda, A Lyons, Ronan, Ma, Jianing, H MacLachlan, Jennifer, R Maddison, Emilie, Maddison, Ralph, Madotto, Fabiana, Walter Mahasha, Phetole, Thi Mai, Hue, Majeed, Azeem, Maled, Venkatesh, Maleki, Shokofeh, Malekzadeh, Reza, Carvalho Malta, Deborah, A Mamun, Abdullah, Manafi, Amir, Manafi, Navid, Manguerra, Helena, Mansouri, Borhan, Ali Mansournia, Mohammad, M Mantilla Herrera, Ana, C Maravilla, Joemer, Marks, Ashley, Rogerlândio Martins-Melo, Francisco, Martopullo, Ira, Zahra Masoumi, Seyedeh, Massano, João, Ballard Massenburg, Benjamin, Raj Mathur, Manu, K Maulik, Pallab, Mcalinden, Colm, J McGrath, John, Mckee, Martin, Mohan Mehndiratta, Man, Mehri, Fereshteh, M Mehta, Kala, Bigyananda Meitei, Wahengbam, N Memiah, Peter T, Mendoza, Walter, G Menezes, Ritesh, Worku Mengesha, Endalkachew, Berwo Mengesha, Meresa, Mereke, Alibek, Meretoja, Atte, J Meretoja, Tuomo, Mestrovic, Tomislav, Miazgowski, Bartosz, Miazgowski, Tomasz, Maria Michalek, Irmina, Mulatu Mihretie, Kebadnew, R Miller, Ted, J Mills, Edward, Mirica, Andreea, M Mirrakhimov, Erkin, Mirzaei, Hamed, Mirzaei, Maryam, Mirzaei-Alavijeh, Mehdi, Temesgen Misganaw, Awoke, Mithra, Prasanna, Moazen, Babak, Moghadaszadeh, Masoud, Mohamadi, Efat, K Mohammad, Dara, Mohammad, Yousef, Mohammad Gholi Mezerji, Naser, Mohammadian-Hafshejani, Abdollah, Mohammadifard, Noushin, Mohammadpourhodki, Reza, Mohammed, Shafiu, H Mokdad, Ali, Molokhia, Mariam, C Momen, Natalie, Monasta, Lorenzo, Mondello, Stefania, D Mooney, Meghan, Moosazadeh, Mahmood, Moradi, Ghobad, Moradi, Masoud, Moradi-Lakeh, Maziar, Moradzadeh, Rahmatollah, Moraga, Paula, Morales, Linda, Morawska, Lidia, Moreno Velásquez, Ilai, Morgado-da-Costa, Joana, Douglas Morrison, Shane, F Mosser, Jonathan, Mouodi, Simin, Meysam Mousavi, Seyyed, Mousavi Khaneghah, Amin, Otto Mueller, Ulrich, B Munro, Sandra, K Muriithi, Mose, Imran Musa, Kamarul, Muthupandian, Saravanan, Naderi, Mehdi, Jayaraman Nagarajan, Ahamarshan, Nagel, Gabriele, Naghshtabrizi, Behshad, Nair, Sanjeev, K Nandi, Anita, Nangia, Vinay, Richie Nansseu, Jobert, C Nayak, Vinod, Nazari, Javad, Negoi, Ionut, Irina Negoi, Ruxandra, Biresaw Netsere Netsere, Henok, W Ngunjiri, Josephine, Tat Nguyen, Cuong, Nguyen, Jason, Nguyen, Michele, Nguyen, Minh, Nichols, Emma, Nigatu, Dabere, T Nigatu, Yeshambel, Nikbakhsh, Rajan, R Nixon, Molly, A Nnaji, Chukwudi, Nomura, Shuhei, Norrving, Bo, Jacques Noubiap, Jean, Nowak, Christoph, Nunez-Samudio, Virginia, Oţoiu, Adrian, Oancea, Bogdan, M Odell, Christopher, Akpojene Ogbo, Felix, Oh, In-Hwan, Wandera Okunga, Emmanuel, Oladnabi, Morteza, T Olagunju, Andrew, Olubukunola Olusanya, Bolajoko, Olusegun Olusanya, Jacob, Morenike Oluwasanu, Mojisola, Omar Bali, Ahmed, Omer Omer, Muktar, L Ong, Kanyin, E Onwujekwe, Obinna, U Orji, Aislyn, M Orpana, Heather, Ortiz, Alberto, M Ostroff, Samuel, Otstavnov, Nikita, S Otstavnov, Stanislav, Øverland, Simon, O Owolabi, Mayowa, P A, Mahesh, Rao Padubidri, Jagadish, P Pakhare, Abhijit, Palladino, Raffaele, Pana, Adrian, Panda-Jonas, Songhomitra, Pandey, Anamika, Park, Eun-Kee, G Kumari Parmar, Priya, Kumar Pasupula, Deepak, Kishor Patel, Sangram, J Paternina-Caicedo, Angel, Pathak, Ashish, Pathak, Mona, B Patten, Scott, C Patton, George, Paudel, Deepak, Pazoki Toroudi, Hamidreza, E Peden, Amy, Pennini, Alyssa, Christian Filipino Pepito, Veincent, K Peprah, Emmanuel, Pereira, Alexandre, M Pereira, David, Perico, Norberto, Quang Pham, Hai, R Phillips, Michael, M Pigott, David, Pilgrim, Thoma, M Pilz, Tessa, Pirsaheb, Meghdad, Plana-Ripoll, Oleguer, Plass, Dietrich, Narayan Pokhrel, Khem, V Polibin, Roman, Polinder, Suzanne, R Polkinghorne, Kevan, J Postma, Maarten, Pourjafar, Hadi, Pourmalek, Farshad, Pourmirza Kalhori, Reza, Pourshams, Akram, Poznańska, Anna, I Prada, Sergio, Ria Angga Pribadi, Dima, Pupillo, Elisabetta, Quazi Syed, Zahiruddin, Rabiee, Mohammad, Rabiee, Navid, Radfar, Amir, Rafiee, Ata, Rafiei, Alireza, Raggi, Alberto, Rahimi-Movaghar, Afarin, Aziz Rahman, Muhammad, Rajabpour-Sanati, Ali, Rajati, Fatemeh, Ramezanzadeh, Kiana, Lal Ranabhat, Chhabi, C Rao, Puja, J Rao, Sowmya, Rasella, Davide, Rastogi, Prateek, Rathi, Priya, Laith Rawaf, David, Rawaf, Salman, Rawal, Lal, Razo, Christian, Boston Redford, Sofia, C Reiner Jr, Robert, Reinig, Nickola, Bettay Reitsma, Marissa, Remuzzi, Giuseppe, Renjith, Vishnu, N Renzaho, Andre M, Resnikoff, Serge, Rezaei, Nima, Sadegh Rezai, Mohammad, Rezapour, Aziz, Rhinehart, Phoebe-Anne, Mohammad Riahi, Seyed, P Ribeiro, Antonio Luiz, Cury Ribeiro, Daniel, Ribeiro, Daniela, Rickard, Jennifer, S Roberts, Nicholas L, Roberts, Shaun, R Robinson, Stephen, Roever, Leonardo, Rolfe, Sam, Ronfani, Luca, Roshandel, Gholamreza, A Roth, Gregory, Rubagotti, Enrico, Fred Rumisha, Susan, Sabour, Siamak, S Sachdev, Perminder, Saddik, Basema, Sadeghi, Ehsan, Sadeghi, Masoumeh, Saeidi, Shahram, Safi, Sare, Safiri, Saeid, Sagar, Rajesh, Sahebkar, Amirhossein, Ali Sahraian, Mohammad, Mohammad Sajadi, S, Reza Salahshoor, Mohammad, Salamati, Payman, Salehi Zahabi, Saleh, Salem, Hosni, R Rashad Salem, Marwa, Salimzadeh, Hamideh, A Salomon, Joshua, Salz, Inbal, Samad, Zainab, M Samy, Abdallah, Sanabria, Juan, Francesco Santomauro, Damian, S Santos, Itamar, Vasco Santos, João, M Santric-Milicevic, Milena, Yegnanarayana Iyer Saraswathy, Sivan, Sarmiento-Suárez, Rodrigo, Sarrafzadegan, Nizal, Sartorius, Benn, Sarveazad, Arash, Sathian, Brijesh, Sathish, Thirunavukkarasu, Sattin, Davide, N Sbarra, Alyssa, E Schaeffer, Lauren, Schiavolin, Silvia, Inês Schmidt, Maria, Elisabeth Schutte, Aletta, C Schwebel, David, Schwendicke, Falk, Muleta Senbeta, Anbissa, Senthilkumaran, Subramanian, G Sepanlou, Sadaf, Anne Shackelford, Katya, Shadid, Jamileh, Shahabi, Saeed, A Shaheen, Amira, Ali Shaikh, Masood, S Shalash, Ali, Shams-Beyranvand, Mehran, Shamsizadeh, Morteza, Shannawaz, Mohammed, Sharafi, Kiomar, Sharara, Fablina, S Sheena, Brittney, Sheikhtaheri, Abba, S Shetty, Ranjitha, Shibuya, Kenji, Shibabaw Shiferaw, Wondimeneh, Shigematsu, Mika, Il Shin, Jae, Shiri, Rahman, Shirkoohi, Reza, G Shrime, Mark, Shuval, Kerem, Siabani, Soraya, Dora Sigfusdottir, Inga, Sigurvinsdottir, Rannveig, Pedro Silva, João, E Simpson, Kyle, Singh, Ambrish, A Singh, Jasvinder, Skiadaresi, Eirini, T Skou Skou, Søren, Yurievich Skryabin, Valentin, Sobngwi, Eugene, Sokhan, Anton, Soltani, Shahin, D Sorensen, Reed J, B Soriano, Joan, Bekele Sorrie, Muluken, N Soyiri, Ireneou, T Sreeramareddy, Chandrashekhar, D Stanaway, Jeffrey, A Stark, Benjamin, Cătălina Ştefan, Simona, Stein, Caroline, Steiner, Caitlyn, J Steiner, Timothy, A Stokes, Mark, Jacob Stovner, Lar, L Stubbs, Jacob, Sudaryanto, Agu, Babale Sufiyan, Mu'Awiyyah, Sulo, Gerhard, Sultan, Iyad, L Sykes, Bryan, O Sylte, Dillon, Szócska, Mikló, Tabarés-Seisdedos, Rafael, M Tabb, Karen, Kumar Tadakamadla, Santosh, Taherkhani, Amir, Tajdini, Masih, Takahashi, Ken, Taveira, Nuno, L Teagle, Whitney, Teame, Hirut, Tehrani-Banihashemi, Arash, Fseha Teklehaimanot, Berhane, Terrason, Sonyah, Tadesse Tessema, Zemenu, Raman Thankappan, Kavumpurathu, M Thomson, Azalea, Reza Tohidinik, Hamid, Tonelli, Marcello, Topor-Madry, Roman, E Torre, Anna, Touvier, Mathilde, Roberto Roberto Tovani-Palone, Marco, Xuan Tran, Bach, Travillian, Ravensara, E Troeger, Christopher, Clement Truelsen, Thoma, C Tsai, Alexander, Tsatsakis, Aristidi, Tudor Car, Lorainne, Tyrovolas, Stefano, Uddin, Riaz, Ullah, Saif, A Undurraga, Eduardo, Unnikrishnan, Bhaskaran, Vacante, Marco, Vakilian, Alireza, R Valdez, Pascual, Varughese, Santosh, Juhani Vasankari, Tommi, Vasseghian, Yasser, Venketasubramanian, Narayanaswamy, S Violante, Francesco, Vlassov, Vasily, Emil Vollset, Stein, Vongpradith, Avina, Vukovic, Ana, Vukovic, Rade, Waheed, Yasir, K Walters, Madgalene, Wang, Jiayu, Wang, Yafeng, Wang, Yuan-Pang, L Ward, Joseph, Watson, Alexandrea, Wei, Jingkai, G Weintraub, Robert, J Weiss, Daniel, Weiss, Jordan, Westerman, Ronny, L Whisnant, Joanna, A Whiteford, Harvey, Wiangkham, Taweewat, E Wiens, Kirsten, Wijeratne, Tissa, B Wilner, Lauren, Wilson, Shadrach, Wojtyniak, Bogdan, A Wolfe, Charles D, E Wool, Eve, Wu, Ai-Min, Wulf Hanson, Sarah, Yong Wunrow, Han, Xu, Gelin, Xu, Rixing, Yadgir, Simon, Hossein Yahyazadeh Jabbari, Seyed, Yamagishi, Kazumasa, Yaminfirooz, Mousa, Yano, Yuichiro, Yaya, Sanni, Yazdi-Feyzabadi, Vahid, A Yearwood, Jamal, Y Yeheyis, Toma, Gizachew Yeshitila, Yordano, Yip, Paul, Yonemoto, Naohiro, Yoon, Seok-Jun, Yoosefi Lebni, Javad, Z Younis, Mustafa, Patrick Younker, Theodore, Yousefi, Zabihollah, Yousefifard, Mahmoud, Yousefinezhadi, Taraneh, Yousuf Yousuf, Abdilahi, Yu, Chuanhua, Yusefzadeh, Hasan, Zahirian Moghadam, Telma, Zaki, Leila, Bin Zaman, Sojib, Zamani, Mohammad, Zamanian, Maryam, Zandian, Hamed, Zangeneh, Alireza, Sergeevich Zastrozhin, Mikhail, Alemayehu Zewdie, Kaleab, Zhang, Yunquan, Zhang, Zhi-Jiang, T Zhao, Jeff, Zhao, Yingxi, Zheng, Peng, Zhou, Maigeng, Ziapour, Arash, M Zimsen, Stephanie R, Naghavi, Mohsen, L Murray, Christopher J, Tampere University, Tays Research Services, Health Sciences, Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., Abolhassani, H., Aboyans, V., Abrams, E. M., Abreu, L. G., Abrigo, M. R. M., Abu-Raddad, L. J., Abushouk, A. I., Acebedo, A., Ackerman, I. N., Adabi, M., Adamu, A. A., Adebayo, O. M., Adekanmbi, V., Adelson, J. D., Adetokunboh, O. O., Adham, D., Afshari, M., Afshin, A., Agardh, E. E., Agarwal, G., Agesa, K. M., Aghaali, M., Aghamir, S. M. K., Agrawal, A., Ahmad, T., Ahmadi, A., Ahmadi, M., Ahmadieh, H., Ahmadpour, E., Akalu, T. Y., Akinyemi, R. O., Akinyemiju, T., Akombi, B., Al-Aly, Z., Alam, K., Alam, N., Alam, S., Alam, T., Alanzi, T. M., Albertson, S. B., Alcalde-Rabanal, J. E., Alema, N. M., Ali, M., Ali, S., Alicandro, G., Alijanzadeh, M., Alinia, C., Alipour, V., Aljunid, S. M., Alla, F., Allebeck, P., Almasi-Hashiani, A., Alonso, J., Al-Raddadi, R. M., Altirkawi, K. A., Alvis-Guzman, N., Alvis-Zakzuk, N. J., Amini, S., Amini-Rarani, M., Aminorroaya, A., Amiri, F., Amit, A. M. L., Amugsi, D. A., Amul, G. G. H., Anderlini, D., Andrei, C. L., Andrei, T., Anjomshoa, M., Ansari, F., Ansari, I., Ansari-Moghaddam, A., Antonio, C. A. T., Antony, C. M., Antriyandarti, E., Anvari, D., Anwer, R., Arabloo, J., Arab-Zozani, M., Aravkin, A. Y., Ariani, F., Arnlov, J., Aryal, K. K., Arzani, A., Asadi-Aliabadi, M., Asadi-Pooya, A. A., Asghari, B., Ashbaugh, C., Atnafu, D. D., Atre, S. R., Ausloos, F., Ausloos, M., Ayala Quintanilla, B. P., Ayano, G., Ayanore, M. A., Aynalem, Y. A., Azari, S., Azarian, G., Azene, Z. N., Babaee, E., Badawi, A., Bagherzadeh, M., Bakhshaei, M. H., Bakhtiari, A., Balakrishnan, S., Balalla, S., Balassyano, S., Banach, M., Banik, P. C., Bannick, M. S., Bante, A. B., Baraki, A. G., Barboza, M. A., Barker-Collo, S. L., Barthelemy, C. M., Barua, L., Barzegar, A., Basu, S., Baune, B. T., Bayati, M., Bazmandegan, G., Bedi, N., Beghi, E., Bejot, Y., Bello, A. K., Bender, R. G., Bennett, D. A., Bennitt, F. B., Bensenor, I. M., Benziger, C. P., Berhe, K., Bernabe, E., Bertolacci, G. J., Bhageerathy, R., Bhala, N., Bhandari, D., Bhardwaj, P., Bhattacharyya, K., Bhutta, Z. A., Bibi, S., Biehl, M. H., Bikbov, B., Bin Sayeed, M. S., Biondi, A., Birihane, B. M., Bisanzio, D., Bisignano, C., Biswas, R. K., Bohlouli, S., Bohluli, M., Bolla, S. R. R., Boloor, A., Boon-Dooley, A. S., Borges, G., Borzi, A. M., Bourne, R., Brady, O. J., Brauer, M., Brayne, C., Breitborde, N. J. K., Brenner, H., Briant, P. S., Briggs, A. M., Briko, N. I., Britton, G. B., Bryazka, D., Buchbinder, R., Bumgarner, B. R., Busse, R., Butt, Z. A., Caetano dos Santos, F. L., Camera, L. L. A., Campos-Nonato, I. R., Car, J., Cardenas, R., Carreras, G., Carrero, J. J., Carvalho, F., Castaldelli-Maia, J. M., Castaneda-Orjuela, C. A., Castelpietra, G., Castle, C. D., Castro, F., Catala-Lopez, F., Causey, K., Cederroth, C. R., Cercy, K. M., Cerin, E., Chandan, J. S., Chang, A. R., Charlson, F. J., Chattu, V. K., Chaturvedi, S., Chimed-Ochir, O., Chin, K. L., Cho, D. Y., Christensen, H., Chu, D. -T., Chung, M. T., Cicuttini, F. M., Ciobanu, L. G., Cirillo, M., Collins, E. L., Compton, K., Conti, S., Cortesi, P. A., Costa, V. M., Cousin, E., Cowden, R. G., Cowie, B. C., Cromwell, E. A., Cross, D. H., Crowe, C. S., Cruz, J. A., Cunningham, M., Dahlawi, S. M. A., Damiani, G., Dandona, L., Dandona, R., Darwesh, A. M., Daryani, A., Das, J. K., Das Gupta, R., das Neves, J., Davila-Cervantes, C. A., Davletov, K., De Leo, D., Dean, F. E., Decleene, N. K., Deen, A., Degenhardt, L., Dellavalle, R. P., Demeke, F. M., Demsie, D. G., Denova-Gutierrez, E., Dereje, N. D., Dervenis, N., Desai, R., Desalew, A., Dessie, G. A., Dharmaratne, S. D., Dhungana, G. P., Dianatinasab, M., Diaz, D., Dibaji Forooshani, Z. S., Dingels, Z. V., Dirac, M. A., Djalalinia, S., Do, H. T., Dokova, K., Dorostkar, F., Doshi, C. P., Doshmangir, L., Douiri, A., Doxey, M. C., Driscoll, T. R., Dunachie, S. J., Duncan, B. B., Duraes, A. R., Eagan, A. W., Ebrahimi Kalan, M., Edvardsson, D., Ehrlich, J. R., El Nahas, N., El Sayed, I., El Tantawi, M., Elbarazi, I., Elgendy, I. Y., Elhabashy, H. R., El-Jaafary, S. I., Elyazar, I. R., Emamian, M. H., Emmons-Bell, S., Erskine, H. E., Eshrati, B., Eskandarieh, S., Esmaeilnejad, S., Esmaeilzadeh, F., Esteghamati, A., Estep, K., Etemadi, A., Etisso, A. E., Farahmand, M., Faraj, A., Fareed, M., Faridnia, R., Farinha, C. S. E. S., Farioli, A., Faro, A., Faruque, M., Farzadfar, F., Fattahi, N., Fazlzadeh, M., Feigin, V. L., Feldman, R., Fereshtehnejad, S. -M., Fernandes, E., Ferrari, A. J., Ferreira, M. L., Filip, I., Fischer, F., Fisher, J. L., Fitzgerald, R., Flohr, C., Flor, L. S., Foigt, N. A., Folayan, M. O., Force, L. M., Fornari, C., Foroutan, M., Fox, J. T., Freitas, M., Fu, W., Fukumoto, T., Furtado, J. M., Gad, M. M., Gakidou, E., Galles, N. C., Gallus, S., Gamkrelidze, A., Garcia-Basteiro, A. L., Gardner, W. M., Geberemariyam, B. S., Gebrehiwot, A. M., Gebremedhin, K. B., Gebreslassie, A. A. A. A., Gershberg Hayoon, A., Gething, P. W., Ghadimi, M., Ghadiri, K., Ghafourifard, M., Ghajar, A., Ghamari, F., Ghashghaee, A., Ghiasvand, H., Ghith, N., Gholamian, A., Gilani, S. A., Gill, P. S., Gitimoghaddam, M., Giussani, G., Goli, S., Gomez, R. S., Gopalani, S. V., Gorini, G., Gorman, T. M., Gottlich, H. C., Goudarzi, H., Goulart, A. C., Goulart, B. N. G., Grada, A., Grivna, M., Grosso, G., Gubari, M. I. M., Gugnani, H. C., Guimaraes, A. L. S., Guimaraes, R. A., Guled, R. A., Guo, G., Guo, Y., Gupta, R., Haagsma, J. A., Haddock, B., Hafezi-Nejad, N., Hafiz, A., Hagins, H., Haile, L. M., Hall, B. J., Halvaei, I., Hamadeh, R. R., Hamagharib Abdullah, K., Hamilton, E. B., Han, C., Han, H., Hankey, G. J., Haro, J. M., Harvey, J. D., Hasaballah, A. I., Hasanzadeh, A., Hashemian, M., Hassanipour, S., Hassankhani, H., Havmoeller, R. J., Hay, R. J., Hay, S. I., Hayat, K., Heidari, B., Heidari, G., Heidari-Soureshjani, R., Hendrie, D., Henrikson, H. J., Henry, N. J., Herteliu, C., Heydarpour, F., Hird, T. R., Hoek, H. W., Hole, M. K., Holla, R., Hoogar, P., Hosgood, H. D., Hosseinzadeh, M., Hostiuc, M., Hostiuc, S., Househ, M., Hoy, D. G., Hsairi, M., Hsieh, V. C. -R., Hu, G., Huda, T. M., Hugo, F. N., Huynh, C. K., Hwang, B. -F., Iannucci, V. C., Ibitoye, S. E., Ikuta, K. S., Ilesanmi, O. S., Ilic, I. M., Ilic, M. D., Inbaraj, L. R., Ippolito, H., Irvani, S. S. N., Islam, M. M., Islam, M., Islam, S. M. S., Islami, F., Iso, H., Ivers, R. Q., Iwu, C. C. D., Iyamu, I. O., Jaafari, J., Jacobsen, K. H., Jadidi-Niaragh, F., Jafari, H., Jafarinia, M., Jahagirdar, D., Jahani, M. A., Jahanmehr, N., Jakovljevic, M., Jalali, A., Jalilian, F., James, S. L., Janjani, H., Janodia, M. D., Jayatilleke, A. U., Jeemon, P., Jenabi, E., Jha, R. P., Jha, V., Ji, J. S., Jia, P., John, O., John-Akinola, Y. O., Johnson, C. O., Johnson, S. C., Jonas, J. B., Joo, T., Joshi, A., Jozwiak, J. J., Jurisson, M., Kabir, A., Kabir, Z., Kalani, H., Kalani, R., Kalankesh, L. R., Kalhor, R., Kamiab, Z., Kanchan, T., Karami Matin, B., Karch, A., Karim, M. A., Karimi, S. E., Kassa, G. M., Kassebaum, N. J., Katikireddi, S. V., Kawakami, N., Kayode, G. A., Keddie, S. H., Keller, C., Kereselidze, M., Khafaie, M. A., Khalid, N., Khan, M., Khatab, K., Khater, M. M., Khatib, M. N., Khayamzadeh, M., Khodayari, M. T., Khundkar, R., Kianipour, N., Kieling, C., Kim, D., Kim, Y. -E., Kim, Y. J., Kimokoti, R. W., Kisa, A., Kisa, S., Kissimova-Skarbek, K., Kivimaki, M., Kneib, C. J., Knudsen, A. K. S., Kocarnik, J. M., Kolola, T., Kopec, J. A., Kosen, S., Koul, P. A., Koyanagi, A., Kravchenko, M. A., Krishan, K., Krohn, K. J., Kuate Defo, B., Kucuk Bicer, B., Kumar, G. A., Kumar, M., Kumar, P., Kumar, V., Kumaresh, G., Kurmi, O. P., Kusuma, D., Kyu, H. H., La Vecchia, C., Lacey, B., Lal, D. K., Lalloo, R., Lam, J. O., Lami, F. H., Landires, I., Lang, J. J., Lansingh, V. C., Larson, S. L., Larsson, A. O., Lasrado, S., Lassi, Z. S., Lau, K. M. -M., Lavados, P. M., Lazarus, J. V., Ledesma, J. R., Lee, P. H., Lee, S. W. H., Legrand, K. E., Leigh, J., Leonardi, M., Lescinsky, H., Leung, J., Levi, M., Lewington, S., Li, S., Lim, L. -L., Lin, C., Lin, R. -T., Linehan, C., Linn, S., Liu, H. -C., Liu, S., Liu, Z., Looker, K. J., Lopez, A. D., Lopukhov, P. D., Lorkowski, S., Lotufo, P. A., Lucas, T. C. D., Lugo, A., Lunevicius, R., Lyons, R. A., Ma, J., Maclachlan, J. H., Maddison, E. R., Maddison, R., Madotto, F., Mahasha, P. W., Mai, H. T., Majeed, A., Maled, V., Maleki, S., Malekzadeh, R., Malta, D. C., Mamun, A. A., Manafi, A., Manafi, N., Manguerra, H., Mansouri, B., Mansournia, M. A., Mantilla Herrera, A. M., Maravilla, J. C., Marks, A., Martins-Melo, F. R., Martopullo, I., Masoumi, S. Z., Massano, J., Massenburg, B. B., Mathur, M. R., Maulik, P. K., Mcalinden, C., Mcgrath, J. J., Mckee, M., Mehndiratta, M. M., Mehri, F., Mehta, K. M., Meitei, W. B., Memiah, P. T. N., Mendoza, W., Menezes, R. G., Mengesha, E. W., Mengesha, M. B., Mereke, A., Meretoja, A., Meretoja, T. J., Mestrovic, T., Miazgowski, B., Miazgowski, T., Michalek, I. M., Mihretie, K. M., Miller, T. R., Mills, E. J., Mirica, A., Mirrakhimov, E. M., Mirzaei, H., Mirzaei, M., Mirzaei-Alavijeh, M., Misganaw, A. T., Mithra, P., Moazen, B., Moghadaszadeh, M., Mohamadi, E., Mohammad, D. K., Mohammad, Y., Mohammad Gholi Mezerji, N., Mohammadian-Hafshejani, A., Mohammadifard, N., Mohammadpourhodki, R., Mohammed, S., Mokdad, A. H., Molokhia, M., Momen, N. C., Monasta, L., Mondello, S., Mooney, M. D., Moosazadeh, M., Moradi, G., Moradi, M., Moradi-Lakeh, M., Moradzadeh, R., Moraga, P., Morales, L., Morawska, L., Moreno Velasquez, I., Morgado-da-Costa, J., Morrison, S. D., Mosser, J. F., Mouodi, S., Mousavi, S. M., Mousavi Khaneghah, A., Mueller, U. O., Munro, S. B., Muriithi, M. K., Musa, K. I., Muthupandian, S., Naderi, M., Nagarajan, A. J., Nagel, G., Naghshtabrizi, B., Nair, S., Nandi, A. K., Nangia, V., Nansseu, J. R., Nayak, V. C., Nazari, J., Negoi, I., Negoi, R. I., Netsere, H. B. N., Ngunjiri, J. W., Nguyen, C. T., Nguyen, J., Nguyen, M., Nichols, E., Nigatu, D., Nigatu, Y. T., Nikbakhsh, R., Nixon, M. R., Nnaji, C. A., Nomura, S., Norrving, B., Noubiap, J. J., Nowak, C., Nunez-Samudio, V., Otoiu, A., Oancea, B., Odell, C. M., Ogbo, F. A., Oh, I. -H., Okunga, E. W., Oladnabi, M., Olagunju, A. T., Olusanya, B. O., Olusanya, J. O., Oluwasanu, M. M., Omar Bali, A., Omer, M. O., Ong, K. L., Onwujekwe, O. E., Orji, A. U., Orpana, H. M., Ortiz, A., Ostroff, S. M., Otstavnov, N., Otstavnov, S. S., Overland, S., Owolabi, M. O., P A, M., Padubidri, J. R., Pakhare, A. P., Palladino, R., Pana, A., Panda-Jonas, S., Pandey, A., Park, E. -K., Parmar, P. G. K., Pasupula, D. K., Patel, S. K., Paternina-Caicedo, A. J., Pathak, A., Pathak, M., Patten, S. B., Patton, G. C., Paudel, D., Pazoki Toroudi, H., Peden, A. E., Pennini, A., Pepito, V. C. F., Peprah, E. K., Pereira, A., Pereira, D. M., Perico, N., Pham, H. Q., Phillips, M. R., Pigott, D. M., Pilgrim, T., Pilz, T. M., Pirsaheb, M., Plana-Ripoll, O., Plass, D., Pokhrel, K. N., Polibin, R. V., Polinder, S., Polkinghorne, K. R., Postma, M. J., Pourjafar, H., Pourmalek, F., Pourmirza Kalhori, R., Pourshams, A., Poznanska, A., Prada, S. I., Prakash, V., Pribadi, D. R. A., Pupillo, E., Quazi Syed, Z., Rabiee, M., Rabiee, N., Radfar, A., Rafiee, A., Rafiei, A., Raggi, A., Rahimi-Movaghar, A., Rahman, M. A., Rajabpour-Sanati, A., Rajati, F., Ramezanzadeh, K., Ranabhat, C. L., Rao, P. C., Rao, S. J., Rasella, D., Rastogi, P., Rathi, P., Rawaf, D. L., Rawaf, S., Rawal, L., Razo, C., Redford, S. B., Reiner, R. C., Reinig, N., Reitsma, M. B., Remuzzi, G., Renjith, V., Renzaho, A. M. N., Resnikoff, S., Rezaei, N., Rezai, M. S., Rezapour, A., Rhinehart, P. -A., Riahi, S. M., Ribeiro, A. L. P., Ribeiro, D. C., Ribeiro, D., Rickard, J., Roberts, N. L. S., Roberts, S., Robinson, S. R., Roever, L., Rolfe, S., Ronfani, L., Roshandel, G., Roth, G. A., Rubagotti, E., Rumisha, S. F., Sabour, S., Sachdev, P. S., Saddik, B., Sadeghi, E., Sadeghi, M., Saeidi, S., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sahraian, M. A., Sajadi, S. M., Salahshoor, M. R., Salamati, P., Salehi Zahabi, S., Salem, H., Salem, M. R. R., Salimzadeh, H., Salomon, J. A., Salz, I., Samad, Z., Samy, A. M., Sanabria, J., Santomauro, D. F., Santos, I. S., Santos, J. V., Santric-Milicevic, M. M., Saraswathy, S. Y. I., Sarmiento-Suarez, R., Sarrafzadegan, N., Sartorius, B., Sarveazad, A., Sathian, B., Sathish, T., Sattin, D., Sbarra, A. N., Schaeffer, L. E., Schiavolin, S., Schmidt, M. I., Schutte, A. E., Schwebel, D. C., Schwendicke, F., Senbeta, A. M., Senthilkumaran, S., Sepanlou, S. G., Shackelford, K. A., Shadid, J., Shahabi, S., Shaheen, A. A., Shaikh, M. A., Shalash, A. S., Shams-Beyranvand, M., Shamsizadeh, M., Shannawaz, M., Sharafi, K., Sharara, F., Sheena, B. S., Sheikhtaheri, A., Shetty, R. S., Shibuya, K., Shiferaw, W. S., Shigematsu, M., Shin, J. I., Shiri, R., Shirkoohi, R., Shrime, M. G., Shuval, K., Siabani, S., Sigfusdottir, I. D., Sigurvinsdottir, R., Silva, J. P., Simpson, K. E., Singh, A., Singh, J. A., Skiadaresi, E., Skou, S. T. S., Skryabin, V. Y., Sobngwi, E., Sokhan, A., Soltani, S., Sorensen, R. J. D., Soriano, J. B., Sorrie, M. B., Soyiri, I. N., Sreeramareddy, C. T., Stanaway, J. D., Stark, B. A., Stefan, S. C., Stein, C., Steiner, C., Steiner, T. J., Stokes, M. A., Stovner, L. J., Stubbs, J. L., Sudaryanto, A., Sufiyan, M. B., Sulo, G., Sultan, I., Sykes, B. L., Sylte, D. O., Szocska, M., Tabares-Seisdedos, R., Tabb, K. M., Tadakamadla, S. K., Taherkhani, A., Tajdini, M., Takahashi, K., Taveira, N., Teagle, W. L., Teame, H., Tehrani-Banihashemi, A., Teklehaimanot, B. F., Terrason, S., Tessema, Z. T., Thankappan, K. R., Thomson, A. M., Tohidinik, H. R., Tonelli, M., Topor-Madry, R., Torre, A. E., Touvier, M., Tovani-Palone, M. R. R., Tran, B. X., Travillian, R., Troeger, C. E., Truelsen, T. C., Tsai, A. C., Tsatsakis, A., Tudor Car, L., Tyrovolas, S., Uddin, R., Ullah, S., Undurraga, E. A., Unnikrishnan, B., Vacante, M., Vakilian, A., Valdez, P. R., Varughese, S., Vasankari, T. J., Vasseghian, Y., Venketasubramanian, N., Violante, F. S., Vlassov, V., Vollset, S. E., Vongpradith, A., Vukovic, A., Vukovic, R., Waheed, Y., Walters, M. K., Wang, J., Wang, Y., Wang, Y. -P., Ward, J. L., Watson, A., Wei, J., Weintraub, R. G., Weiss, D. J., Weiss, J., Westerman, R., Whisnant, J. L., Whiteford, H. A., Wiangkham, T., Wiens, K. E., Wijeratne, T., Wilner, L. B., Wilson, S., Wojtyniak, B., Wolfe, C. D. A., Wool, E. E., Wu, A. -M., Wulf Hanson, S., Wunrow, H. Y., Xu, G., Xu, R., Yadgir, S., Yahyazadeh Jabbari, S. H., Yamagishi, K., Yaminfirooz, M., Yano, Y., Yaya, S., Yazdi-Feyzabadi, V., Yearwood, J. A., Yeheyis, T. Y., Yeshitila, Y. G., Yip, P., Yonemoto, N., Yoon, S. -J., Yoosefi Lebni, J., Younis, M. Z., Younker, T. P., Yousefi, Z., Yousefifard, M., Yousefinezhadi, T., Yousuf, A. Y., Yu, C., Yusefzadeh, H., Zahirian Moghadam, T., Zaki, L., Zaman, S. B., Zamani, M., Zamanian, M., Zandian, H., Zangeneh, A., Zastrozhin, M. S., Zewdie, K. A., Zhang, Y., Zhang, Z. -J., Zhao, J. T., Zhao, Y., Zheng, P., Zhou, M., Ziapour, A., Zimsen, S. R. M., Naghavi, M., Murray, C. J. L., Department of Public Health, Clinicum, Department of Neurosciences, HUS Comprehensive Cancer Center, Environmental Sciences, Public Health, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Microbes in Health and Disease (MHD), Sálfræðideild (HR), Department of Psychology (RU), Samfélagssvið (HR), School of Social Sciences (RU), Háskólinn í Reykjavík, Reykjavik University, GBD 2019 Diseases and Injuries Collaborator, Violante FS, Department of Earth Observation Science, Faculty of Geo-Information Science and Earth Observation, and UT-I-ITC-ACQUAL
- Subjects
Male ,Life expectancy ,Disability-Adjusted Life Year ,Diseases ,Disease ,communicable disease ,systematic analysis ,Global Burden of Disease ,0302 clinical medicine ,80 and over ,Medicine ,10. No inequality ,Child ,11 Medical and Health Sciences ,injuries ,Aged, 80 and over ,education.field_of_study ,Sjúkdómar ,DEMENTIA ,FALLS ,General Medicine ,Forvarnir ,3. Good health ,Child, Preschool ,Human ,GBD ,Population health ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Humans ,Global Burden of Disease Study ,education ,Aged ,Spatial Analysis ,Global burden ,Disability ,Prevention ,DISABILITY ,Infant ,Spatial Analysi ,Mortality rate ,Global Burden of Disease, Diseases, Injuries, Systematic analysis ,PREVENTION ,Years of potential life lost ,Risk factors ,Disease study ,ITC-ISI-JOURNAL-ARTICLE ,RISK-FACTORS ,Clinical Medicine ,RA ,Demography ,Fötlun ,Dánartíðni ,Áhættuþættir ,030204 cardiovascular system & hematology ,Risk Factors ,Cause of Death ,Global health ,030212 general & internal medicine ,1. No poverty ,Disability-Adjusted Life Years ,Public Health, Global Health, Social Medicine and Epidemiology ,Middle Aged ,3142 Public health care science, environmental and occupational health ,Adolescent ,Adult ,Age Distribution ,Female ,Infant, Newborn ,Young Adult ,Lýðheilsa ,CLINICAL-TRIALS ,Population ,Settore MED/01 - Statistica Medica ,diseases ,ITC-HYBRID ,Heilbrigðisvísindi ,General & Internal Medicine ,Mortality ,Preschool ,Disease burden ,business.industry ,Risk Factor ,Klinisk medicin ,Newborn ,purl.org/pe-repo/ocde/ford#3.02.00 [https] ,Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi ,Áverkar ,Systematic analysis ,NA ,business - Abstract
Publisher's version (útgefin grein), Background In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990-2010 time period, with the greatest annualised rate of decline occurring in the 0-9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10-24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10-24 years were also in the top ten in the 25-49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50-74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd., Research reported in this publication was supported by the Bill & Melinda Gates Foundation; the University of Melbourne; Queensland Department of Health, Australia; the National Health and Medical Research Council, Australia; Public Health England; the Norwegian Institute of Public Health; St Jude Children's Research Hospital; the Cardiovascular Medical Research and Education Fund; the National Institute on Ageing of the National Institutes of Health (award P30AG047845); and the National Institute of Mental Health of the National Institutes of Health (award R01MH110163). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated, the National Health Service (NHS), the National Institute for Health Research (NIHR), the UK Department of Health and Social Care, or Public Health England; the United States Agency for International Development (USAID), the US Government, or MEASURE Evaluation; or the European Centre for Disease Prevention and Control (ECDC). This research used data from the Chile National Health Survey 2003, 2009-10, and 2016-17. The authors are grateful to the Ministry of Health, the survey copyright owner, for allowing them to have the database. All results of the study are those of the authors and in no way committed to the Ministry. The Costa Rican Longevity and Healthy Aging Study project is a longitudinal study by the University of Costa Rica's Centro Centroamericano de Poblacion and Instituto de Investigaciones en Salud, in collaboration with the University of California at Berkeley. The original pre-1945 cohort was funded by the Wellcome Trust (grant 072406), and the 1945-55 Retirement Cohort was funded by the US National Institute on Aging (grant R01AG031716). The principal investigators are Luis Rosero-Bixby and William H Dow and co-principal investigators are Xinia Fernandez and Gilbert Brenes. The accuracy of the authors' statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or incorrect use of the data. The Health Behaviour in School-Aged Children (HBSC) study is an international study carried out in collaboration with WHO/EURO. The international coordinator of the 1997-98, 2001-02, 2005-06, and 2009-10 surveys was Candace Currie and the databank manager for the 1997-98 survey was Bente Wold, whereas for the following surveys Oddrun Samdal was the databank manager. A list of principal investigators in each country can be found on the HBSC website. Data used in this paper come from the 2009-10 Ghana Socioeconomic Panel Study Survey, which is a nationally representative survey of more than 5000 households in Ghana. The survey is a joint effort undertaken by the Institute of Statistical, Social and Economic Research (ISSER) at the University of Ghana and the Economic Growth Centre (EGC) at Yale University. It was funded by EGC. ISSER and the EGC are not responsible for the estimations reported by the analysts. The Palestinian Central Bureau of Statistics granted the researchers access to relevant data in accordance with license number SLN2014-3-170, after subjecting data to processing aiming to preserve the confidentiality of individual data in accordance with the General Statistics Law, 2000. The researchers are solely responsible for the conclusions and inferences drawn upon available data. Data for this research was provided by MEASURE Evaluation, funded by USAID. The authors thank the Russia Longitudinal Monitoring Survey, conducted by the National Research University Higher School of Economics and ZAO Demoscope together with Carolina Population Center, University of North Carolina at Chapel Hill and the Institute of Sociology, Russia Academy of Sciences for making data available. This paper uses data from the Bhutan 2014 STEPS survey, implemented by the Ministry of Health with the support of WHO; the Kuwait 2006 and 2014 STEPS surveys, implemented by the Ministry of Health with the support of WHO; the Libya 2009 STEPS survey, implemented by the Secretariat of Health and Environment with the support of WHO; the Malawi 2009 STEPS survey, implemented by Ministry of Health with the support of WHO; and the Moldova 2013 STEPS survey, implemented by the Ministry of Health, the National Bureau of Statistics, and the National Center of Public Health with the support of WHO. This paper uses data from Survey of Health, Ageing and Retirement in Europe (SHARE) Waves 1 (DOI:10.6103/SHARE. w1.700), 2 (10.6103/SHARE.w2.700), 3 (10.6103/SHARE.w3.700), 4 (10.6103/SHARE.w4.700), 5 (10.6103/SHARE.w5.700), 6 (10.6103/SHARE.w6.700), and 7 (10.6103/SHARE.w7.700); see Borsch-Supan and colleagues (2013) for methodological details. The SHARE data collection has been funded by the European Commission through FP5 (QLK6-CT-2001-00360), FP6 (SHARE-I3: RII-CT-2006-062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-028812), FP7 (SHARE-PREP: GA N degrees 211909, SHARE-LEAP: GA N degrees 227822, SHARE M4: GA N degrees 261982) and Horizon 2020 (SHARE-DEV3: GA N degrees 676536, SERISS: GA N degrees 654221) and by DG Employment, Social Affairs & Inclusion. Additional funding from the German Ministry of Education and Research, the Max Planck Society for the Advancement of Science, the US National Institute on Aging (U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_AG025169, Y1-AG-4553-01, IAG_BSR06-11, OGHA_04-064, HHSN271201300071C), and from various national funding sources is gratefully acknowledged. This study has been realised using the data collected by the Swiss Household Panel, which is based at the Swiss Centre of Expertise in the Social Sciences. The project is financed by the Swiss National Science Foundation. The United States Aging, Demographics, and Memory Study is a supplement to the Health and Retirement Study (HRS), which is sponsored by the National Institute of Aging (grant number NIA U01AG009740). It was conducted jointly by Duke University and the University of Michigan. The HRS is sponsored by the National Institute on Aging (grant number NIA U01AG009740) and is conducted by the University of Michigan. This paper uses data from Add Health, a program project designed by J Richard Udry, Peter S Bearman, and Kathleen Mullan Harris, and funded by a grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 17 other agencies. Special acknowledgment is due to Ronald R Rindfuss and Barbara Entwisle for assistance in the original design. Information on how to obtain the Add Health data files is available on the Add Health website. No direct support was received from grant P01-HD31921 for this analysis. The data reported here have been supplied by the United States Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US Government. Collection of data for the Mozambique National Survey on the Causes of Death 2007-08 was made possible by USAID under the terms of cooperative agreement GPO-A-00-08-000_D3-00. This manuscript is based on data collected and shared by the International Vaccine Institute (IVI) from an original study IVI conducted. L G Abreu acknowledges support from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brazil; finance code 001) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, a Brazilian funding agency). I N Ackerman was supported by a Victorian Health and Medical Research Fellowship awarded by the Victorian Government. O O Adetokunboh acknowledges the South African Department of Science and Innovation and the National Research Foundation. A Agrawal acknowledges the Wellcome Trust DBT India Alliance Senior Fellowship. S M Aljunid acknowledges the Department of Health Policy and Management, Faculty of Public Health, Kuwait University and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia for the approval and support to participate in this research project. M Ausloos, C Herteliu, and A Pana acknowledge partial support by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. A Badawi is supported by the Public Health Agency of Canada. D A Bennett was supported by the NIHR Oxford Biomedical Research Centre. R Bourne acknowledges the Brien Holden Vision Institute, University of Heidelberg, Sightsavers, Fred Hollows Foundation, and Thea Foundation. G B Britton and I Moreno Velasquez were supported by the Sistema Nacional de Investigacion, SNI-SENACYT, Panama. R Buchbinder was supported by an Australian National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship. J J Carrero was supported by the Swedish Research Council (2019-01059). F Carvalho acknowledges UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from FCT/MCTES through national funds. A R Chang was supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant K23 DK106515. V M Costa acknowledges the grant SFRH/BHD/110001/2015, received by Portuguese national funds through Fundacao para a Ciencia e Tecnologia, IP, under the Norma Transitaria DL57/2016/CP1334/CT0006. A Douiri acknowledges support and funding from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust and the Royal College of Physicians, and support from the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. B B Duncan acknowledges grants from the Foundation for the Support of Research of the State of Rio Grande do Sul (IATS and PrInt) and the Brazilian Ministry of Health. H E Erskine is the recipient of an Australian NHMRC Early Career Fellowship grant (APP1137969). A J Ferrari was supported by a NHMRC Early Career Fellowship grant (APP1121516). H E Erskine and A J Ferrari are employed by and A M Mantilla-Herrera and D F Santomauro affiliated with the Queensland Centre for Mental Health Research, which receives core funding from the Queensland Department of Health. M L Ferreira holds an NHMRC Research Fellowship. C Flohr was supported by the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust. M Freitas acknowledges financial support from the EU (European Regional Development Fund [FEDER] funds through COMPETE POCI-01-0145-FEDER-029248) and National Funds (Fundacao para a Ciencia e Tecnologia) through project PTDC/NAN-MAT/29248/2017. A L S Guimaraes acknowledges support from CNPq. C Herteliu was partially supported by a grant co-funded by FEDER through Operational Competitiveness Program (project ID P_40_382). P Hoogar acknowledges Centre for Bio Cultural Studies, Directorate of Research, Manipal Academy of Higher Education and Centre for Holistic Development and Research, Kalaghatagi. F N Hugo acknowledges the Visiting Professorship, PRINT Program, CAPES Foundation, Brazil. B-F Hwang was supported by China Medical University (CMU107-Z-04), Taichung, Taiwan. S M S Islam was funded by a National Heart Foundation Senior Research Fellowship and supported by Deakin University. R Q Ivers was supported by a research fellowship from the National Health and Medical Research Council of Australia. M Jakovljevic acknowledges the Serbian part of this GBD-related contribution was co-funded through Grant OI175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. P Jeemon was supported by a Clinical and Public Health intermediate fellowship (grant number IA/CPHI/14/1/501497) from the Wellcome Trust-Department of Biotechnology, India Alliance (2015-20). O John is a recipient of UIPA scholarship from University of New South Wales, Sydney. S V Katikireddi acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_12017/13, MC_UU_12017/15), and the Scottish Government Chief Scientist Office (SPHSU13, SPHSU15). C Kieling is a CNPq researcher and a UK Academy of Medical Sciences Newton Advanced Fellow. Y J Kim was supported by Research Management Office, Xiamen University Malaysia (XMUMRF/2018-C2/ITCM/00010). K Krishan is supported by UGC Centre of Advanced Study awarded to the Department of Anthropology, Panjab University, Chandigarh, India. M Kumar was supported by K43 TW 010716 FIC/NIMH. B Lacey acknowledges support from the NIHR Oxford Biomedical Research Centre and the BHF Centre of Research Excellence, Oxford. J V Lazarus was supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III [ISCIII]/ESF, the EU [CP18/00074]). K J Looker thanks the NIHR Health Protection Research Unit in Evaluation of Interventions at the University of Bristol, in partnership with Public Health England, for research support. S Lorkowski was funded by the German Federal Ministry of Education and Research (nutriCARD, grant agreement number 01EA1808A). R A Lyons is supported by Health Data Research UK (HDR-9006), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, NIHR (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. J J McGrath is supported by the Danish National Research Foundation (Niels Bohr Professorship), and the Queensland Health Department (via West Moreton HHS). P T N Memiah acknowledges support from CODESRIA. U O Mueller gratefully acknowledges funding by the German National Cohort Study BMBF grant number 01ER1801D. S Nomura acknowledges the Ministry of Education, Culture, Sports, Science, and Technology of Japan (18K10082). A Ortiz was supported by ISCIII PI19/00815, DTS18/00032, ISCIII-RETIC REDinREN RD016/0009 Fondos FEDER, FRIAT, Comunidad de Madrid B2017/BMD-3686 CIFRA2-CM. These funding sources had no role in the writing of the manuscript or the decision to submit it for publication. S B Patten was supported by the Cuthbertson & Fischer Chair in Pediatric Mental Health at the University of Calgary. G C Patton was supported by an aNHMRC Senior Principal Research Fellowship. M R Phillips was supported in part by the National Natural Science Foundation of China (NSFC, number 81371502 and 81761128031). A Raggi, D Sattin, and S Schiavolin were supported by grants from the Italian Ministry of Health (Ricerca Corrente, Fondazione Istituto Neurologico C Besta, Linea 4-Outcome Research: dagli Indicatori alle Raccomandazioni Cliniche). P Rathi and B Unnikrishnan acknowledge Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal. A L P Ribeiro was supported by Brazilian National Research Council, CNPq, and the Minas Gerais State Research Agency, FAPEMIG. D C Ribeiro was supported by The Sir Charles Hercus Health Research Fellowship (#18/111) Health Research Council of New Zealand. D Ribeiro acknowledges financial support from the EU (FEDER funds through the Operational Competitiveness Program; POCI-01-0145-FEDER-029253). P S Sachdev acknowledges funding from the NHMRC of Australia Program Grant. A M Samy was supported by a fellowship from the Egyptian Fulbright Mission Program. M M Santric-Milicevic acknowledges the Ministry of Education, Science and Technological Development of the Republic of Serbia (contract number 175087). R Sarmiento-Suarez received institutional support from Applied and Environmental Sciences University (Bogota, Colombia) and ISCIII (Madrid, Spain). A E Schutte received support from the South African National Research Foundation SARChI Initiative (GUN 86895) and Medical Research Council. S T S Skou is currently funded by a grant from Region Zealand (Exercise First) and a grant from the European Research Council under the EU's Horizon 2020 research and innovation program (grant agreement number 801790). J B Soriano is funded by Centro de Investigacion en Red de Enfermedades Respiratorias, ISCIII. R Tabares-Seisdedos was supported in part by the national grant PI17/00719 from ISCIII-FEDER. N Taveira was partially supported by the European & Developing Countries Clinical Trials Partnership, the EU (LIFE project, reference RIA2016MC-1615). S Tyrovolas was supported by the Foundation for Education and European Culture, the Sara Borrell postdoctoral programme (reference number CD15/00019 from ISCIII-FEDER). S B Zaman received a scholarship from the Australian Government research training programme in support of his academic career., "Peer Reviewed"
- Published
- 2020
- Full Text
- View/download PDF
35. The Subsequent Risk for Permanent Pacemaker after Spontaneous Recovery of Atrioventricular Blocks; a Retrospective Cohort Study
- Author
-
Mehdi Mehrani, Kaveh Hosseini, Keyvan Ghasemi, Sajad Ahmadzadeh, Seyedeh Hamideh Mortazavi, Ali Vasheghani Farahani, Masih Tajdini, Saeed Sadeghian, Arash Jalali, and Ali Bozorgi
- Subjects
medicine.medical_specialty ,Subsequent Relapse ,business.industry ,Retrospective cohort study ,medicine.disease ,Surgery ,Discontinuation ,Severity of illness ,Etiology ,Medicine ,Population study ,Cardiology and Cardiovascular Medicine ,business ,Atrioventricular block ,Cohort study - Abstract
Objective A permanent pacemaker (PPM) is necessary for patients with a symptomatic third-degree or advanced second-degree atrioventricular (AV) block. An AV block due to medication use can often be reversed; however, subsequent relapse can occur and necessitate subsequent PPM implantation. The aim of this study was to explore the course and prognosis of patients with an AV block. Methods This historical cohort study was conducted between January 2013 and June 2018. A total of 1900 patient records were analyzed and 1123 subjects with an AV block on admission were enrolled. The patients were categorized into 2 groups: Group 1 comprised patients with an AV block due to medication use (n=316, 28%) and Group 2 included patients with an AV block caused by other etiologies (n=807, 72%). Data of the cause of AV block, recurrence, and PPM implantation were analyzed. Patients in both groups who did not require a PPM during the index admission were followed up regarding subsequent implantation of a PPM. Results AV conduction was recovered in 38 (12%) patients in Group 1 and 48 (6%) patients in Group 2 during the index hospitalization. However, recurrence of the AV block was observed in 18% of Group 1 patients and 40% of Group 2 patients. Only 25 patients in each group (4.5% of the whole study population) remained PPM-free during a median 3-year follow-up period. Conclusion The study findings suggest that drug-induced AV blocks may not be as benign as previously thought. The high relapse rate indicates that watchful follow-up may be required despite discontinuation of the responsible medication and that consideration of earlier PPM implantation in cases of early recurrence may be warranted.
- Published
- 2020
- Full Text
- View/download PDF
36. Predicting Serious Outcomes in Syncope Patients Using Data Mining Techniques
- Author
-
Mohammad Saniee Abadeh, Ardeshir Mansouri, Mohammad Ordikhani, and Masih Tajdini
- Subjects
Intracerebral hemorrhage ,medicine.medical_specialty ,Subarachnoid hemorrhage ,Framingham Risk Score ,biology ,Computer science ,Syncope (genus) ,030204 cardiovascular system & hematology ,Fainting ,medicine.disease ,biology.organism_classification ,Cardiac surgery ,03 medical and health sciences ,0302 clinical medicine ,Emergency medicine ,medicine ,030212 general & internal medicine ,Myocardial infarction ,medicine.symptom ,Adverse effect - Abstract
Syncope or fainting refers to a temporary loss of consciousness usually related to insufficient blood flow to the brain and can be due to several causes, which are either simple or serious conditions. Syncope can be caused by life-threatening conditions not evident in the first evaluations, which can lead to serious outcomes, including death, after discharge from the hospital. We have developed a decision tool to identify syncope patients with 18 years of age or higher who are at risk of a serious event within 30 days after discharge from the hospital.We used the data provided by the Tehran Heart Clinic. In this dataset adults with 18 years old or above with syncope signs are enrolled. The patients presented themselves within 24 hours after the event to the THC. Standardized variables from clinical evaluation and investigations have been collected. Serious adverse events included death, Intracerebral hemorrhage (ICH) or Subarachnoid hemorrhage (SAH), Cerebrovascular accident (CVA), Device Implantation, myocardial infarction, arrhythmia, traumatic syncope or cardiac surgery within 30 days. 356 patients were enrolled with syncope; the mean age was 44.5 years and 53.6% were women. Serious events occurred among 26 (7.3%) of the patients within 30 days of discharge from the hospital.Different machine learning algorithms such as Decision Tree, SMO, Neural Networks, Naive Bayes and Random Forest have been used on the dataset to predict patients with serious adverse outcomes and the WEKA program has been used to validate the results.Results show that when using Random Forrest Algorithm, the accuracy rate and ROC Area reached 91.09% and 0.90. However, previous statistical risk scores such as the San Francisco Score resulted in lower ROC Area readings.
- Published
- 2019
- Full Text
- View/download PDF
37. Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review
- Author
-
Aziz Rezapour, Saeed Sheikh Gholami, Masih Tajdini, and Farbod Ebadi Fard Azar
- Subjects
Male ,medicine.medical_specialty ,Cost effectiveness ,medicine.medical_treatment ,Cost-Benefit Analysis ,MEDLINE ,Argentina ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Percutaneous Coronary Intervention ,medicine ,Humans ,030212 general & internal medicine ,Coronary Artery Bypass ,Mexico ,Czech Republic ,Netherlands ,Health economics ,Wales ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,United States ,Treatment Outcome ,England ,Heart failure ,Austria ,Emergency medicine ,Economic evaluation ,Conventional PCI ,Female ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine ,business ,Brazil ,Switzerland - Abstract
Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
- Published
- 2019
38. Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial
- Author
-
Shahin Akhondzadeh, Masih Tajdini, Somayeh Yadangi, Saeed Tofighi, Saeed Sadeghian, Ali Vasheghani-Farahani, Nazila Shahmansouri, Arya Aminorroaya, Arash Jalali, Ali Bozorgi, and Hamed Tavolinejad
- Subjects
Subgroup analysis ,030204 cardiovascular system & hematology ,Norepinephrine reuptake inhibition ,Placebo ,Atomoxetine hydrochloride ,Syncope ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Syncope, Vasovagal ,Clinical endpoint ,medicine ,Diseases of the circulatory (Cardiovascular) system ,030212 general & internal medicine ,Vasovagal syncope ,Original Paper ,business.industry ,Atomoxetine ,medicine.disease ,Blood pressure ,RC666-701 ,Anesthesia ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background: Despite the reduced quality of life in patients with recurrent vasovagal syncope (VVS), pharmacologic treatment options remain limited. Studies indicate that norepinephrine reuptake inhibition reduces tilt-induced syncope/pre-syncope. This study aimed to evaluate the effects of atomoxetine on syncopal/pre-syncopal episodes in patients with recurrent VVS. Methods: In a placebo-controlled trial, we randomized patients with newly diagnosed VVS who experienced ≥3 syncopal episodes in the past three months to receive either atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks) or placebo. The primary endpoint was the combined number of syncopal and pre-syncopal episodes. Results: Among 843 patients initially screened, 46 were randomized (N = 23 in each group) and reevaluated at one and three months. Compared to placebo, atomoxetine significantly reduced the primary endpoint after three months (P
- Published
- 2021
- Full Text
- View/download PDF
39. Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up
- Author
-
Masih Tajdini, Adel Joharimoghadam, and Ali Bozorgi
- Subjects
Male ,medicine.medical_specialty ,Saliva ,medicine.drug_class ,Pilot Projects ,02 engineering and technology ,Sensitivity and Specificity ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,Natriuretic Peptide, Brain ,medicine ,Natriuretic peptide ,Humans ,In patient ,Aged ,Aged, 80 and over ,Heart Failure ,Plasma samples ,business.industry ,Middle Aged ,021001 nanoscience & nanotechnology ,medicine.disease ,Endocrinology ,Heart failure ,Chronic Disease ,Biomarker (medicine) ,Female ,0210 nano-technology ,Cardiology and Cardiovascular Medicine ,business ,Hospital stay ,Biomarkers ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Background: Frequent hospital admissions and reduced quality of life are the main complications of heart failure (HF). Plasma B-type natriuretic peptide (BNP) levels have been considered as a cost-effective method of screening for left ventricular dysfunction. Studies regarding BNP-guided therapy revealed reduction in death or hospital stay for HF. Aim: As saliva has fewer limitations than blood in regard to sampling, the aim of the present study was to test if salivary BNP concentration might be a new biomarker in patients with chronic HF. Methods: This pilot study involved 35 admitted patients with decompensated HF diagnosis and 35 HF patients who had come for a check-up at the Department of Cardiology. The control group consisted of 25 people with no history of cardiac events. Saliva and plasma samples of all the participants were collected. Results: Mean plasma NT-proBNP was found at higher levels in admitted HF patients compared to outpatient HF (9.37 vs. 6.62 pg/mL, p < 0.001) and control groups (9.37 vs. 4.69 pg/mL, p < 0.001). Also, mean salivary BNP levels were higher in admitted patients with HF (6.50 ng/L, p < 0.001); and outpatient HF group (5.87 ng/L, p = 0.02) compared to the control group (5.64 ng/L). Conclusions: Our study demonstrated that BNP could be detected in saliva and that the level is higher in HF patients, especially symptomatic ones. This means that salivary BNP may be useful in the diagnosis and follow-up for patients with HF, especially in emergency settings.
- Published
- 2017
- Full Text
- View/download PDF
40. The association of statins for secondary prevention with progression to diabetes in patients with prediabetic state after coronary artery bypass graft surgery: A retrospective cohort study
- Author
-
Ario Mohammadi, Hamed Tavolinejad, Hamidreza Poorhosseini, Masih Tajdini, Arya Aminorroaya, Shahrzad Saleh Beigi, Ozra Aasham, Jamshid Bagheri, Arash Jalali, Hamidreza Soleimani, and Saeed Sadeghian
- Subjects
medicine.medical_specialty ,Statin ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,Population ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Prediabetic State ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Diabetes mellitus ,Secondary Prevention ,Internal Medicine ,medicine ,Humans ,cardiovascular diseases ,Myocardial infarction ,Coronary Artery Bypass ,education ,Retrospective Studies ,education.field_of_study ,Unstable angina ,business.industry ,nutritional and metabolic diseases ,Retrospective cohort study ,medicine.disease ,Surgery ,Treatment Outcome ,Diabetes Mellitus, Type 2 ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Body mass index ,Mace - Abstract
Aim Despite proven benefits of statins for secondary prevention of coronary artery diseases, their diabetogenic effect is still controversial. We aimed to examine the occurrence of type 2 diabetes mellitus (T2DM) in prediabetic patients after coronary artery bypass grafting (CABG). Methods The retrospective cohort population comprised of post-CABG patients who were prediabetic at the time of surgery and were taking statins. Patients were categorized into the high- and low-intensity statin regimens according to the commonly used dose during the follow-up. Moreover, we calculated the cumulative dose (milligrams*days) by taking into account that patients were on different doses of statins during different periods of time. We observed patients for occurrence of T2DM or major adverse cardiovascular events (MACE) as a composite of death, myocardial infarction, cerebrovascular accident, and hospitalization for unstable angina or heart failure. Results We studied 819 patients for a median of 37.8 months after CABG. T2DM occurred in 8.1% (n = 66). The rate of T2DM development was not different between the high- and low-intensity groups (P = 0.715) and also according to the cumulative dose (P = 0.962). Furthermore, we found no association (P = 0.938) even after adjustment for confounders including age, sex, body mass index, alcohol use, history of hypertension and hyperlipidemia, and family history of T2DM. Moreover, high- rather than low-intensity statin regimen was correlated with a lower occurrence of MACE (P = 0.027), even after adjustment for confounders (P = 0.015). Conclusions In prediabetic post-CABG patients, treatment with statins was not associated with the development of T2DM and reduced occurrence of MACE after 37 months.
- Published
- 2020
- Full Text
- View/download PDF
41. The coronary slow flow phenomenon and microalbuminuria; is there any relation?
- Author
-
Alireza Amirzadegan, Masih Tajdini, Elham Rayzan, Rosa Ghaderpanah, and Arya Aminorroaya
- Subjects
medicine.medical_specialty ,business.industry ,Case-control study ,030209 endocrinology & metabolism ,medicine.disease ,Chest pain ,Thrombosis ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Cardiology ,Microalbuminuria ,030212 general & internal medicine ,Myocardial infarction ,Endothelial dysfunction ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,TIMI - Abstract
Objective The pathophysiology of coronary slow flow phenomenon (CSFP) is poorly understood. Evidence suggesting endothelial dysfunction in patients with slow coronary flow (SCF) led to this evaluation of a possible correlation between microalbuminuria (MAU), as an indicator of endothelial dysfunction, and CSFP in order to investigate a mutual pathophysiology. Methods In this case-control study, 15786 patients who presented between September 2016 and April 2018 were screened. All patients with CSFP had chest pain and coronary angiography was indicated due to a positive noninvasive test. All cases had a Thrombosis in Myocardial Infarction (TIMI) flow grade of 2 or a corrected TIMI frame count of >27 without any evidence of obstructive coronary artery disease. The patients used as controls had completely normal coronary angiograms. Fasting mid-stream urine samples were analyzed using an immunoturbidimetric assay to determine the albumin-creatinine ratio (ACR) as a surrogate of microalbuminuria (MAU) (ACR: 30-300 mg/g). The prevalence of MAU in the case and control groups was analyzed. Results A total of 154 individuals with a normal coronary angiogram and 46 patients with SCF were enrolled in the study. The prevalence of MAU was greater in patients with SCF than in the control group (8.7% vs 1.9%, respectively; p=0.048). Even after adjustment for major risk factors, the association between MAU and CSPF remained significant. Conclusion The results of this study indicated that there was a relationship between MAU and CSFP and confirmed that endothelial dysfunction is a contributing factor to CSFP. These findings are of utmost importance due to the prognostic value of MAU for both all-cause and cardiovascular mortality rates.
- Published
- 2019
- Full Text
- View/download PDF
42. Upright T Wave in Lead V1 as an Important Predictor of Significant Coronary Artery Disease in Patients with Chest Pain
- Author
-
Younes Nozari, Alireza Amirzadegan, Ehsan Sekhavati Moghaddam, Masih Tajdini, and Kaveh Hosseini
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Cross-sectional study ,business.industry ,lcsh:R ,lcsh:Medicine ,030208 emergency & critical care medicine ,Emergency department ,Odds ratio ,030204 cardiovascular system & hematology ,medicine.disease ,Chest pain ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,T wave ,medicine ,Cardiology ,medicine.symptom ,business ,Electrocardiography ,Dyslipidemia - Abstract
Background Cardiovascular disease is a worldwide great burden on the health care syste early diagnosis and treatment of CAD can reduce the mortality and morbidity. We aimed to determine the association between upright T wave in lead V1 and coronary artery disease (CAD) in patients who presented with chest pain or positive non-invasive tests in emergency department. Methods In this retrospective cross sectional design we reviewed the clinical and coronary angiography data of patients who had normal ECG. Presence of coronary artery disease was compared between patients with and without upright T waves in V1. Results Data of 100 patients with upright T wave more than 1.5 mm in V1 was compared with 100 patients with completely normal ECG. Male patients with coronary artery disease (CAD) were dominant in upright T wave group. However, other traditional cardiovascular risk factors were not statistically different between groups. Based on the multivariate logistic regression model and after adjustment for confounding factors (i.e. gender, dyslipidemia and smoking), presence of upright T wave in the V1 and male gender were still associated with greater risk of coronary artery disease, Odds ratio 4.6 CI 95% (3.1 - 6.3) and 3.4 CI 95% (2.2 - 4.8), respectively. Conclusions In patients with chest pain and unremarkable ECG, presence of upright T wave in lead V1, is an early diagnostic tool for CAD. Male patients with chest pain and upright T wave in lead V1 probably have significant CAD.
- Published
- 2017
43. Does Isolated Left Bundle Block Cause Heart Failure With Reduced Ejection Fraction? A Retrospective Cohort Study
- Author
-
Ali Hosseinsabet, Kaveh Hosseini, Abdolvahab Baradaran, Masih Tajdini, and Alireza Amirzadegan
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,Left bundle branch block ,Cardiomyopathy ,Retrospective cohort study ,Disease ,medicine.disease ,Heart failure ,Concomitant ,Internal medicine ,Diabetes mellitus ,Cardiology ,Medicine ,cardiovascular diseases ,business - Abstract
Background: Left bundle branch block (LBBB) is an important and independent determinant of mortality among patients with cardiovascular disease (CVD). Close follow-up and management of isolated LBBB to prevent cardiomyopathy is controversial. Methods: In this retrospective cohort study, patients with isolated LBBB, with no concomitant evident cardiac disease, or risk factors of heart failure with reduced EF such as hypertension or diabetes mellitus (DM) were included. The mean follow-up of the patients was 56 months. At the onset of the study, coronary angiogram and EF of the patients were normal. Patients with reduced EF underwent coronary angiogram at the end of their follow-up interval. Results: In this study, 36 patients, with the mean age 62.1 years (45 - 81) were followed. LV ejection fraction (EF) was reduced in 24 patients, and the other 11 patients continued to have a normal EF during the follow-up. The follow-up interval between the 2 groups was not statistically different (Mann-Whitney, P = 0.9). Most of the patients with reduced EF were male (Mann-Whitney, P = 0.01). New- onset HTN had a negative correlation with a decrease in EF% (Spearman correlation coefficient = -0.36, P = 0.031). Based on surface ECG parameters, 8 new notched-QRS were detected, all of which had decreased EF during follow-up. Conclusions: Not all patients with isolated LBBB develop cardiomyopathy at a definite time interval. Male gender, notched-QRS in ECG, and longevity of conduction delay are important predictors of cardiomyopathy among these patients. They may benefit from anti-remodeling drugs and routine close follow-ups with echocardiogram.
- Published
- 2017
- Full Text
- View/download PDF
44. Aortic dissection and cystinosis: is there any relationship?
- Author
-
Masih Tajdini, Ali Vasheghani-Farahani, and Mehdi Bayati
- Subjects
Aortic dissection ,Adult ,Pathology ,medicine.medical_specialty ,business.industry ,Cystinosis ,030232 urology & nephrology ,Genetic disorder ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,Aortic Aneurysm ,03 medical and health sciences ,Aortic Dissection ,0302 clinical medicine ,Cystinosin ,Nephropathic Cystinosis ,Echocardiography ,Pediatrics, Perinatology and Child Health ,Medicine ,Humans ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Cystinosis is a rare, autosomal-recessive genetic disorder. The kidneys are commonly involved, as there is cystinosin protein malfunction, and nephropathic cystinosis ensues. Although cardiac and vascular involvements are rare, we describe a unique case of aortic dissection in a 25-year-old female with cystinosis. We discuss the possible aetiologies of aortic dissection in this condition.
- Published
- 2017
45. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial
- Author
-
Mehdi Farokhnia, Habibeh Yekehtaz, Ali Ghaleiha, Amirhossein Gougol, Masih Tajdini, Bahman Salehi, Seyed Mohammadreza Hosseini, Farzin Rezaei, Negar Iranpour, Shahin Akhondzadeh, and Mina Tabrizi
- Subjects
Adult ,Male ,Every Two Weeks ,Adolescent ,Placebo ,Young Adult ,Double-Blind Method ,medicine ,Humans ,Deamino Arginine Vasopressin ,Pharmacology (medical) ,Desmopressin ,Administration, Intranasal ,Biological Psychiatry ,Psychiatric Status Rating Scales ,Pharmacology ,Risperidone ,Positive and Negative Syndrome Scale ,business.industry ,Middle Aged ,medicine.disease ,Diagnostic and Statistical Manual of Mental Disorders ,Clinical trial ,Psychiatry and Mental health ,Treatment Outcome ,Neurology ,Schizophrenia ,Anesthesia ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,Nasal administration ,Neurology (clinical) ,business ,hormones, hormone substitutes, and hormone antagonists ,Antipsychotic Agents ,medicine.drug - Abstract
Considering the role of neurohypophyseal peptides in normal development and function of higher cortical processes along with their proven abnormalities in schizophrenic patients, these pathways have recently attracted greater attention as treatment targets for schizophrenia. Desmopressin (DDAVP) is a synthetic analog of vasopressin. This study aimed to evaluate the efficacy and safety of DDAVP nasal spray as an adjunct to risperidone in improving negative symptoms of schizophrenia. In this randomized double-blind placebo-controlled clinical trial, forty patients aged 18-50 years with a DSM IV-TR diagnosis of chronic schizophrenia and a minimum score of 60 on positive and negative syndrome scale (PANSS) were equally randomized to receive DDAVP nasal spray (20mcg/day) or placebo in addition to risperidone for 8 weeks. Patients were partially stabilized and treated with a stable dose of risperidone (5 or 6mg/day) for at least four weeks prior to entry. Participants were rated by PANSS every two weeks and decrease in the PANSS negative subscale score was considered as our primary outcome. By the study endpoint, DDAVP-treated patients showed significantly greater improvement in the negative symptoms (P=0.001) as well as the PANSS total and general psychopathology subscale scores (P=0.005 and P=0.003; respectively) compared to the placebo group. Treatment group was the strongest predictor of changes in negative symptoms (β=-0.48, t=-3.67, P=001). No serious adverse event or fluid/electrolyte imbalance was reported in this trial. In conclusion, DDAVP nasal spray showed to be an effective and safe medication for improving negative symptoms in patients with chronic schizophrenia.
- Published
- 2014
- Full Text
- View/download PDF
46. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia
- Author
-
Mandana Ashrafi, Farzin Rezaei, Habibeh Yekehtaz, Mina Tabrizi, Maryam Noroozian, Omid Mirshafiee, Sina Ghasemi, Mohammad-Reza Khodaie-Ardakani, Amirhossein Modabbernia, Shahin Akhondzadeh, Masih Tajdini, Mehdi Farokhnia, Bahman Salehi, and Seyed-Mohammad-Reza Hosseini
- Subjects
Adult ,Male ,medicine.medical_specialty ,Indoles ,Side effect ,Tropisetron ,Placebo-controlled study ,Placebo ,Severity of Illness Index ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,Psychiatry ,Pharmacology ,Risperidone ,Positive and Negative Syndrome Scale ,medicine.disease ,Treatment Outcome ,Tolerability ,Schizophrenia ,Chronic Disease ,Regression Analysis ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,Serotonin Antagonists ,Psychology ,Antipsychotic Agents ,medicine.drug - Abstract
A growing body of evidence illustrates that 5-HT3 receptor antagonist drugs may be of benefit in the treatment of negative symptoms in schizophrenia. The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia. In a double-blind, placebo-controlled 8-week trial, 40 patients with chronic schizophrenia who were stabilized on risperidone were randomized into tropisetron or placebo add-on groups. Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) every 2 weeks. Furthermore, extrapyramidal and depressive symptoms as well as side effects were assessed. The primary outcome measure was the difference in change from baseline of negative subscale scores between the two groups at week 8. Tropisetron resulted in greater improvement of the total PANSS scores [F(1.860,70.699) = 37.366, p
- Published
- 2013
- Full Text
- View/download PDF
47. Should we think of Urbach–Wiethe disease in refractory epilepsy? Case report and review of the literature
- Author
-
Seyed Mohammadreza Hosseini, Babak Ghelichnia, Masih Tajdini, Abbas Tafakhori, Vajiheh Aghamollaii, Elham Rahimian, and Hossein Ali Ghelichnia Omrani
- Subjects
medicine.medical_specialty ,Adolescent ,Drug Resistance ,Epilepsy, Partial, Motor ,Disease ,Urbach–Wiethe disease ,Diagnosis, Differential ,Epilepsy ,medicine ,Humans ,Psychiatry ,Hoarseness ,partial seizures ,business.industry ,medicine.disease ,Dermatology ,Neurology ,Mood disorders ,Schizophrenia ,Refractory epilepsy ,Lipoid Proteinosis of Urbach and Wiethe ,Anxiety ,Female ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Urbach-Wiethe disease (UWD) is an autosomal recessive disease characterized by both neurological and dermatological manifestations. Face specially eyelids are commonly involved. Alopecia, nail dystrophy and dental anomalies have been reported as less frequent symptoms. Some patients show evidences of epilepsy and psychiatric symptoms such as schizophrenia, mood disorders, and anxiety due to calcium deposits in different parts of the brain. In this report, we describe the case of a young woman affected by UWD presenting with neurological involvements and no dermatological manifestations. This patient is a unique case of UWD as she has partial seizures and hoarseness. Also we summarize relevant data from the literature.
- Published
- 2012
- Full Text
- View/download PDF
48. What about Common Carotid Ultrasonography in Heart Failure?
- Author
-
Masih Tajdini and Abbas Tafakhori
- Subjects
History ,medicine.medical_specialty ,business.industry ,Ultrasound ,Carotid ultrasonography ,Cognition ,medicine.disease ,Omics ,Computer Science Applications ,Education ,Quality of life ,Internal medicine ,Heart failure ,Cardiology ,Carotid flow ,Medicine ,In patient ,business ,Biomedical engineering - Abstract
Heart failure (HF) is a major health problem causing frequent hospital admissions and reduced quality of life. Cognitive impairment (CI) is a common finding in patients with HF that leads to higher mortality and less successful treatment. Evidences suggest that cognitive impairment can be diagnosed by common carotid flow velocity. As mild CI is not clinically measurable in most cases we can use ultrasound to develop a relevant screening model for cognitive dysfunction in HF.
- Published
- 2015
- Full Text
- View/download PDF
49. Tissue hypoxia in pathogenesis of ulcerative colitis: should we change all our beliefs?
- Author
-
Mohammad Reza Ostovaneh, Roozbeh Nikooie, Seyed Amir Mirbagheri, Seyed Mohammad Ghoreyshi Hefzabad, Seyed Mohammad Reza Hosseini, Sushil Kumar Garg, and Masih Tajdini
- Subjects
business.industry ,Colon ,Gastroenterology ,Case-control study ,Ischemia ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Ulcerative colitis ,Pathogenesis ,Immune system ,Case-Control Studies ,Immunology ,Medicine ,Tissue hypoxia ,Humans ,Colitis, Ulcerative ,Colitis ,business ,Hypoxia ,Biomarkers - Abstract
Many studies have focused on the role of irregular mucosal immune response, but there are noteworthy evidences regarding the role of ischemia in pathogenesis of ulcerative colitis (UC). Hypoxia-ind...
- Published
- 2013
50. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study
- Author
-
Mina Tabrizi, Masih Tajdini, Shahin Akhondzadeh, Ali Ghaleiha, Farzin Rezaei, Mandana Ashrafi, Bahman Salehi, Morteza Jafarinia, Seyed Mohammadreza Hosseini, and Amirhossein Modabbernia
- Subjects
Adult ,Male ,endocrine system ,medicine.medical_specialty ,Neurology ,Time Factors ,Adolescent ,Placebo-controlled study ,Pilot Projects ,Iran ,Oxytocin ,behavioral disciplines and activities ,Severity of Illness Index ,Young Adult ,Double-Blind Method ,mental disorders ,Medicine ,Humans ,Pharmacology (medical) ,Administration, Intranasal ,Psychiatric Status Rating Scales ,Risperidone ,business.industry ,Middle Aged ,medicine.disease ,Oxytocin receptor ,Psychiatry and Mental health ,Treatment Outcome ,Tolerability ,Schizophrenia ,Anesthesia ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,Neurology (clinical) ,Psychopharmacology ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug ,Antipsychotic Agents - Abstract
Impairment of oxytocinergic function and/or oxytocin receptor genetic abnormalities has been demonstrated in patients with schizophrenia. Oxytocin reverses emotional recognition deficit and might restore sense of trust in patients with schizophrenia. Some short-term studies have shown efficacy and tolerability of oxytocin in patients with schizophrenia. However, there is a lack of evidence on the efficacy and tolerability of oxytocin in patients with schizophrenia beyond 3 weeks.The objective of this study was to assess the efficacy and tolerability of oxytocin intranasal spray (given as an adjuvant to risperidone) in patients with schizophrenia.This was an 8-week, randomized, double-blind, placebo-controlled study.Inpatients of two large referral psychiatric hospitals in Iran were recruited for the study.Forty patients (male and female gender) aged 18-50 years with a diagnosis of schizophrenia (DSM-IV-TR) who were on a stable dose of risperidone for a minimum of 1 month and who were chronically partially responsive to antipsychotic monotherapy were included in the study.The patients were randomly assigned to oxytocin intranasal spray (Syntocinon(®); Novartis, Basel, Switzerland) or placebo intranasal spray containing normal saline (ACER, Tehran, Iran) for 8 weeks. Oxytocin spray was administered as 20 IU (five sprays) twice a day for the first week followed by 40 IU (ten sprays) twice a day for the following 7 weeks. Placebo spray was administered at the same dose as the oxytocin spray. In addition, participants were on a stable dose of risperidone (5 or 6 mg/day).The patients were assessed using Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 0, 2, 4, 6 and 8. Primary outcomes were the differences in the PANSS scores between the two groups at the end of the trial. Adverse effects were recorded using a checklist and the Extrapyramidal Symptom Rating Scale (ESRS) at baseline and at weeks 1, 2, 4, 6 and 8.All patients had at least one post-baseline measurement and 37 patients (19 in the oxytocin and 18 in the placebo group) completed the study. Repeated measure analysis of variance showed significant effect for time X treatment interaction on the PANSS total [F(2.291,87.065) = 22.124, p0.001], positive [F(1.285,48.825) = 11.655, p = 0.001], negative [F(2.754,104.649) = 11.818, p0.001] and general psychopathology [F(1.627,61.839) = 4.022, p = 0.03] subscale scores. By week 8, patients in the oxytocin group showed significantly greater improvement on the positive (Cohen's d = 1.2, 20 % vs. 4 % reduction in score, p0.001), negative (Cohen's d = 1.4, 7 % vs. 2 % reduction in score, p0.001) and general psychopathology (Cohen's d = 0.8, 8 % vs. 2 % reduction in score, p = 0.021) subscales and total (Cohen's d = 1.9, 11 % vs. 2 % reduction in score, p0.001) PANSS scores than the placebo group. Adverse effects including the sodium concentration change were similar between the two groups.Oxytocin as an adjunct to risperidone tolerably and efficaciously improves positive symptoms of schizophrenia. In addition, effects on negative and total psychopathology scores were statistically significant, but likely to be clinically insignificant. The interesting findings from the present pilot study need further replication in a larger population of patients.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.